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Abstract 
Rheumatoid arthritis (RA) is a chronic inflammatory disease with a significant impact on 
patients’ quality of life. One of the well-described features in RA is hypoxia, together with 
increased infiltration of macrophages into the inflamed joints. Members of the Hypoxia-inducible 
factor (HIF) family play key roles in activating the transcription of hypoxia regulated genes. 
Regulation of HIFs, including the enzymes which regulate their stabilisation and transactivation, 
namely prolyl hydroxylase domain (PHD) enzymes and factor inhibiting HIF-1 (FIH-1), were the 
main focus of this thesis. This work aimed to shed more light on the influence of monocyte-to-
macrophage differentiation on the Hypoxia/HIF axis as well as how PHDs are being regulated 
during the differentiation process and thus influence the HIF pathway. For this purpose I have 
used macrophages derived from a monocytic cell line namely THP-1, or from freshly isolated 
monocytes, derived from peripheral blood mononuclear cells. Monocytes were differentiated to 
either the classical (M1) or the alternative (M2) macrophages using granulocyte-macrophage 
colony stimulating factor or macrophage-colony stimulating factor respectively. THP-1 
monocytes were differentiated to a M2-like phenotype using phorbol 12-myristate 13-acetate. 
Possible differences between the two macrophage phenotypes with regard to the Hypoxia/HIF 
pathway were also investigated in this study. 
 One of the major findings was that macrophage differentiation leads to stabilisation of 
HIF-1α isoform even in normoxic (20 % O2) conditions. In particular, in PMA-treated THP-1 
cells, the normoxic HIF-1α stabilisation was partly due to an increased HIF α gene transcription.  
Moreover, PHD-2 expression and enzymatic activity were also affected during the differentiation 
process, and were linked to reduced HIF hydroxylation and increased HIFα protein accumulation. 
However, expression of downstream HIF dependent angiogenic genes was not affected during the 
differentiation process, suggesting an additional level of control, mediated possibly by 
transcriptional inactivation of HIF via asparagine hydroxylation by FIH-1, or inhibition of the HIF 
α nuclear translocation machinery. Using the M1 and M2 polarised macrophages, there were no 
significant differences observed between the two phenotypes with regard to the HIF α isoform 
expression. In both phenotypes downstream gene expression was observed for Bcl2/adenovirus 
E1B 19d-interactin protein (BNIP3) and ephrinA3 (EPHRINA3), although in the M2 phenotype 
expression of both genes was significantly greater. Exposure of macrophages to the hypoxia 
mimetic dimethyloxaloyglycine (DMOG) stabilised both HIF α protein isoforms with no 
siginificant differences in expression levels, and led to transcription of the HIF α target genes 
BNIP3 and EphrinA3. Expresion of PHD-2 and PHD-3 were also increased in response to DMOG 
but more in the M2 macrophages.  
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The effect of HIF stabilisation by DMOG was also studied in two different in vivo mouse 
models of arthritis; collagen induced arthritis (CIA) and antigen induced arthritis (AIA). HIF 
activation by DMOG was observed by imaging analysis, using a previously described transgenic 
mouse oxygen-dependent degradation domain (ODD)-luciferase reporter mice. It was 
demonstrated that DMOG activates the HIF pathway in vivo, and appears to exert a protective role 
in the setting of arthritis (reduced paw/knee swelling), possibly by promoting the expansion of the 
anti-inflammatory M2 macrophage population. Furthermore the effect of DMOG in anaemia of 
inflammation was also observed in the CIA mouse model. Arthritic mice showed decreased 
haematocrit levels, which were corrected back to normal levels after DMOG treatment.  
In conclusion my data contributes to a better understanding of the Hypoxia/HIF pathway 
in RA, and also suggest an additional possibly protective role of HIF possibly by shifting 
macrophages towards a less inflammatory phenotype, and also inhibiting anaemia of 
inflammation. These findings also set the basis for further research that will allow the 
development of new therapeutic strategies for the treatment of RA. 
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1 INTRODUCTION 
Hypoxia is known to occur under both physiological conditions - for example during 
normal embryonic development - and pathological conditions, including inflammation-related 
settings like solid tumours, healing wounds, atherosclerotic plaque formation and rheumatoid 
arthritis (RA).  
A common characteristic of all the above mentioned diseases is increased infiltration by 
inflammatory cells originating from the circulation, the vast majority of which are comprised of 
macrophages. Macrophages exhibit a remarkable functional plasticity and are capable of exerting 
their full spectrum of biological activities under a wide range of microenvironmental tissue 
conditions. A very common situation that macrophages inevitably have to cope with is oxygen-
depleted conditions, as hypoxia has been shown to occur in a variety of inflammatory diseases. 
Macrophages have developed ways to face hypoxia while retaining an optimal level of effector 
functions, thus making adjustment to the hypoxic environment possible through modification of 
their transcriptional and metabolic programs. The key contribution of the O2 levels in shaping 
macrophage behaviour has now been confirmed by studies showing that critical components of 
the Hypoxia/Hypoxia-inducible factor (HIF) signalling axis, namely prolyl hydroxylase domain 
enzymes (PHDs), which control HIF levels -but also HIF itself - can have a direct influence on 
macrophage polarisation. It is not surprising then that genetic or pharmacological manipulation of 
the PHD-HIF axis has now become a novel target for efficient modulation of inflammatory-
immune response via macrophage polarisation.  
1.1 The significance of oxygen homeostasis 
Oxygen (O2) is a key molecular ingredient of life, as its continuous and adequate supply 
is of critical importance for the survival of metazoan organisms. O2 started accumulating in 
Earth’s atmosphere ~2.5 billion years ago. The dimensions of primitive metazoan species were 
small enough such that O2 could diffuse from the atmosphere to all of the organism’s thousand 
cells, as is the case for the worm Caenorhabditis elegans. To escape the restrictions caused by 
diffusion, systems evolved that could conduct air to cells deep within the body, and these designs 
were sufficient for O2 delivery to organisms with hundreds of thousands of cells, such as the fly 
Drosophila melanogaster. The final evolutionary step occurred in vertebrates, and was associated 
with the evolution of complex respiratory, circulatory, and nervous systems designed to 
efficiently capture and distribute O2 to hundreds of millions of cells, such as the adult Homo 
sapiens (Semenza, 2012). Increased availability of atmospheric O2 led to the evolution of an 
extraordinarily efficient system of oxidative phosphorylation, and constitutes a fundamental 
requirement for cellular metabolism, since it serves as the terminal electron acceptor in 
mitochondria to generate energy stored as adenosine triphosphate (ATP) molecules. The oxygen-
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sensing cascade includes heme proteins, such as isoforms of the NADPH oxidase, and non-heme 
oxygen-sensing proteins like the PHD enzymes (Acker et al., 2006) Mammalian life is restricted 
to a narrow range of oxygen tensions and breathing is the most significant limiting factor.  
Tissue oxygenation represents a steady state based on O2 consumption, primarily by 
mitochondrial oxidative phosphorylation, and O2 delivery via erythrocytes traveling through 
tissue capillary networks. This steady state reflects the balance between the requirement for O2 as 
an energy substrate and the potential risk of oxidative damage to molecules. As a result, O2 
homeostasis must be precisely maintained, and its disruption underlies pathologies like heart 
disease, cancer, cerebrovascular disease and chronic lung disease, all of which represent the most 
common causes of mortality in western cultures (Semenza, 2001). In healthy tissues, however, a 
wide range of partial pressure of O2 (ppO2) exists, with the highest levels found in the lung (150 
mm Hg, 20 kPa) and in alveoli (13 kPa, 100 mm Hg). As oxygen pressure decreases with 
increasing distance from the blood vessels, considerably lower levels are seen in veins that reach 
the heart (5 kPa, 40 mm Hg) and in most tissues, where oxygen tension reaches values around 
0.5–2.5 kPa (4–20 mm Hg) (Sitkovsky and Lukashev, 2005). As a consequence, oxygen tensions 
in tissues are low, and certain tissues can even considered to be hypoxic (Vanderkooi et al., 1991). 
For example, pO2 is ∼1.3 kPa (∼10 mm Hg) in the thymus and ∼2.1 kPa (∼16 mm Hg) in the 
spleen (Braun et al., 2001).  
1.2 Hypoxia 
1.2.1 Definition 
There are different kinds of hypoxia depending on the cause: (i) Ischemic hypoxia is a 
result of shortage of the blood supply, i.e. a shortage of oxygen, to an organ due to a blockage of 
the arteries or veins supplying it (Barnabas et al., 2013); (ii) Hypoxic hypoxia which causes 
hypoxemia (decreased oxygen level in blood) is usually a result of lowered oxygen level in the air 
being breathed at high altitudes, or because of the failure of ventilation by the lungs during for 
instance chronic obstructive pulmonary disease (Harris et al., 2013); (iii) Anaemic hypoxia refers 
to haemoglobin deficiency due to inadequately circulating erythrocytes (anaemia) or inability of 
haemoglobin to carry the oxygen for instance during carbon monoxide (CO) poisoning, or 
because haemoglobin has too ‘high affinity’ to oxygen deterring its release in the tissue 
(hemoglobinopathies) (Elmer et al., 2012); (iv) Histotoxic hypoxia is the inability of tissue to 
accept and utilise oxygen from the bloodstream resulting from tissue poisoning caused by alcohol, 
narcotics or cyanide, leading to the cytochrome complexes failure (Busl and Greer, 2010); (v) 
Tissue hypoxia is present in highly metabolically active tissue, such as that found in solid tumours 
and the expanding synovium in RA (Leach and Treacher, 1998). 
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1.2.2 Hypoxia and disease 
Hypoxia is one of the most important features underlying the pathogenesis of many 
diseases including cancer, infections as well as inflammation-related conditions such as RA. 
Cancers contain hypoxic regions due to a combination of cellular proliferation coupled 
with the formation of vasculature which exhibits structural and functional abnormalities. Reduced 
oxygen levels in diagnostic tumour biopsies are associated with increased risk of mortality in 
cancers of the bladder, brain, breast, colon, cervix, endometrium, head/neck, lung, ovary, 
pancreas, prostate, rectum, and stomach (Semenza, 2010). Hypoxia activates transcription of 
genes that play key roles in critical aspects of cancer biology, including stem cell maintenance 
(Wang et al., 2011), cell immortalisation, epithelial-mesenchymal transition (Mak et al., 2010) 
genetic instability (Huang et al., 2007), vascularisation (Liao et al., 2007) glucose metabolism 
(Liu et al., 2008), pH regulation (Swietach et al., 2007) immune evasion (Lukashev et al., 2007) 
invasion and metastasis (Chan and Giaccia, 2007) and radiation resistance (Moeller et al., 2007). 
Hypoxic regions, as identified by immunohistochemical analysis of tumour biopsies, are 
associated with increased risk of metastasis and patient mortality in unselected breast cancer 
patients and in lymph node-positive, lymph node-negative, Human epidermal growth factor 
receptor (HER2)-positive, or estrogen receptor-positive subpopulations (Semenza, 2010). These 
data provide evidence for the role of hypoxia as the driving force behind the expression of 
multiple genes involved in a single (patho)physiological process. 
Hypoxia can also occur during infections with pathogens. For example, infection with 
Bartonella henselae - the causative agent of bacillary angiomatosis - is associated with hypoxia 
and the transcription of genes that typically become transcribed in hypoxic conditions (Kempf et 
al., 2005). Elevated hypoxic levels have also been found in liver-biopsy specimens obtained from 
patients with chronic hepatitis C (Ripoli et al., 2010) and in skin-biopsy specimens obtained from 
patients with cutaneous infections caused by Staphylococcus aureus, varicella-zoster virus, human 
herpesvirus, or Candida albicans (Werth et al., 2010).  
In inflammatory conditions such as RA, the synovial tissue that lines joints and tendons 
becomes inflamed. Normally 1–2 cell layers thick, the RA synovium increases to several cell 
layers, due to a combination of cellular hyperproliferation and infiltration by cells derived from 
the circulation, including T cells and monocytes (Feldmann, 2002). This thickened synovium 
invades cartilage and bone, and the progressive destruction of articular cartilage, subchondral 
bone and periarticular soft tissue eventually leads to functional deterioration and profound 
disability. The increase in synovial tissue mass, due to enhanced proliferation of synovial 
fibroblasts, results in increased oxygen consumption by RA synovium (Lee et al., 2007). In the 
1970s, synovial fluids from patients with RA were reported to also be characterised by low 
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oxygen tension (Lund-Olesen, 1970); however, only with the advent of more sophisticated ana-
lytical approaches (including Magnetic Resonance Imaging, MRI) has the suggestion of an 
anaerobic synovial microenvironment been supported (Hitchon et al., 2009). Furthermore, using 
highly sensitive microelectrodes, it was shown that synovial tissue in patients with RA is indeed 
hypoxic, with ppO2 levels in patients with RA equivalent to 2–4%, compared with 9–12% in 
patients who did not have RA (Sivakumar et al., 2008). An inverse correlation between synovial 
oxygen tension and inflammatory cell markers (CD3 and CD68) has also been described 
(Biniecka et al., 2010; Ng et al., 2010). 
1.3 Hypoxia-Inducible Factor (HIF) 
1.3.1 The discovery of HIFs 
The HIF family of transcription factors was first discovered in 1992 by Semenza and 
Wang while dissecting out a promoter region in the erythropoietin (EPO) gene. It was known 
before that this glycoprotein hormone, which regulates red blood cell production, is increased by 
hypoxia and facilitates tissue oxygen delivery. An electrophoretic mobility shift assay of hepatic 
cells cultured in hypoxia revealed a DNA/protein complex with reduced mobility. A nuclear 
factor which bound to the EPO promoter was described and the DNA-binding activity of this 
factor was found to be tightly regulated by cellular oxygen tension, therefore the protein was 
designated hypoxia-inducible factor (HIF-1) (Semenza and Wang, 1992). Subsequent purification 
studies revealed HIF was a heterodimeric complex consisting of a novel protein, HIF-1α, and the 
aryl hydrocarbon nuclear translocator (ARNT, also termed HIF-1β), previously identified as a 
binding partner of the dioxin/aryl hydrocarbon receptor (DR/AhR) (Hoffman et al., 1991; Wang 
et al., 1995; Wang and Semenza, 1995). Subsequently, HIF-1α has been independently cloned as 
a binding partner of both ARNT and p300/CBP (Arany et al., 1996; Li et al., 1996). The studies 
also revealed the core hypoxia-responsive element (HRE) or HIF-binding site composed of the 
consensus sequence 5’-(A/G)CGTG-3’, which determines HIF-1 transcriptional activity 
(Semenza et al., 1996). HIF-1 was believed to be the main oxygen sensor for nearly a decade 
being maximally stabilised in HeLa cells exposed to 0.5% O2 (Jiang et al., 1996), until the 
discovery of the upstream regulators of HIF, known as PHD enzymes, which are described later. 
1.3.2 HIF structure 
HIF is a heterodimeric transcription factor composed of two different subunits: HIF-α, 
which is unique to the hypoxic response and HIF-β, which is constitutively expressed in the 
nucleus (Wang et al., 1995). Three HIF-α isoforms have been identified so far namely HIF-1α, 
HIF-2α and HIF-3α the functional role of each will be discussed later. HIF-α and HIF-β are 
members of the same superfamily of proteins containing a basic helix-loop-helix (bHLH) region 
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located at the N-terminal part of the proteins, responsible for DNA binding. The basic region 
consists of approximately 15 predominantly basic amino acids responsible for direct DNA 
binding. This region is adjacent to two amphipathic α helices, separated by a loop of variable 
length, which forms the primary dimerisation interface between family members (Moore et al., 
2000). 
Further downstream is the Per-ARNT-Sim (PAS) domain which has been identified to 
have sequence homology to the Drosophila melanogaster proteins Per and Sim and to the 
mammalian proteins AhR and ARNT. The PAS domain has been shown to be involved in nuclear 
dimerisation (Hogenesch et al., 1997; Wang et al., 1995). Despite not directly binding DNA, the 
PAS domain has also been reported to confer target gene specificity to the Drosophila proteins 
Trachealess (Trh) and Single minded (Sim) (Zelzer et al., 1997). The mechanism by which this 
occurs remains unknown, as does the full extent of functions played by the PAS domain in the 
HIFs. 
Downstream of the bHLH- PAS domain, in the central region of the molecule, is located 
the oxygen dependent degradation domain (ODD). The ODD domain consists of approximately 
200 amino acids and is common between HIF-1α and HIF-2α isoforms. The ODD domain, which 
plays a crucial role for the proteolytic regulation of HIF via the von Hippel Lindau (VHL) 
mediated proteasomal pathway -discussed later-, includes the N-terminal transactivation domain 
(N-TAD) (Huang et al., 1998). A second transactivation domain located at the C-terminal part of 
the molecule, C-TAD, although not directly involved in the proteolytic regulation, has been 
shown to interact with transcriptional co-activators, including p300/CREB binding protein and 
p160/ steroid receptor co-activator-1 facilitating transcriptional activation as shown in Figure 1-1. 
Recently, the chromatin remodelling factor Pontin was demonstrated to be a HIF-1α coactivator 
by mediating the binding between p300 and HIF-1α under hypoxia (Lee et al., 2011). Thus, HIF-α 
has bifunctional transcriptional activity, which, depending on the activity of another enzyme, 
factor inhibiting HIF (FIH-1) (discussed in more detail later) allows for differential gene 
activation that is either N- or C-TAD controlled (Dayan et al., 2006). In particular the HIF 
heterodimers bind to a core DNA motif  in the HRE, which are present within a broad range of 
target genes (Jiang et al., 1997). It has to be mentioned here that HIF-α-mediated transactivation 
of target genes is modulated by the relative abundance of transcriptional coactivators and/or 
corepressors, that affect the physical accessibility of, or affinity between, HIF-α and its cofactors. 
Acetylation of the residue lysine-674 on HIF-1α by p300/CBP-associated factor also enhances 
binding between p300 and HIF-1α, while deacetylation of the same lysine residue by the NAD-
dependent deacetylase sirtuin-1 (SIRT1) blocks p300 recruitment and transactivation of HIF1α-
target genes (Lim et al., 2010; Xenaki et al., 2008).  CBP/p300 interacting transactivator with ED-
rich tail (CITED)2 and CITED4 have been shown to bind p300/CBP at the same domain required 
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demonstrated by the use of proteasomal inhibitors or mutation of the E1 ubiquitin activating 
enzyme (Huang et al., 1998; Kallio et al., 1999). PHDs require oxygen for catalytic activity; thus, 
prolyl hydroxylation of HIFα is abrogated under hypoxia, allowing HIFα to escape recognition by 
the VHL ubiquitin–ligase complex and accumulate in the nucleus. Similarly, biallelic inactivation 
of VHL has a profound stabilising effect on HIFα protein levels, thereby implicating pVHL as a 
predominant HIFα antagonist. Via a mechanism analogous to proline hydroxylation, Lando and 
co-workers demonstrated that the C-TADs of both HIF-1α and HIF-2α are hydroxylated in an 
oxygen-dependent manner (Lando et al., 2002b). Similar to proline hydroxylation, modification 
of the C-TAD occurs at normoxia and involves an O2, iron and 2-oxoglutarate (2-OG) dependent 
hydroxylase termed FIH-1. In contrast to the control of protein stability, however, this 
hydroxylation modifies an asparagine residue (N803 in HIF-1α and N851 in HIF-2α) and 
functions to inhibit the association of HIF-1α and HIF-2α with CBP/p300 at normoxia (Lando et 
al., 2002b; Sang et al., 2002). Alanine mutation of the asparagine therefore permits coactivator 
binding at normoxia and full transactivation capacity. In the context of full-length protein 
however, mutation of both hydroxylated proline and asparagine residues is required for the 
generation of a protein with full constitutive activity. Thus, hypoxic induction of both HIF-1α and 
HIF-2α involves a two-step mechanism of increased protein stability and transcriptional activity, 
both mediated by O2-dependent hydroxylation. In hypoxic conditions or in VHL
_/_ cells, stabilised 
HIFα dimerises with HIFβ before binding to HREs comprising a core 50-[A/G]CGTG-30 
consensus sequence and highly variable flanking sequences in the promoters of HIF-responsive 
genes (Wenger et al., 2005). FIH-1-mediated asparagine-803 hydroxylation is also reduced when 
oxygen is depleted, thereby allowing HIFα to interact with the transcriptional coactivators 
p300/Creb-binding protein (CBP) (Arany et al., 1996) as shown in Figure 1-2. 
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Figure 1-2 Regulation of HIF by the PHD enzymes, FIH-1 and VHL  
In the presence of oxygen HIFα is hydroxylated (OH) at two prolyl residues (P) and one asparaginyl residue 
(N). These lie within the oxygen dependent destruction domain (ODDD) and C terminal transactivation 
domain (CTAD). The prolyl hydroxylation leads to capture by VHL, which forms part of a multiprotein 
ubiquitin E3 ligase complex (not shown). The asparaginyl hydroxylation blocks coactivator recruitment. 
This leads to HIF destruction. In the absence of hydroxylation, HIFα moves to the nucleus where it 
heterodimerizes with HIF-1β/ARNT and the CTAD recruits the coactivator CBP/P300 and activates 
expression of target genes (Kiriakidis et al., 2007). 
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An overview of the list including genes whose expression depends on HIF activation is 
shown in Figure 1-3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-3 HIF-regulated genes 
Genes that are involved in many processes are transcriptionally activated by HIF-1. ADM, adrenomedullin; 
ALDA, aldolase A; ALDC, aldolase C; AMF, autocrine motility factor; CATHD, cathepsin D; EG-VEGF, 
endocrine-gland-derived VEGF; ENG, endoglin; ET1, endothelin-1; ENO1, enolase 1; EPO, erythropoietin; 
FN1, fibronectin 1; GLUT1, glucose transporter 1; GLUT3, glucose transporter 3; GAPDH, 
glyceraldehyde-3-P-dehydrogenase; HK1, hexokinase 1; HK2, hexokinase 2; IGF2, insulin-like growth-
factor 2; IGF-BP1, IGF-factor-binding-protein 1; IGF-BP2, IGF-factor-binding-protein 2; IGF-BP3, IGF-
factor-binding-protein 3; KRT14, keratin 14; KRT18, keratin 18; KRT19, keratin 19; LDHA, lactate 
dehydrogenase A; LEP, leptin; LRP1, LDL-receptor-related protein 1; MDR1, multidrug resistance 1; 
MMP2, matrix metalloproteinase 2; NOS2, nitric oxide synthase 2; PFKBF3, 6-phosphofructo-2-
kinase/fructose-2,6-biphosphatase-3; PFKL, phosphofructokinase L; PGK 1, phosphoglycerate kinase 1; 
PAI1, plasminogen-activator inhibitor 1; PKM, pyruvate kinase M; TGF-, transforming growth factor-; 
TGF-3, transforming growth factor-3; TPI, triosephosphate isomerase; VEGF, vascular endothelial growth 
factor; UPAR, urokinase plasminogen activator receptor; VEGFR2, VEGF receptor-2; VIM, vimentin. 
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1.3.3.2 Oxygen-independent regulation of HIF 
It is now clear from published studies in literature that a number of non-hypoxic stimuli, 
namely, hormones, growth factors, cytokines and bacterial by-products can strongly increase the 
HIF-1 complex in normal oxygen conditions and modulate the transcription of hypoxic genes in a 
wide range of either permanent cell lines or primary cultures.  
It was shown that HIF-1α protein levels are strongly increased by fetal calf serum in 
quiescent vascular smooth muscle cells. More interestingly, Angiotensin II, thrombin, platelet-
derived growth factor, and other hormones can also increase HIF-1α in vascular smooth muscle 
cells to levels that are substantially more elevated than the hypoxic treatment. HIF-1α induced by 
Angiotensin II is located in the nucleus, binds to the hypoxic response element, and is 
transcriptionally active. The induction of HIF-1α by hormones is mediated through the production 
of reactive oxygen species (ROS), since it can be blocked by the ROS inhibitors, 
diphenyleneiodonium and catalase (Richard et al., 2000). Moreover, stimulation of HCT116 
human colon cancer cells with insulin-like growth factor 1 (IGF-1) induces the expression of HIF-
1α as well as vascular endothelial growth factor (VEGF). Of note is that, in contrast to hypoxia, 
which induces HIF-1α expression by inhibiting its ubiquitination and degradation, IGF-1 did not 
inhibit these processes, indicating an effect on HIF-1α protein synthesis. IGF-1 stimulation of 
HIF-1α protein and VEGF mRNA expression was inhibited by treating cells with inhibitors of 
phosphatidylinositol 3-kinase (PI3K) and Mitogen-Activated Protein Kinases (MAPK) signaling 
pathways. These inhibitors also blocked the IGF-1-induced phosphorylation of the translational 
regulatory proteins 4E-Binding Protein 1, p70, S6 kinase, and eukaryotic Initiation Factor-4E 
(eIF-4E), thus providing a mechanism for the modulation of HIF-1α protein synthesis (Fukuda et 
al., 2002). 
In terms of HIF regulation by cytokines, interleukin (IL)-1β and tumour necrosis factor-α 
(TNF-α) were first shown to increase HIF-1 activity in the human hepatoma cell line HepG2 
(Hellwig-Burgel et al., 1999). Interestingly, whereas IL-1β increased both HIF-1α protein levels 
and HIF-1 DNA binding capacity in normoxic HepG2 cells, TNF-α appeared to selectively 
stimulate HIF-1 DNA binding, while the nuclear HIF-1α protein level remained unaffected. In 
HepG2 cells, neither IL-1β nor TNF-α affected HIF-1α mRNA levels. The effect of IL-1β has 
been confirmed in a number of other permanent cell lines as well as in primary cultures of human 
proximal tubular epithelial cells (El Awad et al., 2000), synovial and gingival fibroblasts 
(Thornton et al., 2000) and polymorphonuclear leukocytes (PMN). IL-1β and TNF-α are known 
to activate several intracellular signaling pathways, including PI3K, p38 MAPK, p42/p44 MAPK, 
c-jun N-terminal kinase (JNK)/stress-activated protein kinase (SAPK), and Nuclear Factor-kappa 
B (NFκB). PI3K activity is clearly required for the induction of HIF-1α by IL-1β and TNF-α 
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(Sandau et al., 2001b; Stiehl et al., 2002). Studies using human lung epithelial cells (line A549) 
indicate that IL-1β increases HIF-1α levels in two ways. First, IL-1β stimulates HIF-1α 
production through activation of NFκB in a pathway involving PI3K/Akt/mTOR. Second, IL-1β 
inhibits pVHL-dependent degradation of HIF-1α (Jung et al., 2003).  
Blouin et al (Blouin et al., 2004) have reported that HIF-1α levels, HIF-1 DNA binding, 
and HIF-1-dependent gene expression increase in macrophage cultures (primary mouse bone 
marrow-derived or NR 8383 cells) on the addition of bacterial lipopolysaccharide (LPS). This 
response is delayed when compared with the induction by hypoxia and involves protein kinase C 
(PKC) signaling and increased HIF-1α mRNA levels. It remains to be investigated though 
whether the LPS-induced HIF-1 activation is exclusively caused by LPS itself or is supported by 
the paracrine action of IL-1β and TNF-α released into the culture medium. 
Frede et al (Frede et al., 2006) reported that LPS induces HIF-1α mRNA expression and 
HIF-1α protein accumulation in human monocytes as well as in non-differentiated and 
differentiated cells of the human monocytic cell line THP-1 under normoxic conditions. LPS and 
hypoxia act synergistically in activating HIF-1 in that, LPS increased HIF-1α mRNA expression 
through activation of a NFκB site in the promoter of the HIF-1α gene, hypoxia post-
translationally stabilised HIF-1α protein. HIF-1α activation was also followed by increased 
expression of the HIF-1 target gene encoding ADM (adrenomedullin). Simultaneously with HIF-1 
activation, an increase in p44/42 MAPK phosphorylation was observed after incubation with LPS. 
In cells pretreated with the p44/42 MAPK inhibitor PD 98059 or with RNAi directed against 
p44/42 MAPK, LPS-induced HIF-1α accumulation and ADM expression were significantly 
decreased. 
Of relevance to this PhD project are studies referring to increased HIF activity during 
monocyte to macrophage differentiation. It was shown that macrophage differentiation of THP-1 
cells or monocytes from peripheral blood induces increased expression of HIF-1α and HIF-1β as 
well as increased HIF-1 transcriptional activity leading to increased expression of HIF-1 target 
genes. The increased HIF-1 activity in differentiated THP-1 cells resulted from the combined 
effect of increased HIF-1α mRNA levels and increased HIF-1α protein synthesis and seemed to 
rely on the PKC or MAPK pathway (Oda et al., 2006). Another group using phorbol-12-myristate 
13-acetate (PMA)-induced differentiated monocytic U937 and THP1 cells showed that HIF-1α 
was markedly upregulated because of failure of HIF-1α prolyl hydroxylation despite the presence 
of O2. Fluorescence measurements showed that differentiation was associated with marked 
reduction of the labile iron pool. Both the reduction in labile iron pool and the up-regulation of 
HIF-1α were suppressed by RNA interference-mediated down-regulation of the iron transporter 
natural resistance-associated macrophage protein 1 (Nramp). Even more recently, Fangradt et al 
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(Fangradt et al., 2012) moved one step further showing  that the localisation of HIF-1 during the 
differentiation process is shifted from the cytosol (in monocytes) into the nucleus (in 
macrophages), apparently as an adaptation to a low oxygen environment. The authors suggest that 
for this localisation change, protein kinase C alpha/beta 1 (PKC-α/β1) plays an important role and 
that in monocytes; it is NFκB1, and not HIF-1α, which is of central importance for the expression 
of hypoxia-regulated genes. 
1.3.4 Role of HIF isoforms 
HIF-1α and HIF-2α share a number of similarities, including genomic organisation, 
protein structure and regulation. They are both complementary in total amino acid sequence of 
approximately 48% (Figure 1-1) and they share identity up to 80% in nucleotide sequence. Both 
HIF-α subunits contain two specific prolyl residues within the ODD domain and one asparaginyl 
residue in the C-TAD. Both α-subunits are subjected to oxygen-dependent regulation described in 
Section 1.3.3.1 in a similar manner by HIF hydroxylases, PHDs and FIH-1, targeting their ODD 
and C-TAD segments. The mechanism of action, meaning the transactivation of target genes by 
both HIF-1α and HIF-2α, is also alike and includes the ability to dimerise with HIF-1β via the 
PAS domain, DNA recognition and binding to HRE in the gene promoters via the bHLH domain 
(Wang et al., 1995).  
Due to structural similarities, mentioned above, it was believed that HIF-1α and HIF-2α 
respond in a similar manner to hypoxia. Indeed they share some common target genes such as 
VEGF and/or EPO, suggesting they may have similar role in regulating processes including 
angiogenesis and/or erythropoiesis (Hu et al., 2006; Hu et al., 2003; Raval et al., 2005; Wang et 
al., 1995; Warnecke et al., 2004). However, it was demonstrated that HIF-1α and HIF-2α may 
bind to different HRE in the same target genes, for instance VEGF and Glucose Transporter-1 
(GLUT-1), each of them having at least two potential HIF-binding sites (Hu et al., 2006). It has 
been suggested that although α-subunits can regulate common targets, such as VEGF, they may 
still affect different stages of the same biological process. For instance, HIF-1α is believed to be 
involved in vasculogenesis and angiogenesis (Carmeliet et al., 1998; Iyer et al., 1998a; Ryan et 
al., 1998), whereas HIF-2α is important at the later stage of vessel development which is vascular 
remodelling (Peng et al., 2000). Despite high similarity with respect to protein sequence and 
activation pathway, a growing number of physiological and mechanistic differences between HIF-
1α and HIF-2α are being evaluated, implying that the HIF isoforms have distinct biological roles 
in different cell types. Differences include embryonic deletion phenotype, unique tissue 
distribution and targets, specific coactivators and effects on tumour growth (Patel and Simon, 
2008). One of the first distinctions is presence in other species, with HIF-1α being older 
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evolutionally, existing from Caenorhabditis elegans to humans, whereas HIF-2α is present only 
in complex vertebrates such as mice and mammals (Hu et al., 2003). The first functional 
difference between HIF-1α and HIF-2α has been shown in mouse models exhibiting distinct 
phenotypes in the absence of either HIF-α isoform. Hif1a-/- embryonic stem cells that did not 
express the O2-regulated HIF-1α subunit, levels of mRNAs encoding glucose transporters and 
glycolytic enzymes were reduced, and cellular proliferation was impaired. VEGF mRNA 
expression was also markedly decreased in hypoxic Hif1a-/- embryonic stem cells and cystic 
embryoid bodies. Complete deficiency of HIF-1α resulted in developmental arrest and lethality by 
E11 of Hif1a-/- embryos that manifested neural tube defects, cardiovascular malformations, and 
marked cell death within the cephalic mesenchyme. In Hif1a+/+ embryos, HIF-1α expression 
increased between E8.5 and E9.5, coincident with the onset of developmental defects and cell 
death in Hif1a-/- embryos. In addition HIF-1α-/- mice, showed initially and properly formed 
vascular plexus which subsequently degenerated and the mice developed both cardiac and 
vascular malformations, suggesting that the first processes of vascular development, namely 
vasculogenesis and angiogenesis, are dependent on HIF-1α. These results demonstrate that HIF-
1α is a master regulator of cellular and developmental O2 homeostasis (Iyer et al., 1998a). Hif-2α-
/- mice also die in utero with abnormalities in yolk sac angiogenesis, placental vascularization, 
development of the autonomic nervous system, and impaired production of lung surfactant before 
birth (Compernolle et al., 2002). Particularly, mice with deficiency in their Hif-2α gene, suffered 
fatal respiratory distress syndrome (RDS) due to insufficient surfactant production by alveolar 
type 2 cells and reduced VEGF levels. Impaired ROS homeostasis has also been reported as a 
characteristic of Hif-2α-/- mice (Scortegagna et al., 2003a). A description of HIF knockout mice 
and general functions of α-subunits is shown in Table 1-1. 
Studies from Hif-1α+/- and Hif-2α+/- mice revealed also defects in hypoxic responses- 
including erythropoiesis, ventilator responses, and susceptibility to cardiac ischemic injury 
(Brusselmans et al., 2003; Kline et al., 2002; Manalo et al., 2005). Of note, these animals do not 
exhibit significant phenotypic abnormalities under baseline conditions, thus implying that 
moderate genetic changes in the HIF system are relatively tolerable but have a major impact on 
the response to altered oxygenation.  
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Characteristic HIF-1 HIF-2
KO mice Lethal
(Iyer et al 1998, Kotch et al 1999)
Lethal
(Tian et al 1998, Scortegagna et al 2003)
KO phenotype Cardiac malformation, 
vascular regression
Heart failure, bradycardia, impaired 
ROS metabolism
Specific genes GLUT-1, BNIP-3, CA9
(Iyer et al 1998, Greijer&van der Wall 2004, 
Zhong et al 1999) 
cyclin D, TGF-, ANGPT2, VEGFR1 
(Raval et al 2005, Aprelikova et al 2006,
Nagao et al 2011)
General function Metabolism, apoptosis, angiogenesis Vascular remodelling, hematopoiesis, 
cancerogenesis
HIF-associated 
diseases
Majority of cancers  
(Zhong et al 1999, Semenza 2010)
RCC, polycythaemia
(Raval et al 2005,  Ang et al 2002)
Table 1-1 Description of HIF knockout mice and general functions of α-subunits 
Abbreviation used in the table: GLUT-1-glutamin-1, BNIP-3-Bcl2/adenovirus E1B 19d-interacting protein, 
CA9-carbonic anhydrase 9, TGF-β transforming growth factor beta, ANGPT2 - angiopoietin 2, VEGFR1 - 
VEGF receptor 1, RCC - renal cell carcinoma, KO - knockout. 
 
 
 
  
 
 
 
 
With regard to the tissue expression pattern, HIF-1α appears to be ubiquitously expressed, 
compared to HIF-2α, thus partially explaining the fact that the vast majority of HIF-regulating 
genes are HIF-1α dependent (Warnecke et al., 2008), as well as the idea that HIF-2α has more 
specialised functions. Particularly high levels of HIF-2α mRNA were found in renal cells, 
hepatocytes, epithelial cells, cardiomyocytes, astrocytes and pneumocytes (Wiesener et al., 2003). 
Some of the specific HIF-2α functions include promotion of differentiation of adipocytes (Shimba 
et al., 2004) and regulation of stem cell pluripotency regulated by specific gene Oct-4 (Hu et al., 
2003). Hypoxic induction of the chondrocyte phenotype was shown to be HIF-2-dependent by up-
regulation of cartilage matrix genes and the transcription factor SOX9 (Lafont et al., 2007). 
Interestingly, HIF-2α is believed to be involved in osteoarthritis (OA). In particular, chondrocyte 
hypertrophy followed by cartilage matrix degradation and vascular invasion, characterised by 
expression of type X collagen, MMP-13 and VEGF, respectively, are considered to be central 
steps of endochondral ossification during normal skeletal growth and osteoarthritis development. 
A COL10A1 promoter assay identified HIF-2α as the most potent transactivator of COL10A1 
(Saito et al., 2010). Of note, HIF-2α has a particular role in ROS homeostasis by regulating 
antioxidant enzymes (Scortegagna et al., 2003b) and in iron metabolism by inducing transferring 
transcripts (Rankin et al., 2007; Rolfs et al., 1997). 
The differences between HIF-1α and HIF-2α concern also mRNA and protein stability, 
with HIF-1α being transiently expressed, and HIF-2α being sustained in prolonged hypoxia (Chen 
et al., 2006; Li et al., 2006; Uchida et al., 2004). Cobalt chloride (CoCl2), which inhibits 
hydroxylation of prolines, dramatically decreases mRNA half-life of HIF-1α from 19.3 hours in 
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Characteristic HIF-1 HIF-2 HIF-3 Reference
Size (amino acids) 826 870 662 Source: PubMed
Molecular weight (kDa) 120 115 73 Gu et al 1998
mRNA stability in 
hypoxia
Unstable Stable Stable Uchida et al 2006
Thrash-Bingham 1999
mRNA in hypoxia Decreased Unchanged Increased Ema et al 1997
Gu et al 1998
Protein in hypoxia Increased Increased Increased
or decreased
Jiang et al 1996
Makino et al 2002
Specific co-factors HNF4, Smad3, 
STAT3, c-Myc
NEMO, CITED-2 - Warnecke et al 2008
Aprelikova et al 2006
Regulation by cytokines Th1 Th2 - Takeda et al 2010
Tissue distribution Ubiquitously 
expressed
Mainly lungs, heart, 
kidneys, liver
Mainly corneal 
retina, brain, heart, 
lung
Ema et al 1997
Makino et al 2001, 
Makino et al 2002
normoxia to 2.6 hours. Interestingly, HIF-2α is not changed by CoCl2 (18.2 hours in normoxia 
versus 17.2 hours), which means that sustained hypoxia decreases HIF-1α but not HIF-2α, mRNA 
stability (Uchida et al., 2004). Measuring the half-life of HIF-α mRNA in hypoxia-treated cells by 
inhibition of transcription after adding actinomycin D, revealed again that HIF-1α is less stable 
compared to HIF-2α with the half-life of approximately 160 minutes for HIF-1α mRNA, whereas 
HIF-2α mRNA remains relatively unchanged (Li et al., 2006). HIF-1α protein is more sensitive, 
whereas HIF-2α protein seems to be relatively resistant to degradation at oxygen levels that 
normally lead to degradation of HIF-1α (Lofstedt et al., 2007). HIF-α isoforms can also be 
differentially activated: HIF-1α is induced by Th1 cytokines in M1 macrophage polarisation; 
whereas HIF-2α is induced by Th2 cytokines during an M2 response (M1/M2 macrophage 
polarisation will be discussed in more details later) (Takeda et al., 2010). Major differences 
between the HIF α subunits are shown in Table 1-2. 
Table 1-2 Major differences between the HIF α subunits 
Abbreviation used in the table: HNF4 - hepatic nuclear factor 4, Smad3 - mothers against decapentaplegic 
homolog 3, STAT3 - signal transducer and activator of transcription 3, c-Myc, NEMO - NFκB essential 
modulator, CITED-2 - CBP/p300-interacting modulator, Th1 cytokines - pro-inflammatory cytokines, Th2 
cytokines - anti-inflammatory cytokines, kDa - kilo Dalton. 
 
 
 
 
 
 
 
 
 
The relative contribution of HIF isoforms to the development and establishment of cancer 
appears to be cancer type-specific. Particularly, Semenza et al provided (1) pre and/or clinical 
data associating increased HIF-1α levels with patient mortality; (2) molecular data linking 
specific HIF-1α target gene products to critical aspects of cancer biology (brain, breast, ovarian 
and bladder cancer) and (3) pharmacological data showing anticancer effects of HIF-1α inhibitors 
in mouse models of human cancer (Semenza, 2010). Another study made a comparative analysis 
of the functions of HIF-1α and HIF-2α in renal cell carcinoma (RCC) and non-RCC cells. They 
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showed that HIF-α isoforms display unexpected suppressive interactions in RCC cells, with 
enhanced expression of HIF-2α suppressing HIF-1α and vice-versa. In VHL-defective RCC cells, 
they demonstrated that the protumourigenic genes encoding cyclin D1, transforming growth 
factor α, and vascular endothelial growth factor respond specifically to HIF-2α and that the 
proapoptotic gene encoding BNip3 responds positively to HIF-1α and negatively to HIF-2α, 
indicating that HIF-1α and HIF-2α have contrasting properties in the biology of RCC.  
HIF-3α is less closely related and has been associated with a negative regulation 
mechanism of HIF induced gene transcription (Gu et al., 1998; Hara et al., 2001; Makino et al., 
2001; Makino et al., 2002). HIF-1α and HIF-2α are believed to be the main transcription factors 
as they contain all 4 domains required for the absolute activity of gene activation. HIF-3α also 
belongs to the bHLH-PAS family and consequently HIF-3α is able to dimerise with HIF-1α and 
HRE also activating HIF target gene expression, but to a lesser extent than HIF-1α and HIF-2α. 
Six transcript variants/isoforms of HIF-1α, one for HIF-2α, and six for HIF-3α have been 
identified. (Chun et al., 2002; Chun et al., 2001; Chun et al., 2003; Gothie et al., 2000; Iyer et al., 
1998b; O'Rourke et al., 1999; Tian et al., 1997; Wang and Semenza, 1995; Wiesener et al., 1998). 
Some of these isoforms lack parts of the ODD and the C-TAD but can dimerise with ARNT or 
HIF-1α. In this case, dimerisation leads to transcriptionally inactive heterodimers underlining a 
post-transcriptional regulatory mechanism, which inhibits the HIF target gene expression. One of 
these shortened isoforms is the human HIF-3α2, also known as inhibitory PAS protein (Gu et al., 
1998; Hara et al., 2001; Makino et al., 2001; Makino et al., 2002). A novel hypoxia-inducible 
product of the HIF-3α gene is expressed predominantly during embryonic and neonatal stages and 
thereby designated NEPAS (neonatal and embryonic PAS). Yamashita et al generated mice with a 
targeted disruption of the NEPAS/HIF-3α locus, and found that homozygous mutant mice 
(NEPAS/HIF-3α-/-) were viable but displayed enlargement of the right ventricle and impaired 
lung remodeling. The expression of endothelin 1 and platelet-derived growth factor β was 
increased in the lung endothelial cells of NEPAS/HIF-3α-null mice thus suggesting that negative 
regulation of endothelin 1 expression by NEPAS is important for lung development (Yamashita et 
al., 2008). 
1.4 HIF hydroxylases 
1.4.1 Discovery of HIF hydroxylases 
Since the discovery of HIF transcription factors in 1992 (Semenza and Wang, 1992), it 
was believed that HIFs were the main oxygen sensors controlling the response to hypoxia. Almost 
a decade passed before that view was changed. Further investigation into the regulation of HIF 
subunits brought a new idea on how the HIF pathway works, giving the primary role in sensing 
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hypoxia to a group of oxygen-dependent hydroxylases. It dates back in 1967 when Hutton et al 
reported an oxygenase-catalysed reaction that requires 2-OG while working with collagen prolyl 
hydroxylase (CPH) (Hutton et al., 1967). After the seminal work on CPH, 2-OG oxygenases were 
shown to mediate a wide variety of roles in plants and animals ranging from biosynthesis (Jenkins 
and Raines, 2002; Myllyharju and Kivirikko, 2004), metabolism (Schofield and McDonough, 
2007), oxygen sensing (Jaakkola et al., 2001; Masson et al., 2001) and DNA repair (Ringvoll et 
al., 2006; Sedgwick et al., 2007). Of relevance to this work is the role of HIF hydroxylases in 
oxygen sensing. In 1996, Jiang and co-workers found that levels of HIF-1α protein differ 
exponentially over a physiologically concentration range of O2 tension, suggesting a potential role 
for HIF as an oxygen sensor (Jiang et al., 1996). While investigating the oxygen-dependent HIF 
regulation, it was reported that hydroxyprolines (Ivan et al., 2001; Jaakkola et al., 2001; Masson 
et al., 2001) are approximately 100-fold more tightly bound by pVHL than non-hydroxylated 
prolines (Chan et al., 2002), accelerating the process of HIF protein ubiquitylation and 
degradation. In 2001, a conserved family of oxygen-dependent HIF hydroxylases responsible for 
post-translational modification of HIFs was identified (Bruick and McKnight, 2001; Epstein et al., 
2001; Lando et al., 2002a). These enzymes couple a two electron oxidation reaction to oxidative 
decarboxylation of 2-OG to release succinate and carbon dioxide and the other atom of oxygen is 
directly incorporated into the HIF-α unit as shown in Figure 1-4. 
 
   
 
 
 
Figure 1-4 Reaction catalysed by prolyl hydroxylase- containing enzymes 
In the presence of the co-substrate 2-oxoglutarate (2-OG) and co-factors (ascorbate and Fe2+), one atom of 
oxygen is added to substrate (e.g. HIF) and the second one to 2-OG, producing hydroxyprotein, succinate 
and releasing CO2. 
 
Since then it has been accepted that these enzymes are the key factors upstream of HIFs 
responding to fluctuations in oxygen levels and they became the main oxygen sensors. HIF-α 
undergoes hydroxylation of specific prolyl residues located within the ODD domain (Pro-
402/Pro-564 in the case of HIF-1α and Pro-405/Pro-530 in the case of HIF-2α) (Gaber et al., 
2005). This prolyl hydroxylation reaction is catalysed by oxygenases, PHDs. The reaction 
requires ferrous iron as a cofactor, and 2-OG and molecular oxygen as co-substrates. In addition 
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to hydroxylated HIF residue this reaction also produces succinate and carbon dioxide (Schofield 
and Ratcliffe, 2004). To date, there are four prolyl-hydroxylase domain containing enzymes, with 
a great amount of research carried out for PHD-1/2/3. 
An addition level of regulation is mediated by an asparaginyl hydroxylase designated 
factor inhibiting HIF-1 (FIH-1), identified by a two-hybrid screen as a protein that interacts with 
and targets the C-TAD and as a result inhibits HIF-α transactivation (Mahon et al., 2001). FIH-1 
catalyses β-carbon of a single conserved asparaginyl residue (McNeill et al., 2002). 
Hydroxylation of a specific asparagine residue located within the C-TAD (Asn-803 in case of 
HIF-1α, Asn-851 in case of HIF-2α) has been shown to prevent its interaction with the 
transcriptional co-activator p300/CBP thereby blocking HIF-α heterodimerisation with HIF-β and 
HIF transactivation under normoxic conditions (Ema et al., 1999). The crystal structure of FIH-1 
showed it to be a homodimeric protein with the hydroxylation site to form a loop conformation, 
contrasting with a helical conformation for the same residues when bound to p300/CBP (Elkins et 
al., 2003). One property of FIH-1 which contrasts with that of the PHD is its ability to remain 
functional even under hypoxic conditions that would render the PHDs inactive, and so might 
suppress the activity of HIF-α proteins that escape destruction in moderate hypoxia. 
1.4.2 Structural and functional properties of PHDs/FIH-1 
As previously mentioned, a great amount of research has been carried out for the first 
three PHD isoforms namely PHD-1, PHD-2 and PHD-3. These isoenzymes consist of 407, 426 
and 239 amino acids, respectively (Taylor, 2001). All PHDs demonstrate expression of several 
mRNA species due to alternative splicing or translation initiation with poorly understood function 
(Hirsila et al., 2003; Tian et al., 2006). Overall the PHDs show a 42–59% sequence similarity. 
PHD-2 is most closely related ancestrally to the HIF PHDs in Drosophila melanogaster and 
Caenorhabditis elegans (Taylor, 2001).  
Given the high Km values of PHDs (Hirsila et al., 2003), they respond fairly linearly to 
the wide range of physiological oxygen tension and thereby seem to be well suited as cellular 
oxygen sensors. Interestingly though, PHD-2 and PHD-3 have been shown to retain significant 
activity in hypoxic conditions (Appelhoff et al., 2004). All PHDs can hydroxylate HIF-α in vitro 
(Bruick and McKnight, 2001; Epstein et al., 2001; Hirsila et al., 2003; Huang et al., 2002). 
However, PHD-2 has been proposed to be the main regulator of HIF-1α, as silencing of PHD-2 is 
sufficient to induce HIF-α subunits in normoxia, whereas silencing of PHD-1 and PHD-3 had no 
effect on the stability of HIF-1α in normoxia or upon re-oxygenation of cells briefly exposed to 
hypoxia (Berra et al., 2003). 
It is now accepted that different PHDs have different specificities towards the different 
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HIF hydroxylation sites (Epstein et al., 2001; Hirsila et al., 2003; Masson et al., 2001). PHD-3 
mainly hydroxylates the C terminal hydroxylation site Pro-564 (Pro-530 in HIF-2α) and has 
essentially no activity on the N-terminal hydroxylation site Pro402 (Pro-405 in HIF-2α). No 
marked difference was found in the efficiencies of PHD-1 and -2 in this respect (Appelhoff et al., 
2004; Epstein et al., 2001; Hirsila et al., 2003). PHD-2 on the other hand has relatively more 
influence on HIF-1α than HIF-2α, whereas PHD-3 more efficiently regulates HIF-2α (Appelhoff 
et al., 2004). 
The expression of the three PHD isoforms has been studied at protein and mRNA levels 
in various normal human and murine tissues. PHDs have unique but also partially overlapping 
expression patterns. PHD-2 demonstrates the most abundant mRNA expression across tissues 
while the tissue distribution of PHD-1 and -3 is more restricted (Cioffi et al., 2003; Hirsila et al., 
2003; Lieb et al., 2002). PHD-1 mRNA is particularly abundant in the testis and placenta and is 
slightly less expressed in the brain, liver, heart and adipose tissue (Cioffi et al., 2003; Lieb et al., 
2002; Oehme et al., 2002; Willam et al., 2006). PHD-2 mRNA is widely expressed in most tissues 
and has a more uniform expression pattern, which seems particularly abundant in adipose tissue 
and heart. PHD-3 mRNA is also expressed at low level in many tissues but is most abundant in 
the heart and placenta and to a lesser extent in skeletal muscle and adipose tissue (Cioffi et al., 
2003; Lieb et al., 2002; Willam et al., 2006). With regard to the subcellular localisation of HIF 
hydroxylases, PHD-1 was found to be exclusively nuclear, PHD-2 and FIH-1 were mainly 
cytoplasmic, while PHD-3 was distributed evenly between the nucleus and the cytoplasm (Metzen 
et al., 2003a). Major differences between the HIF hydroxylases are summarised in Table 1-3. 
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Characteristic PHD-1 PHD-2 PHD-3 FIH-1
Size (amino acids) 407 426 239 348
Molecular weight (kDa) 43.6 46 27.3 40.6
Tissue distribution Testis Heart, adipose tissue Heart, placenta Ubiquitously 
expressed
Intracellular 
localisation
Cytoplasm
(Soilleux et al 2005)
Cytoplasm 
(Soilleux et al 2005)
Nucleus in hypoxia
(Yasumoto et al 2009)
Cytoplasm and
Nucleus
(Soilleux et al 2005)
Cytoplasm
(Soilleux et al 2005)
Presence of HRE - HRE
(Metzen et al 2005)
HRE
(Pescador et al 2005)
-
mRNA in hypoxia Unchanged Induced Induced Unchanged 
Protein in hypoxia Unchanged Induced Induced Unchanged 
Preferences towards 
HIF
HIF-2
(Appelhoff et al 2004,
Takeda et al 2008,
Aragones et al 2008)
HIF-1
(Berra et al 2003,
Hirsila et al 2003,
Appelhoff et al 2004)
HIF-2
(Appelhoff et al 2004,
Takeda et al 2008,
Bishop et al 2008)
HIF-1
(Koivunen et al 2004)
Interacting proteins Siah1/2
(Nakayama et al 2004)
FKBP38 
(Barth et al 2007)
ATF-4, Siah2
(Koditz et al 2007,
Nakayama et al 2007)
Siah1
(Fukuba et al 2007)
Non-HIF substrates IKK
(Cummins et al 2006)
IKK
(Cummins et al 2006)
Pax2 
(Yan et al 2011)
ARD
(Cockmann et al 2009)
Table 1-3 Major differences between the HIF hydroxylases 
Abbreviations used in the table: ARD - ankyrin repeat domain-containing proteins, ATF-4 - activating 
transcription factor 4, IKKβ - inhibitor of NFκB kinase beta, FKBP38 - FK506-binding protein 38, HRE - 
hypoxia-responsive element, Pax2 - paired box 2, Siah1 - seven in absentia homologue 1. 
 
 
 
 
 
 
 
 
 
 
 
The role of each of the four PHDs has been unveiled using a combination of either global 
knockout mice studies with deleted genes encoding Phds and Fih-1 or exploiting conditional gene 
strategy allowing for lineage-specific elimination of the gene of interest thus contributing to a 
better understanding of the roles between HIF hydroxylases.  
Aragones et al in 2008 showed that loss of PHD-1 lowers oxygen consumption in skeletal 
muscle cells by reprogramming glucose metabolism from oxidative to more anaerobic ATP 
production through activation of a peroxisome proliferator-activated receptors alpha (PPARα) 
pathway. This metabolic adaptation to oxygen conservation seemed to impair oxidative muscle 
performance in healthy conditions and that was the reason why mice bearing Phd1-/- skeletal 
muscle cells were less resistant to exercise. On the other hand Phd1 loss provided acute protection 
of myofibers against lethal ischemia. Hypoxia tolerance was found not to be due to HIF-
dependent angiogenesis, erythropoiesis or vasodilation, but rather due to reduced generation of 
oxidative stress, which allowed Phd1-deficient myofibers to preserve mitochondrial respiration. 
Hypoxia tolerance relied primarily on HIF-2α and was not observed in heterozygous Phd2-
deficient or homozygous Phd3-deficient mice. That study shed more light on the molecular 
mechanisms underlying the adaptations in response to hypoxia tolerance or oxygen conservation. 
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In general, oxygen conservation relies on a rapid, reversible metabolic switch from carbohydrate 
oxidation to anaerobic glucose utilisation to anaerobic glucose utilisation (Kim et al., 2006; 
Papandreou et al., 2006) through upregulation of pyruvate dehydrogenase kinases (PDKs) whose 
duty is to restrict the entry of glycolytic intermediates into the tricarboxylic acid (TCA) cycle 
(Sugden and Holness, 2006) . The major finding coming out from that mouse genetic study was 
that PHD-1 deficiency was the reason for PDK1 and PDK4 induction, thereby lowering oxidative 
glucose utilisation and oxygen consumption while at the same time unravelling a novel non-HIF 
related PHD-1 target namely PDKs. Overall, these findings highlighted a new role for Phd1 in 
hypoxia tolerance therefore offering new treatment perspectives for disorders characterised by 
oxidative stress (Aragones et al., 2008).  
Studies on the ubiquitin E3 ligase Siah (seven in absentia homolog) 1/2 showed that in 
hypoxia Siah determines the availability of PHD-1 and PHD-3 (Nakayama et al., 2004). To 
identify Siah2-interacting proteins coimmunoprecipation experiments followed by mass 
spectrometry were performed. That approach identified several enzymes associated with 
oxygenation and hydroxylation processes thus prompting testing the possibility that Siah could be 
involved in the regulation of PHD stability. Importantly, PHD-1 was degraded by both Siah1 and 
Siah2, although Siah2 was more potent in mediating the process (Nakayama et al., 2004). PHD-1 
was identified to be estrogen and tamoxifen inducible in breast cancer cells thereby stimulating 
proliferation in vitro (Seth et al., 2002); whether this mirrors an HIF-independent PHD-1 function 
still remains to be elucidated. PHD-1 was also shown to modulate NF-κB activity through 
inhibition of the upstream (IκB) kinase (IKK) β, possibly through hydroxylation therefore 
contributing to the expansion of the non-HIF targets (Cummins et al., 2006). The functional 
outcome of the PHD-1-mediating IKKβ hydroxylation in the setting of inflammatory immune 
response will be discussed later. 
With regard to Phd2, the Takeda group (Takeda et al., 2006) disrupted all three Phd genes 
and found that Phd2-/- embryos died between embryonic days 12.5 and 14.5 whereas Phd1-/- or 
Phd3-/- mice were apparently normal. In Phd2-/- mice, severe placental and heart defects 
preceded embryonic death. Placental defects included significantly reduced labyrinthine 
branching morphogenesis, widespread penetration of the labyrinth by spongiotrophoblasts, and 
abnormal distribution of trophoblast giant cells. The expression of several trophoblast markers 
was also altered. In the heart, trabeculae were poorly developed, the myocardium was thinner, and 
interventricular septum was incompletely formed. Since normal embryos are known to be under 
physiological hypoxia (Lee et al., 2001; Ryan et al., 1998) these findings indicate that PHD-2 is 
essential in the hypoxic environment during development. On the other hand, in vitro studies have 
shown that PHD-2 is mainly functional under normoxia (Appelhoff et al., 2004; Berra et al., 
2003) and that PHD-2 activity is severely inhibited by hypoxia (D'Angelo et al., 2003). To 
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explain this apparent controversy, authors proposed several models. In the first model, they 
suggest that the severity of hypoxia may vary both temporally and spatially during development 
and that PHD-2 is functional when and where oxygen supply is adequate. In a second model, even 
in hypoxic regions, PHD-2 may still be partially active, exerting its residual hydroxylase activity 
and imposing limits on HIF-α expression. A third possibility is that PHD-2 may have 
hydroxylase-independent functions, such as inhibition of HIF-1α transcriptional activity by direct 
binding interactions (Ozer et al., 2005; To and Huang, 2005). Particularly, it was found that the 
candidate tumour suppressor protein inhibitor of growth family member 4 (ING4) is implicated as 
a repressor of angiogenesis and tumour growth through association with NFκB in a PHD-2-
dependent manner. ING4 was found to directly associate with PHD-2; however, ING4 association 
with PHD-2 does not seem to affect hydroxylase activity or HIF stability. Instead, ING4 
recruitement by PHD-2 to HIF under hypoxic conditions, acts as an adapter protein to recruit 
transcriptional repressors to mediate HIF transactivity. These data support a model in which, in 
addition to regulating HIF stability, HIF prolyl hydroxylases can modulate HIF function through 
the recruitment of ING4, a likely component of a chromatin-remodeling complex (Ozer et al., 
2005) and a new PHD-2 target. Whereas PHD-1 proteolysis has been shown to be regulated by 
Siah2 ubiquitin E3 ligase-mediated polyubiquitylation and proteasomal destruction -as mentioned 
earlier- protein regulation of the PHD-2, remained unknown until 2009. It was reported that the 
FK506-binding protein (FKBP) 38 specifically interacts with PHD-2 and determines PHD-2 
protein stability in a peptidyl-prolyl cis-trans isomerase-independent manner, thus giving insight 
into the PHD-2 regulation and also identifying new PHD-2 interacting proteins (Barth et al., 
2009). Another post-transcriptional mechanism found to control PHD-2 protein levels is through 
TGFβ signaling via the Type I TGFβ receptor - a member of the activin-like receptor kinase 
(ALK) family of receptors that bind several distinct ligand families including TGFβs, activins, 
and bone morphogenic proteins- (Derynck and Zhang, 2003; Shi and Massague, 2003). In 
particular, it was found that Toxoplasma gondii infection increases HIF-1α stability through 
selective decrease of PHD-2 protein levels in a manner involving the ALK signalling (Wiley et 
al., 2010). 
To better understand the function of PHD-3 in vivo, Bishop et al (Bishop et al., 2008) 
created Phd3-/- mice and analysed the neuronal phenotype. Reduced apoptosis in superior 
cervical ganglion (SCG) neurons cultured from Phd3-/- mice was found to be associated with an 
increase in the number of cells in the SCG, as well as in the adrenal medulla and carotid body. 
Genetic analysis by intercrossing Phd3-/- mice with HIF-1a-/- and HIF-2a-/- mice demonstrated 
an interaction with HIF-2α but not HIF-1α, supporting the non-redundant involvement of a PHD-
3-HIF-2α pathway in the regulation of sympathoadrenal development. Despite the increased 
number of cells, the sympathoadrenal system appeared hypofunctional in Phd3-/- mice, with 
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reduced target tissue innervation, adrenal medullary secretory capacity, sympathoadrenal 
responses, and systemic blood pressure. These observations suggested that the role of PHD-3 in 
sympathoadrenal development extends beyond simple control of cell survival and organ mass, 
with functional PHD-3 being required for proper anatomical and physiological integrity of the 
system.  
Interestingly, unlike other PHDs, PHD-3 can induce apoptosis (Lee et al., 2005). For 
example, PHD-3 appears to be necessary for neuronal cells apoptosis after neuronal growth factor 
(NGF) withdrawal. PHD-3-mediated apoptosis, is not prevented by the simultaneous production 
of stabilized versions of HIF-1α, HIF-2α, or both, suggesting that PHD-3 might have targets other 
than HIF-α (Lee et al., 2005). Indeed, PHD-3 has been reported to bind to, and regulate the 
stability of, activating transcription factor 4 (ATF4) an important molecule in signaling by 
unfolded proteins within the endoplasmic reticulum (ER stress response) (Koditz et al., 2007). 
PHD-3 has also been reported to regulate myogenin a key-role player in myogenic differentiation 
(Fu et al., 2007). However, that PHD-3 can actually mediate hydroxylation of the above 
mentioned proteins needs further investigation. Among the divergent hydroxylation substrates of 
PHD-3 is also included the MAPK organizer 1 (MORG1), an interaction confirmed both in vitro 
and in vivo. MORG1 specifically interacts with PHD-3 most likely by acting as a molecular 
scaffold thus providing a molecular framework between HIF regulation and other signaling 
pathways (Hopfer et al., 2006). Moreover, in 2011 a novel role for PHD-3 in the regulation of 
glucose metabolism in cancer cells was unravelled. In particular, the Warburg effect, meaning the 
preference of tumour cells to rely almost completely on anaerobic glycolysis even in adequate 
conditions of oxygen was found to be dependent on the M2 isoform of the glycolytic enzyme 
pyruvate kinase PK-M2. PK-M2 was shown to associate directly with HIF-1α and HIF-2α, thus 
enhancing HIF-1α and HIF-2α binding to HREs, and promoting HIF-1α- and -2α-mediated gene 
transactivation. This effect was mediated by prolyl hydroxylation of PK-M2 by PHD3. 
Additionally, PK-M2 also appeared to indirectly bind p300, enhancing recruitment of p300 and 
further contribute to HIF-α transactivity. Depletion of either PK-M2 or PHD-3 resulted in a 
significant reduction of HIF-1α-dependent metabolic gene expression (Luo et al., 2011). 
Apart from the three well-described orthologues of PHDs, one more - namely proline 4-
hydroxylase (PH-4) or HIF-prolyl hydroxylase 4 (HIF-P4H)- was shown to suppress HIF activity 
through the same mechanism of hydroxylation of prolyl residues in the ODD domain in HIF-1α 
(Oehme et al., 2002). PH-4 is highly expressed in most organs, is upregulated by hypoxia but 
unlike the other PHDs it is anchored in the endoplasmic reticulum membrane with its catalytic 
domain located in the lumen rather than cytosol (Koivunen et al., 2007). Although PH-4 is known 
to hydroxylate the α subunit of HIF in vitro and in cultured cells, nothing was known about its 
roles in mammalian erythropoiesis.  It was very recently shown that administration of a HIF-PHD 
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inhibitor called FG-4497, to P4h-tm-/- mice caused larger increases in serum Epo concentration 
and kidney but not liver HIF-1α and HIF-2α protein and Epo mRNA levels than in wild-type 
mice, while the liver hepcidin mRNA level was lower in the P4h-tm -/- mice than in the wild type 
thus indicating a role in the regulation of EPO production, hepcidin expression and erythropoiesis 
(Laitala et al., 2012). 
In terms of FIH-1, Zhang et al (Zhang et al., 2010) generated mice with a null mutation in 
the FIH gene, and found that it has little or no discernible role in mice in altering classical aspects 
of HIF function, e.g., angiogenesis, erythropoiesis, or development. Rather, it is an essential 
regulator of metabolism as mice lacking FIH-1 exhibited reduced body weight, elevated 
metabolic rate, hyperventilation, improved glucose and lipid homeostasis, and were resistant to 
high fat diet-induced weight gain and hepatic steatosis. Moreover, neuron-specific loss of FIH-1 
phenocopied some of the major metabolic phenotypes of the global null animals. Those mice had 
reduced body weight, increased metabolic rate, enhanced insulin sensitivity, and were also 
protected against high fat diet-induced weight gain. These results demonstrated that FIH-1 acts to 
a significant degree through the nervous system to regulate metabolism.  
Proteins containing ankyrin repeat domain (ARD)-motifs within their structure have now 
been identified as alternative (non-HIF) FIH-1 substrates, including several IκB and Notch 
receptor family members (Cockman et al., 2006; Coleman et al., 2007; Ferguson et al., 2007; 
Zheng et al., 2008). Of note is that ARD proteins from both NFκB and Notch systems were found 
to compete with HIF-α for FIH-dependent hydroxylation and in most cases were actually better 
substrates than HIF-α in vitro (Loenarz and Schofield, 2008). For instance, evidence for FIH-
mediated ARD hydroxylation comes from a study showing that ASB4 (ankyrin repeat and SOCS 
box protein 4) can be targeted for hydroxylation by FIH. It is proposed that the functional 
outcome of that hydroxylation reaction is to enable FIH-1 to target proteins for ubiquitin-
mediated degradation in an oxygen-dependent fashion in an analogous manner to HIF-α prolyl 
hydroxylation (Ferguson et al., 2007). IκBα can also be hydroxylated by FIH-1; however, the 
functional effect of IκBα hydroxylation by FIH-1, in terms of effects on NFκB signaling, is still 
unclear and needs further investigation (Cockman et al., 2006). FIH-1 also catalyses 
hydroxylation of highly conserved asparaginyl residues within ARDs of endogenous Notch 
receptors. The net effect is a decrease in the extent of ARD binding to FIH-1 while not affecting 
signaling through the canonical Notch pathway. Therefore, ARD proteins function as natural 
inhibitors of FIH-1 and hydroxylation status of these proteins provides another oxygen-dependent 
interface that modulates HIF signalling (Coleman et al., 2007). In addition to HIF-1α interaction 
with the Notch intracellular domain as a mean to augment the Notch downstream response an 
additional level of complexity in that context has been revealed: FIH-1 regulates not only HIF 
activity, but also the Notch signalling output and in addition plays a role in how Notch signalling 
Chapter 1 
45 
Characteristic PHD-1 PHD-2 PHD-3 FIH-1
KO mice Viable
(Aragones et al 2008)
Lethal
(Takeda et al 2006)
Viable
(Bishop et al 2008)
Viable 
(Zhang et al 2010)
KO phenotype Hypoxia tolerance of 
muscles
Placental and heart 
defects
Decreased neuronal
cells apoptosis
Enhanced metabolic 
rate, reduced body 
mass
General function Hypoxic adaptation Angiogenesis Sympathoadrenal
development
Metabolic adaptation
modulates the hypoxic response (Zheng et al., 2008). It was very recently showed that FIH-1 
expression is upregulated in diseased epidermis and corneal epithelium and those elevated FIH-1 
levels in primary human epidermal keratinocytes (HEKs) and human corneal epithelial 
keratinocytes (HCEKs) impair keratinocyte in part, via a coordinate decrease in Notch signalling. 
Ectopically expression of microRNA-31 (miR-31) -an endogenous negative regulator of FIH-1 
expression- in an undifferentiated corneal epithelial cell line promoted differentiation and 
recapitulated a corneal epithelium in a three-dimensional raft culture model thus identifying a 
previously unknown mechanism for keratinocyte fate decisions where Notch signaling potential 
is, in part, controlled through a miR-31/FIH-1 nexus (Peng et al., 2012). The phenotype of the 
HIF hydroxylase knockout mice are summarised in Table 1-4. 
Table 1-4 HIF hydroxylase knockout mice  
 
 
 
 
 
1.4.3 Regulation of HIF hydroxylases 
1.4.3.1 Regulation of HIF hydroxylase activity 
The activity of PHDs and FIH-1 is regulated by the availability of substrates, including 
molecular oxygen, HIF and 2-OG, and by the presence of cofactors such as Fe2+ and ascorbate 
(Ivan et al., 2002; McNeill et al., 2002). Therefore any changes in these parameters interfere with 
reactions catalysed by these enzymes. Like every iron-dependent enzyme, hydroxylases bind Fe2+ 
which keeps the catalytic centre of the enzyme ready for substrate binding. Therefore any 
molecules chelating Fe2+ (iron antagonists) such as desferrioxamine (DFO) or 
dimethyloxaloyglycine (DMOG), CoCl2, Ni
2+ ions, NO or ROS, oxidising Fe2+ to Fe3+, act as 
PHDs/FIH-1 inhibitors. Recent data suggest that Co2+ does not affect intracellular iron pools 
directly, but depletes intracellular ascorbate, owing to metal-ion induced degradation (Salnikow et 
al., 2004). As ascorbate is maintaining iron in its active (reduced) Fe2+ state, it is essential for 
proper PHD and FIH-1 function.  
The fact that PHDs have an absolute requirement for the TCA cycle intermediate 2-OG, 
and that several glycolysis and TCA cycle metabolites can inhibit the enzyme activity of PHDs 
adds to the complexity of the oxygen sensing mechanism. These findings have recently shed light 
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to pathological mechanisms of particular cancer types. The glucose metabolites pyruvate, 
oxaloacetate, citrate, isocitrate, malate and fumarate all have been reported to inhibit PHDs by 
binding to the 2-OG sites of the enzymes (Dalgard et al., 2004; Hewitson et al., 2007; Isaacs et al., 
2005; Koivunen et al., 2004; Lu et al., 2005; Selak et al., 2005). However, there are differences as 
to which intermediates are the most potent ones as well as to which dioxygenases are 
preferentially inactivated. Fumarate and succinate have the most consistent effects. They inhibit 
all three PHDs competitively with respect to 2-OG but neither of them inhibits FIH. In contrast, 
FIH-1 seems to be more sensitive to citrate and oxaloacetate (Hewitson et al., 2007; Isaacs et al., 
2005; Koivunen et al., 2004).  
Nitric oxide has been known for some time to modify the hypoxic response. However, the 
outcome of increased nitric oxide in normoxia and hypoxia is still controversial. In normoxia 
nitric oxide causes stabilization of HIF but in hypoxia increased degradation, both of which may 
operate through the PHDs. The normoxic stabilisation of HIF is likely to occur by direct 
inhibition of the PHD-2 enzymatic activity perhaps by affecting the oxidation of iron (Berchner-
Pfannschmidt et al., 2007; Metzen et al., 2003b). In contrast, the hypoxic reduction in HIF 
accumulation that is observed with nitric oxide treatment has generated more controversy 
(Berchner-Pfannschmidt et al., 2008; Hagen et al., 2003; Sandau et al., 2001a). It has been 
proposed that nitric oxide, by inhibiting the mitochondrial respiration chain, allows more oxygen 
to be available for the PHDs in the proximity of the mitochondria. This would result in enhanced 
PHD activity and HIF degradation (Hagen et al., 2003). The proposed mechanism however, has 
not been fully supported by other studies (Doege et al., 2005). 
Interestingly, regulation of PHD activity can also be mediated through the Toll-like 
receptors (TLRs) signalling. TLRs are key components of the innate immune system that allow 
immune cells to specifically detect pathogens by recognizing their specific molecular patterns. 
HIF-1α is known to have a critical role in TLR downstream signalling by promoting energy 
metabolism, expression of pro-inflammatory cytokines and pro-angiogenic factors. Sumbayev et 
al (Nicholas and Sumbayev, 2010) reported that R848 (specific ligand)-induced activation of 
endosomal TLRs 7 and 8 (which recognize viral single-stranded RNA) and lipopolysaccharide 
(LPS)-induced activation of TLR4 (which specifically recognises LPS as a ligand) leads to 
downregulation of HIF-1α prolyl hydroxylation and degradation. In the case of TLR7/8, this 
downregulation is achieved through redox- and reactive nitrogen species (RNS)-dependent 
mechanisms. S-nitrosation of HIF-1α protein was also observed. In the case of LPS-induced 
TLR4 activation, only a redox-dependent mechanism was shown to be involved. RNS and p38 
MAP kinase (known to contribute to LPS-induced TLR4-dependent accumulation of HIF-1α 
protein) didn’t seem to have an effect on HIF-1α prolyl hydroxylation. Interestingly, 
downregulation of HIF-1α prolyl hydroxylation was correlated with a decrease in intracellular 
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iron (II). With regard to the ROS-mediated regulation of PHDs Finley et al reported that the 
mitochondrial deacetylase sirtuin-3 (SIRT3) destabilises HIF-1α by inhibiting ROS production, 
thereby promoting maximal prolyl-hydroxylase activity of PHDs. The net effect of SIRT3-
mediated HIF-1α destabilisation was a shift away from glycolytic metabolism and unchecked 
proliferation (Finley et al., 2011). 
1.4.3.2 Regulation of HIF hydroxylase expression 
Several microenvironmental factors, such as growth factors and hormones regulate PHD 
expression. PHD-1 mRNA levels are known to be oestrogen inducible (Appelhoff et al., 2004). In 
fact, PHD-1 was first cloned as an oestrogen-induced gene in a breast cancer cell line (Seth et al., 
2002). Out of the growth factors at least TGFβ1 has been shown to markedly down-regulate PHD-
2 mRNA and protein expression levels, thereby increasing the levels of HIF-1α as mentioned in 
Section 1.4.2 (McMahon et al., 2006). In particular, they demonstrated that TGFβ1 markedly and 
specifically decreased both mRNA and protein levels of PHD-2, through the Smad signaling 
pathway. Moreover, inhibition of the TGFβ1 converting enzyme, furin, resulted in increased 
PHD-2 expression, and decreased basal HIF-1α and VEGF levels, suggesting that endogenous 
production of bioactive TGFβ1 efficiently regulates HIF-1-targeted genes. This was reinforced by 
results from HIF-1α knock-out or HIF-1α inhibited cells that show impairment in VEGF 
production in response to TGFβ (McMahon et al., 2006).  
1.5 Hypoxia/HIF in inflammation and immunity 
The concept that hypoxia and inflammation may interact has gained general acceptance 
from studies of the hypoxia signaling pathway. In persons with mountain sickness, for example, 
levels of pro-inflammatory cytokines increase, and “vascular leakage” causes pulmonary or 
cerebral edema (Grocott et al., 2009; Hackett and Roach, 2001; Semenza, 2007). Increased serum 
levels of pro-inflammatory mediators were observed in healthy persons who volunteered to spend 
3 nights at high altitude (higher than 3400 metres) (Hartmann et al., 2000). Moreover, vascular 
leakage, accumulations of inflammatory cells in multiple organs, and elevated serum levels of 
cytokines occur in mice after short-term exposure to low oxygen concentrations (Eckle et al., 
2008; Eltzschig et al., 2005; Eltzschig et al., 2003; Rosenberger et al., 2009; Thompson et al., 
2004). Of clinical relevance, ischemia in organ grafts increases the risk of inflammation leading to 
graft failure or rejection. In patients undergoing kidney transplantation, the renal expression of 
TLR4 was shown to correlate with the severity of ischemic injury (Kruger et al., 2009). Just as 
hypoxia can induce inflammation, inflamed lesions often become severely hypoxic. In 
inflammatory bowel disease for example, not only does the entire mucosa becomes hypoxic, but 
surgical specimens of the inflamed intestine contain elevated levels of HIF-1α and HIF-2α 
(Giatromanolaki et al., 2003b). The co-existence of hypoxia and inflammation is well 
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characterised in a wide range of pathological conditions including solid tumours, healing wounds, 
ischemic conditions - cerebral ischemia, stroke, myocardial infarction- atherosclerotic plaque 
formation and RA (Harris, 2002). The latter will be discussed in more detail in Section 1.6. The 
activation of the innate/adaptive immune system in response to the pathological conditions 
mentioned above is mainly mediated by the cells comprising these systems and therefore 
inevitably exposed to Hypoxia/HIF affecting their functions and gene transcription programs.  
Cells of the innate immune system can rapidly eliminate pathogens and amplify the 
adaptive immune response. Such cells are neutrophils, macrophages, mast cells, dendritic cells 
(DC), and natural killer (NK) cells. The first indication that HIF plays a role in the behaviour of 
these cells came from a study by Cramer et al in 2003. In that seminal study, a conditional gene 
targeting strategy exploiting Cre–LoxP recombination was used for lineage specific elimination of 
HIF-1α in macrophages and neutrophils. A mouse line was engineered to contain LoxP sites 
flanking the Hif1a gene, and these mice were then crossed with mice in which the myeloid cell 
specific lysozyme M promoter drives Cre recombinase expression. The resultant mice, which 
showed markedly decreased HIF-1α expression levels specifically in myeloid cells, had no 
obvious phenotypic abnormalities under normal conditions, but showed marked aberrations in 
experimental models of acute inflammation. In contrast to their wild type littermates, mice with a 
myeloid cell Hif1a conditional deletion did not develop severe joint swelling and cartilage 
destruction in the collagen induced arthritis (CIA) model of RA and showed no cutaneous redness 
or oedema following application of a chemical irritant to the skin, indicating impaired 
inflammatory responses. The HIF-1α deficient macrophages and neutrophils had lower levels of 
cellular ATP (15–40% of wild type levels), highlighting the crucial role of the transcription factor 
for energy generation through glycolysis in these immune cells (Cramer et al., 2003). Therefore, it 
can be assumed that HIF-1α allows myeloid cells to generate ATP in oxygen-deprived inflamed 
tissues, thereby stimulating the aggregation, motility, and invasiveness of myeloid cells. 
Neutrophils and macrophages are not only participants in acute and chronic inflammatory 
pathologies but are also key-role players of innate host defence against invading microbial 
pathogens. As already mentioned, markedly lower levels are characteristic of wounds and sites of 
infection. Thus, phagocytic cells must be adapted to generate energy and function effectively in 
oxygen deprived conditions, especially as many common bacterial pathogens proliferate readily in 
anaerobic microenvironments. Peyssonnaux et al in 2005 (Peyssonnaux et al., 2005) when 
challenging mice with a myeloid cell Hif1a conditional deletion subcutaneously with group A 
streptococcus, found that these mice not only were unable to eradicate these bacterial loads but 
instead supported the formation of more necrotic areas and lesions. Conversely, activation of the 
HIF-1α pathway through deletion of vHL tumour-suppressor protein or pharmacologic inducers 
supported myeloid cell production of defence factors and improved bactericidal capacity 
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(Peyssonnaux et al., 2005). These data were further confirmed in 2007 by Anand et al by 
knocking down HIF-1α RNA, which reversed effects of hypoxia on phagocytosis (Anand et al., 
2007). 
Additionally, HIF-1α regulates several crucial functions of neutrophils. It was in 2005 
when Walmsley et al found that HIF-1α also prolongs the lifespan of neutrophils in hypoxic 
conditions by inhibiting apoptosis (Walmsley et al., 2005). They examined the mechanism by 
which hypoxia causes an inhibition of neutrophil apoptosis in human and murine neutrophils. 
Using HIF-1α-deficient myeloid cells they demonstrated that HIF-1α is directly involved in 
regulating neutrophil survival in hypoxia through NFκB activation since inhibition of NFκB by 
gliotoxin or parthenolide resulted in the abrogation of hypoxic survival (Walmsley et al., 2005). 
In addition to the ATP-dependent loss of function and diminished migratory potential observed in 
mice bearing HIF-1α-deficient myeloid cells used in the Cramer study, these data suggest that a 
second mechanism, namely decreased neutrophil survival, may also contribute to the impaired 
inflammatory response observed in these animals. The ability of HIF to promote neutrophil 
survival is not only observed under hypoxic conditions but also in response to normoxia. It was 
the same group (Walmsley et al., 2005) found that in vHL disease, neutrophils are also 
characterised by reduced apoptosis and enhanced phagocytosis of bacteria under normoxic 
conditions, presumably owing to the failure to degrade HIF-1α (Walmsley et al., 2006). The same 
group recently reported a role for PHD-3 in the hypoxic regulation of neutrophilic inflammation 
in humans and mice. They examined PHD expression in human neutrophils and found that PHD-3 
was strongly induced in response to hypoxia and inflammatory stimuli in vitro and in vivo. Using 
neutrophils from mice deficient in Phd3, they demonstrated a unique role for Phd3 in prolonging 
neutrophil survival during hypoxia, distinct from other hypoxia-associated changes in neutrophil 
function and metabolic activity. In vivo, using an acute lung injury model, they observed 
increased levels of neutrophil apoptosis and clearance in Phd3-deficient mice compared with wild 
type controls. They also observed reduced neutrophilic inflammation in an acute mouse model of 
colitis thus proposing a novel function for PHD-3 in regulating neutrophil survival in hypoxia 
which might contribute to the development of new therapeutics for inflammatory disease 
(Walmsley et al., 2011). Additionally, in neutrophils, HIF induces β2 integrin expression and 
thereby promotes neutrophil binding to the epithelium (Kong et al., 2004). Moreover, HIF 
increases neutrophil expression of antimicrobial molecules such as cathelicidin peptides and the 
granule proteases cathepsin G and elastase (Peyssonnaux et al., 2005).  HIF markedly increases 
the release of pro-inflammatory cytokines and the expression of costimulatory molecules by 
murine DCs, enhancing their ability to induce allogeneic lymphocyte proliferation and therefore 
helping to bridge innate and adaptive immune responses (Jantsch et al., 2008). 
A growing body of evidence suggest that HIF is a key regulator of the intrinsic immune 
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and inflammatory responses in various non-myeloid cell types, including tissue epithelial cells 
and other specialised leukocytes. In response to bacterial pathogens, keratinocytes produce 
peptides of the cathelicidin and β-defensin family that can directly kill microbial pathogens (Braff 
et al., 2005). HIF is expressed at high levels in the skin, which is a hypoxic organ even in non-
inflammatory settings (Peyssonnaux et al., 2008). Following targeted deletion of Hif1a in 
keratinocytes, mice show a defect in controlling necrotic skin infection by group A streptococci 
(Peyssonnaux et al., 2008). 
Evidence has recently emerged supporting a role for HIF in driving the differentiation of 
T-cells -known to constitute central components of inflamed sites such as RA synovium 
contributing to the chronic nature of inflammatory diseases - towards the disease-promoting Th17 
phenotype. For example, mice selectively lacking HIF-1α in T-cells were resistant to 
experimental autoimmune encephalomyelitis. This was suggested to be due to the ability of HIF-
1α to drive T-cell differentiation towards the disease-promoting Th17 phenotype. Particularly, 
HIF-1 enhances Th17 development through direct transcriptional activation of RORγt and via 
tertiary complex formation with RORγt and p300 recruitment to the IL-17 promoter, thereby 
regulating Th17 signature genes. Concurrently, HIF-1 attenuates Treg development by binding 
Foxp3 and targeting it for proteasomal degradation. Importantly, this regulation occurs under both 
normoxic and hypoxic conditions. (Dang et al., 2011; Shi et al., 2011; Yin and Li, 2011).  
1.5.1 Hypoxia and macrophages 
1.5.1.1 M1/M2 macrophage polarisation 
Macrophages demonstrate considerable plasticity allowing them to respond efficiently to 
a huge variety of environmental cues as well as exerting their phagocytic and regulatory functions 
under a wide variety of tissue conditions. Adverse microenvironmental conditions, including 
reduced oxygen levels, are situations that myeloid cells have to cope with upon migrating to the 
tissue, the milieu of which can be either physiological or inflamed (Harris, 2002; Le et al., 2004; 
Vaupel and Hockel, 2003). Therefore, macrophages need be able to quickly adapt to the wide 
range of O2 tensions - present in the surrounding microenvironment - and efficiently exert their 
functions. Hypoxia seems to strongly affect their functions and critically modulate their 
transcriptional, metabolic polarisation status in order to elicit specific responses under different 
conditions (Pugh and Ratcliffe, 2003; Sitkovsky and Lukashev, 2005; Takeda et al., 2011). 
Environmental signals such as changes in oxygen tension can give rise to different populations of 
macrophages (i.e. polarisation) with distinct functions, although Mosser et al in 2008 favours the 
idea of a continuum of macrophage polarisation resulting from the incorporation of various 
signals from the surrounding environment (Mosser and Edwards, 2008).  
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Mimicking the T-cell literature, macrophages have been classified as either M1 or M2 
macrophages. M1 macrophage classification refers to classically activated macrophages whereas 
M2 designation refers to alternatively activated macrophages (Gordon, 2003). What should be 
noted is that there may be different levels of activation allowing for the existence of macrophage 
populations sharing characteristics of both macrophage populations, thus forming the basis of a 
spectrum of macrophage activation (Mosser and Edwards, 2008). In the presence of interferon-γ 
(IFNγ) and TNF, the macrophage population is characterised by enhanced 
microbicidal/tumouricidal capacity and secretion of high levels of pro-inflammatory cytokines 
and mediators such as IL-1β, TNF, IL-6, IL-12, IL-15) (Mackaness, 1977; O'Shea and Murray, 
2008). IFNγ can be of either innate (NK cells) or adaptive (Th1 cells) immune cell origin (Dale et 
al., 2008). M1 macrophages are characterised by enhanced ability to kill intracellular micro-
organisms and exhibit pro-inflammatory properties. Classically activated M1 macrophages also 
stimulate delayed-type hypersensitivity responses, and have increased surface levels of MHC 
class II molecules as well as expression of markers such as inducible nitric oxide synthase 
(iNOS). These classically activated macrophages are crucial players of host defence, but their 
activation must be tightly controlled because the cytokines and mediators that they produce can 
lead to host-tissue damage (Kolls and Linden, 2004). M2 or alternatively activated macrophages 
arise in the presence of innate or adaptive immune signals. Th2-derived cytokines like IL-4 and 
IL-13, as well as IL-10, TGFβ, macrophage colony stimulating factor (M-CSF) and 
glucocorticoids, are the most common stimuli for the generation of an M2 macrophage population 
(Fleetwood et al., 2009; Fleetwood et al., 2007). Basophils and mast cells are the most important 
early sources of innate IL-4 production, although other granulocytes might also contribute (Brandt 
et al., 2000). They are characterised by a more anti-inflammatory phenotype with scavenging, 
tumour-promoting, tissue repair and pro-angiogenic properties (Gordon, 2003; Gordon and 
Martinez, 2010; Mantovani et al., 2002; Verreck et al., 2004).  
Other groups have extended the definition of alternative macrophage activation very 
loosely to include additional mediators of macrophage function, such as IL-10, 
glucocorticosteroids and TGF-β (Goerdt and Orfanos, 1999). There was a need for a more refined 
nomenclature of M2 macrophages as each stimulus induces both unique and overlapping gene 
expression repertoires. Mantovani and colleagues suggested a further subdivision of M2 
macrophages into M2a (IL-4/IL-13 stimulated, alternatively activated macrophages), M2b 
(immune complexes, TLR ligand or IL-1β stimulated, type II activated macrophages) and M2c 
(IL-10 stimulated, deactivated macrophages) (Mantovani et al., 2004) (Figure 1-5). In addition to 
the M2 macrophage subtypes discussed above, tumor-associated macrophages (TAMs) are 
considered to have an M2-like phenotype. TAMs are recruited into the tumor environment as 
monocytes from the bloodstream by chemoattractants by both malignant and stromal tumors. 
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Several studies have indicated that tumors provide a cytokine environment which favours an 
alternative activation of macrophages. For example, TAMs upregulate the expression of IL-10, 
TGF-β and other M2-associated genes while downregulating IL-12 expression, antigen 
presentation, antimicrobial and antitumor properties (Biswas and Mantovani, 2010; Gordon and 
Martinez, 2010; Hagemann et al., 2009; Mantovani et al., 2002). 
 
 
 
 
 
 
 
 
Figure 1-5  Inducers and selected properties/functions of polarized macrophages 
Macrophage exposure to IFN-γ and LPS drives M1 polarisation equipping them with cytotoxic and 
antitumoral properties. In contrast, M2 macrophages are in general more prone to immunoregulatory and 
immunosuppressive functions. In particular, M2a (exposure to IL-4/IL-13) and M2b (exposure to immune 
complexes and TLR ligands) exert immunoregulatory functions and drive Th2 responses, whereas M2c 
(exposure to IL-10 or Glucocorticosteroids) are more related to suppression of immune responses and tissue 
remodelling. 
 
A major distinguishing feature between M1/M2 macrophage populations is the metabolic 
fate of arginine. iNOS – primarily expressed by M1 macrophages - produces NO by metabolising 
its substrate, the amino acid L-arginine (Bronte and Zanovello, 2005). Macrophages also have 
another arginine-metabolising enzyme, arginase1 (Arg1), which is expressed at high levels by M2 
macrophages to generate ornithine and urea (Durante et al., 2007), precursors of polyamines and 
collagen, thereby contributing to the production of the extracellular matrix (Kreider et al., 2007). 
Therefore, there is a competition between Arg1 and iNOS for their common substrate arginine  
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(Bansal and Ochoa, 2003). With regard to expression, M‑CSF normally circulates at detectable 
levels under homeostatic conditions, and it is constitutively produced in vitro by several cell 
types, including fibroblasts, endothelial cells, and macrophages thus supporting the idea that 
macrophages are M2-preconditioned. By contrast, the production of GM‑CSF to induce the M1 
phenotype usually requires stimulation, for example by IL-1 or LPS (Metcalf, 1995).  
1.5.1.2 HIF-α isoform expression in monocytes/macrophages 
HIF-1α is expressed abundantly by macrophages in most rheumatoid synovia, 
predominantly close to the intimal layer but also in the subintimal zone, thus suggesting that HIF-
1α could serve as an important new therapeutic target in RA, targeting both angiogenesis and 
inflammation. Expression of HIF-1α is markedly lower in OA synovia, and it is absent from all of 
the healthy synovia (Brouwer et al., 2009; Hollander et al., 2001). The relative contribution of 
each of the HIF-α isoforms to the overall regulation of macrophage functions still remains under 
debate. HIF-2α was apparently the predominant isoform to be expressed by hypoxic PMA-treated 
U937 cells, shown by Western blotting and immunostaining but it is not clear if HIF-1α was 
assessed (Talks et al., 2000). However, another study shows that human macrophages accumulate 
higher levels of HIF-1α than HIF-2α when exposed to tumour-specific levels of hypoxia in vitro 
(Burke et al., 2002b). Additionally, these authors showed that expression from HRE-driven 
reporter constructs in the human macrophage-like cell line MonoMac 6 correlates more closely 
with HIF-1α than with HIF-2α up-regulation under hypoxia thus placing HIF-1α as the major HIF 
in macrophages (Burke et al., 2002b). Using a variety of solid tumours, including bladder, brain, 
breast, colon, ovarian, pancreatic, prostate, and renal carcinomas, nuclear expression of HIF-1α 
and -2α was observed in varying subsets of the tumour cells. HIF-2α was also strongly expressed 
by subsets of tumour-associated macrophages, sometimes in the absence of any tumour cell 
expression (Talks et al., 2000). However, Burke et al provided data showing expression of HIF-1α 
by tumour associated macrophages (TAMs) in tumour sections (Burke et al., 2002b). TAMs 
constitute major infiltrates of tumours and exhibit a mix M1/M2 phenotype, with the M2 
signature being the most predominate one. TAMs stimulate tumor angiogenesis (Lin et al., 2006), 
and high TAM numbers correlate with a poor prognosis in cancer patients (Bingle et al., 2002). 
Werno et al in 2010 generated tumour-associated macrophages (TAMs) from CD11b splenocytes 
infiltrating breast tumour spheroids. Conditional (myeloid-specific) HIF-1α-/- macrophages 
expressed higher levels of the macrophage M2 markers CD206 and stabilin-1 compared to wild 
type. Stimulation of infiltrated TAMs with LPS/IFNγ revealed reduced expression of IL-6, TNF 
and iNOS in HIF-1α-/- macrophages. HIF-1α-/- macrophages were less cytotoxic towards tumour 
cells. Ability to stimulate differentiation of stem cells towards CD31 positive cells was triggered 
by wild type but not by HIF-1α-/- macrophages, suggesting differential roles of HIF-1α and HIF-
2α in inflammation versus angiogenesis respectively (Werno et al., 2010b). The same group also 
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showed that mice lacking HIF-2α in myeloid cells were resistant to LPS-induced endotoxemia 
and displayed inability to mount inflammatory responses to cutaneous and peritoneal irritants. 
Furthermore, M1 cytokines activated bone marrow-derived macrophages (BMDM) to increase 
IL-1 and IL-12, and synergised with hypoxia, and this synergy was diminished in HIF-2α-/- cells 
(Imtiyaz et al., 2010). A highly proangiogenic TAM subset, the TIE2-expressing macrophages 
(TEMs), are present in a variety of mouse and human tumors (De Palma et al., 2005; De Palma et 
al., 2003) and physically interact with newly forming tumor blood vessels (De Palma et al., 2005; 
De Palma et al., 2003) and express high levels of several proangiogenic factors (Coffelt et al., 
2010). Increased TEM infiltration occurs in mouse glioblastoma following high-dose radiation 
therapy and is associated with tumor revascularization and relapse (Kioi et al., 2010). TEMs have 
also been implicated in the regrowth of subcutaneous breast and lung carcinomas after local 
irradiation. Lewis et al in 2011 showed that TEMs limit the therapeutic efficacy of the vascular-
disrupting agent combretastatin A4 phosphate in tumor-bearing mice (Welford et al., 2011). A 
study in 2008, comparing the effects of hypoxia on HIF-α isoforms expression between human 
monocytes and macrophages showed that primary human macrophages but not monocytes 
upregulated both HIF-α proteins in response to hypoxia, and that these proteins were then 
translocated to the nucleus. Of note is that compared to HIF-1α, HIF-2α expression was prolonged 
and persisted with re-oxygenation (Elbarghati et al., 2008). In contrast, a recently published study 
provided data showing that monocytes were also able to stabilise HIF-1α which remained 
exclusively in the cytoplasm, compared to HIF-1α expression by 7 days MCSF-differentiated 
macrophages which was mainly nuclear (Fangradt et al., 2012).  
1.5.1.3 Hypoxia/HIF-mediated responses in monocytes/macrophages 
In an effort to characterise the molecular bases underlying monocyte functions within a 
hypoxic microenvironment, Bosco et al investigated the transcriptional profile induced by 
hypoxia in primary human monocytes using high-density oligonucleotide microarrays. This study 
revealed expression of known hypoxia-responsive genes including adrenomedullin (ADM), 
BNIP3, IL-1, LDH, PDK1, PGK1, PHD-2, TNF, VEGF, and VEGF receptor (VEGFR) 1. New 
genes involved in immune responses included scavenger receptors, cytokines and chemokines, in 
particular CCL20/MIP-3α (a chemoattractant for immature dendritic cells, activated/memory T 
lymphocytes, and naive B cells) also appeared to be upregulated following hypoxia exposure 
(Bosco et al., 2006). On the other hand, Fang et al studying the gene expression profile in primary 
human and murine macrophages in response to hypoxia they found molecules being upregulated 
including the cell surface receptors, CXCR4 and GLUT1, and the potent, tumour-promoting 
cytokines, VEGFA,  IL-1β, IL-8, ADM, CXCR4, and angiopoietin-2 (Fang et al., 2009). A study 
comparing the survival potential among murine BMDM, human monocytes and human 
monocyte-derived macrophages (MDM) showed that hypoxia prolongs the survival of murine 
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BMDM an effect requiring shifting of metabolism to anaerobic glycolysis. Human monocytes 
responded similarly to low oxygen, and a number of genes associated with glycolysis were shown 
by microarray analysis and quantitative PCR to be upregulated including GLUT1, LDH, PGK. 
Interestingly, human MDM showed evidence of enhanced glycolysis even under aerobic 
conditions (Roiniotis et al., 2009).  
The contribution of HIF factors to macrophage polarisation is evident in the case of 
tumour-associated macrophages that normally exhibit an M1/M2 mixed polarisation phenotype. 
In the case of HIF-1α, HIF-1α-deficient macrophages develop a more prominent TAM marker 
profile (M2-skewed) together with reduced cytotoxicity, but also display reduced angiogenesis-
promoting TAMs (Werno et al., 2010a). HIF-2α has also been described as an important 
component for TAM migration by increasing M-CSF receptor and the chemokine receptor 
CXCR4, thus suggesting a role for HIF-2α in promoting tumour progression (Imtiyaz et al., 
2010). As previously mentioned, enhanced killing ability -a characteristic of M1 macrophages- is 
mainly HIF-1α-dependent as HIF-1α-deficient macrophages exhibited reduced antibacterial 
function (Peyssonnaux et al., 2005). 
1.5.1.4 Convergence between hypoxia and the NFκB signalling pathway 
The presence of hypoxia and HIF expression against a background of inflammation has 
prompted the question of whether hypoxia can activate signaling pathways other than the HIF 
cascade. Of particular relevance in inflammation is the dynamic interplay between HIF and the 
NFκB pathways. The NFκB pathway is activated in many different cells, including macrophages, 
DC, fibroblasts and endothelial cells, important components in the establishment and progression 
of RA. Activation of this key transcription factor can be induced by a large number of stimuli, 
including bacterial products, viral molecules and pro-inflammatory cytokines. In the canonical 
pathway of NFκB activation, activity of this protein is controlled by inhibitor of NFκB (IκB) 
kinases IKK, mainly IKK2 (also known as inhibitor of NFκB kinase subunit β), which mediates 
serine phosphorylation and degradation of IκBα, the natural inhibitor of NFκB. IκBα degradation 
enables nuclear accumulation of NFκB, which in turn regulates the expression of many pro-
inflammatory genes and growth factors important for the activation of immune responses, cell 
survival and angiogenesis. Genes under the control of NFκB include TNF, as well as other 
cytokines (IL-6, IL-8), chemokines and angiogenic factors such as VEGF and matrix degrading 
enzymes (MMP1, MMP3, MMP13) (Simmonds and Foxwell, 2008). 
Hypoxia has been shown to drive NFκB activation and thereby regulate the release of 
critical pro-inflammatory mediators (Oliver et al., 2009; Taylor, 2008). The very first indication 
that HIF induces NFκB activation came from Walmsley et al providing data showing that hypoxia 
promotes human neutrophil survival, an effect requiring HIF α-dependent regulation of IκBα and 
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NFκB (Walmsley et al., 2005); however, activation might not follow the canonical pathway, but 
could involve tyrosine phosphorylation of IκBα, instead of serine phosphorylation (Koong et al., 
1994). A study showing NFκB activation by hypoxia in the absence of IκBα degradation, which 
involved IKK and the upstream IKK kinase TAK1 (also known as NR2C2) has formed the basis 
for a series of studies supporting the involvement of other possible pathways (Culver et al., 2010). 
Furthermore, the participation of HIF hydroxylase PHDs in NFκB activation has been proposed 
(Cummins et al., 2006; Oliver et al., 2009). Indeed, within its activation loop, IKK2 contains an 
evolutionarily conserved LxxLAP consensus motif that can potentially be hydroxylated by PHD, 
although it has yet to be demonstrated that PHD can actually modify IKK. Mimicking hypoxia by 
treatment of HeLa cells with small interfering RNA against PHD-1 or PHD-2 resulted in NFκB 
activation via serine phosphorylation-dependent IκBα degradation (Cummins et al., 2006). This 
finding is supported by other similar studies (Fu and Taubman, 2010; Xue et al., 2010), which 
suggests that PHD might negatively regulate IKK via prolyl hydroxylation. Other studies have 
also suggested that HIFα is not the only target for asparaginyl hydroxylation by FIH1. Other 
proteins with an ankyrin repeat domain within their structure can also be hydroxylated by FIH1, 
including IκBα (Cockman et al., 2006; Ferguson et al., 2007). However, the functional effect of 
IκBα hydroxylation by FIH-1, in terms of effects on NFκB signaling, is still unclear and needs 
further investigation. 
Potential candidates for the NFκB activation in the setting of RA include mainly 
cytokines, which are likely to cause a vicious cycle of signals that result in chronic inflammation 
(Simmonds and Foxwell, 2008). Moreover, hypoxia, which is a feature of RA which leads to 
transcription of HIF-dependent genes is a potential stimulus of NFκB signaling, possibly due to 
the derepression of IKK2 as a consequence of inactivity of oxygen-dependent PHD. Together, 
activation of NFκB and HIF by converging hypoxic and inflammatory signaling pathways 
probably leads to pathological changes associated with RA, such as inflammation, angiogenesis 
and bone or cartilage destruction. 
On the other hand, a number of studies have also suggested that NFκB activates the HIF 
pathway. ROS activate HIF-1α via NFκB in smooth muscle cells (Bonello et al., 2007). The 
involvement of IKK2 and NFκB in HIFα stabilisation in hypoxic conditions has also been 
confirmed in mice, raising the possibility that the observed normoxic stabilisation of HIF-1α in 
most cell types might be due to NFκB activity (Rius et al., 2008).  
In summary, crosstalk between the HIF α and the NFκB pathway is now well recognised. 
Understanding all the different aspects of the hypoxia/HIF pathway regulation and the crosstalk 
with other inflammatory signaling pathways will shed more light on the complex molecular 
mechanisms involved in inflammatory diseases such as RA. 
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1.6 RA: the pathogenesis and the dynamic interplay between 
hypoxia, inflammation and angiogenesis 
The pathophysiological role of angiogenesis and hypoxia in diseases such as cancer and 
RA is now well documented. Hypoxia is a feature of diseases where increased tissue mass and 
cellular metabolism result in oxygen demand exceeding supply. In RA, the synovial tissue 
increases to several cell layers, due to a combination of cellular hyperproliferation of the synovial 
resident fibroblasts and cellular infiltration including T cells and monocytes (Feldmann, 2002). 
The increase in synovial tissue mass, results in increased oxygen consumption by RA synovium 
(Lee et al., 2007) thus contributing to a hypoxic synovial microenvironment. It is now accepted 
that synovial fluids from RA patients are characterised by low oxygen tension (Lund-Olesen, 
1970) and the advent of more sophisticated techniques supported the presence of an anaerobic 
synovial microenvironment (Hitchon et al., 2009). Synovial hypoxia is probably one of the main 
driving forces behind angiogenesis in RA. VEGF is one of the best characterised HRE-containing 
genes, and increased levels of VEGF and VEGF receptors in RA have been described (Fava et al., 
1994; Koch et al., 1994; Kurosaka et al., 2010; Paleolog et al., 1998). In fact, hypoxia drives the 
expression of many other pro-angiogenic mediators including the chemokines IL-8 (also known 
as CXC-chemokine ligand 8 or CXCL8) (Ahn et al., 2008), CC chemokine ligand 20 (CCL20) 
(Bosco et al., 2008) and SDF1 (del Rey et al., 2009; Santiago et al., 2011). Synovial hypoxia is, 
therefore, likely to contribute to RA by promoting inflammation, angiogenesis, cellular infiltration 
(through induction of chemokines) and cartilage degradation. The mechanisms of RA 
pathogenesis are illustrated in Figure 1-6. Hypoxia-mediated angiogenesis via enhanced blood 
vessel formation facilitates tissue oxygen delivery thus contributing to repair of injured tissues, 
which is a characteristic function of M2 macrophages.  HIF factors induce the expression of 
proangiogenic molecules such as VEGF. However, a differential role for macrophage HIF-1α and 
HIF-2α in proangiogenic capacity has been reported (Eubank et al., 2011), raising the possibility 
that hypoxia, canonically thought to promote angiogenesis, also stimulates antiangiogenic 
molecules from macrophages. In this regard, HIF-1α exhibits proangiogenic behaviour via its 
effects on VEGF secretion, but HIF-2α would display anti-angiogenic behaviour through the 
production of the endogenous angiogenesis inhibitorsVEGFR-1 (Eubank et al., 2011). 
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However, the theory that activation, rather than inhibition, of the HIF pathway could be 
of therapeutic benefit is worth mentioning. The first evidence confirming the beneficial effects of 
the HIF pathway on the function of myeloid cells came in 2003 when Cramer et al showed that 
HIF-1-/-α macrophages were unable to operate energy-requiring procedures including 
aggregation, motility, infiltration and invasiveness due to reduced levels of intracellular ATP 
(Cramer et al., 2003). Two years later the Peyssonnaux group when challenged mice bearing HIF-
1-/-α macrophages subcutaneously with group A streptococcus found that these HIF-1-/-α 
macrophages not only were unable to get rid of the bacterial loads but supported the formation of 
more necrotic and ulcerative lesions (Peyssonnaux et al., 2005). Therefore these results illustrate 
the critical role for HIF-1α in the survival and function of macrophages under oxygen-depleted 
conditions occurring for example in the synovial microenvironment. The PHD/HIF pathway also 
contributes to enhanced neutrophil survival. Inhibition of PHDs stabilises HIF and induces IKKβ 
function (via inhibiting PHD-1); both will foster activation of NFκB, thereby promoting 
neutrophil survival. Therefore, in addition to reduced ATP levels another reason accounting for 
the impaired inflammatory responses exhibited by mice bearing HIF-1-/-α macrophages is 
reduced neutrophil survival (Walmsley et al., 2005). It is moreover proposed that certain 
monocyte/macrophage populations survive better under conditions of low oxygen, thereby 
contributing to their increased numbers at sites of chronic inflammation and tumours (Roiniotis et 
al., 2009). 
There is further evidence for a beneficial role for HIF from patients with inflammatory 
bowel disease (ulcerative colitis and Crohn’s disease), in whom overexpression of HIF has been 
reported, (Giatromanolaki et al., 2003b) but HIF-1 has actually been proposed to exert a 
protective role. These findings are based on studies using mice with intestinal epithelium-targeted 
expression of either mutant HIF-1 or mutant vHL. Loss of epithelial HIF-1α expression resulted 
in a more severe phenotype in a murine model of colitis, whilst mutations in vHL resulted in HIF-
1α overexpression and protection against disease (Karhausen et al., 2004). Furthermore, 
stabilisation of HIF protein levels through inhibition of PHD (using small molecule inhibitors or 
hypoxia mimetics like DMOG) was protective in models of inflammatory bowel disease, 
(Cummins et al., 2008; Robinson et al., 2008) and in agreement with this finding, mice lacking 
PHD-1 were less susceptible to the development of colitis (Tambuwala et al., 2010). Another 
study confirming the protective role of hypoxia/HIF in the context of inflammatory diseases 
utilised mice treated with DMOG before LPS-mediated induction of endotoxic shock, and found 
that DMOG attenuated systemic LPS-induced activation of the NFκB pathway. Furthermore, 
DMOG-treated mice had significantly increased survival in LPS-induced shock, an effect 
associated with a promotion of M2 polarisation in macrophages within the peritoneal cavity, thus 
resulting in the downregulation of pro-inflammatory cytokines such as TNF-α. In addition, in vivo 
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DMOG treatment upregulated IL-10 expression, specifically in the peritoneal B1 cell population, 
thus demonstrating cell type-specific roles for hydroxylase inhibition in vivo and providing insight 
into the mechanism underlying the protection conveyed by DMOG in models of inflammation 
(Hams et al., 2011). 
The first findings implying a potential therapeutic utility of the specific intervention of 
the PHD/HIF signaling axis (as opposed to studies using the pan-specific hypoxia mimetics) came 
from Mazzone et al studying the role of endothelial PHD-2 in vessel shaping by implanting 
tumours in PHD-2+/- mice. Haplodeficiency of PHD-2 normalised the endothelial lining and 
vessel maturation, thus resulting in improved tumour perfusion, oxygenation and inhibition of 
tumour cell invasion, intravasation, and metastasis. Interestingly, heterozygous loss of PHD-2 
redirected the specification of endothelial tip cells to a more quiescent cell type, lacking filopodia 
and arrayed in a phalanx formation, an effect associated with up-regulation of (soluble) VEGFR-1 
and VE-cadherin (Mazzone et al., 2009). A follow-on from the above study managed to associate 
therapeutic manipulation of the PHD/HIF axis with modulation of macrophage polarisation status 
by utilising a hindlimb model of ischemia. In particular, Phd2+/- mice which displayed preformed 
collateral arteries that preserved limb perfusion and prevented tissue necrosis in ischemia. 
Improved arteriogenesis in Phd2+/- mice was due to an expansion of tissue-resident, M2-like 
macrophages. Gene-profiling of Phd2+/− peritoneal macrophages showed higher expression of 
M2-type (pro-angiogenic) genes, including Tie2, Arg1, CXCR4, HGF, Fizz, NRP1, VEGF and 
TGFβ, than wild type cells Conversely, several pro-inflammatory or anti-angiogenic (M1-type) 
molecules were downregulated in Phd2+/- macrophages: IL6, iNOS and IL12 (Takeda et al., 
2011). In a very recent study it was shown that tumour vessel normalisation by genetic 
inactivation of Phd2 increases the delivery of chemotherapeutics to the tumour and, hence, their 
antitumour and antimetastatic effect. Interestingly, in response to chemotherapy-induced 
oxidative stress, pharmacological inhibition or genetic inactivation of Phd2 enhances a HIF-
mediated detoxification program in healthy organs, which prevents oxidative damage, organ 
failure, and tissue demise (Leite de Oliveira et al., 2012). 
1.6.1 In vivo models of RA 
Animal models have been used extensively in studies of rheumatoid arthritis 
pathogenesis. Despite the inherent limitations of all animal models, several rodent models have 
significantly progressed our understanding of the fundamental mechanisms underpinning 
rheumatoid arthritis and contributed to several current major advances in treatment. These models 
include the induced arthritis models such as collagen-induced arthritis (CIA), collagen antibody-
induced arthritis, zymosan induced arthritis, and the methylated BSA model (mBSA or antigen 
induces arthritis, AIA), and the genetically manipulated or spontaneous arthritis models such as 
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the TNF-α-transgenic mouse, K/BxN mouse, and the Skg mouse (Courtenay et al., 1980). In the 
context of this study the CIA and AIA murine models of arthritis have been used. 
The CIA model shares many similarities with human RA. Two characteristics of the CIA 
model -breach of tolerance and generation of autoantibodies toward self and collagen – make CIA 
the gold standard in vivo model for RA studies. CIA was first described in rats (Trentham et al., 
1977) and subsequently shown to be inducible in susceptible strains of mice (Courtenay et al., 
1980), following inoculation with type II heterologous collagen in complete Freund’s adjuvant. 
Susceptibility has been linked to strains that have MHC Class II I-Aq haplotypes; however, it is 
clear that many mouse strains have variable degrees of susceptibility to CIA. Similarly restricted 
class II genotypes can be found in RA patients, for whom pathogenesis is associated with HLA-
DR1 and HLA-DR4 (Brand et al., 2003). DBA/1 mice (a mouse strain also used in my study) are 
most widely used in the CIA model. Clinical signs of disease typically develop 21–25 days after 
the initial inoculation and presents as a polyarthritis, which is most prominent in the limbs and 
characterised by synovial inflammatory infiltration, cartilage and bone erosion and synovial 
hyperplasia similar to human RA. The development of CIA is associated with both B- and T-
lymphocyte responses with the production of anti-collagen type II antibodies and collagen-
specific T cells. The auto-antibody response in CIA is predominated by the IgG2 subclass with 
high levels of both IgG2a and IgG2b present at the peak of arthritis. Disease severity is expected 
to peak at approximately day 35, after which DBA/1 mice enter remission, marked by increased 
concentrations of serum IL-10 and a subsequent decrease in pro-inflammatory Th1 cytokines 
(Mauri et al., 1996). As with most models of disease there is a requirement for uniformity in 
which disease severity is assessed and presented to provide clarity and direct comparability of 
results. It is generally recognised that variable incidence, severity and intergroup inconsistency is 
a feature of the CIA model, reflecting in part the model’s exquisite sensitivity to environment, 
maintenance conditions and general stress in the animals. Thus careful, independent, internal 
controls are mandatory for valid interpretation of data. 
Various strains of mice develop inflammatory arthritis when primed with an antigen (e.g. 
methylated BSA in complete Freund’s adjuvant) and subsequently challenged by intra-articular 
injection of the same antigen (Brackertz et al., 1977a; Brackertz et al., 1977b). Such models are 
useful in that mice of several strains can be investigated to establish a hierarchical role for given 
factors in adaptive immunemediated articular damage. Subsequent pathology comprises immune 
complexmediated inflammation followed by articular T-cell-mediated responses. The model does 
not however recapitulate the endogenous breach of tolerance that is typical of RA pathogenesis 
and as such the model has limitations in applicability to RA. An alternative development of this 
model comprises of prior adoptive transfer of transgenic ovalbumin-specific T cells followed by 
ovalbumin priming and later intra-articular challenge (Maffia et al., 2004). The recipient mice 
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develop arthritis, which is followed by the emergence of auto-reactivity to collagen, and the 
presence over time of rheumatoid factors. This model has the advantage of facilitating imaging of 
the pathogenic T cells that in turn promote breach of self-tolerance to articular antigens (Nickdel 
et al., 2009). 
1.7 Hypothesis 
Preliminary investigations in the lab have shown that levels of HIF hydroxylases are 
decreased during PMA differentiation of THP-1 monocytic cells into macrophages under 
normoxic (20% O2) conditions. We hypothesised that this is a key component of human monocyte 
to macrophage differentiation, and would most likely affect HIF activation and HIF downstream 
effects, and may also have also a significant impact on macrophages activity and their role in 
inflammation. Thus, modulation of HIF hydroxylases in vivo may represent a potentially 
therapeutic intervention in the setting of RA. 
1.8 Objectives 
Τhe study described in this thesis aimed to shed more light on the influence of monocyte-
to-macrophage differentiation on the Hypoxia/HIF axis, as well as on how PHDs are being 
regulated during the differentiation process and influence the HIF pathway. Therefore, the key 
questions addressed were the following: 
1) How is expression of the HIF hydroxylase enzymes affected during the 
differentiation process of monocytes to macrophages, and what is the impact on 
HIF and the HIF pathway?  
2) What is the effect of modulating HIF hydroxylases on inflammatory and immune 
cell function in vitro and in vivo? 
3) Would pharmacological/chemical intervention of the PHD/HIF axis be of 
therapeutic benefit in the setting of RA?  
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2 MATERIALS AND METHODS 
All reagents used in this study are described in Table 2-8 and all apparatus is outlined in Table 
2-9. 
2.1 BIOLOGICAL MATERIAL AND CELL CULTURE 
2.1.1 In vitro studies using human cells 
2.1.1.1 THP-1 cells 
Human monocytic THP-1 cells (derived from the peripheral blood of a patient with acute 
monocytic leukemia) were purchased from the American Type Culture Collection (ATCC, 
Maryland, USA), and cultivated in 75cm2 flasks, in complete RPMI 1640 medium (Roswell Park 
Memorial Institute; PAA Laboratories GmbH, Pasching, Austria) supplemented with 10% (v/v) 
heat-inactivated foetal bovine serum (FBS; BioSera, Sussex, UK), 100U/mL penicillin and 
100μg/mL streptomycin (PAA Laboratories, Pasching, Austria). Cells were maintained in 
humidified incubator at 37°C and 5% CO2 (Digital CO2, Incubator 6500, Napco, Hong Kong), and 
were passaged every 2-3 days at a ratio of between 1:2 and 1:3. 
2.1.1.2 Peripheral blood mononuclear cells (PBMCs) 
Peripheral blood mononuclear cells (PBMCs) were isolated from blood cones of healthy 
donors purchased from the National Blood Service (Colindale, Edgware London, UK) using 
density gradient centrifugation. Blood from the cones (approximately 10mL) was drained into a 
falcon tube and made up to 50mL with HBSS (Hank’s Balanced Salt Solution, Invitrogen Crp., 
Carlsbad, CA, USA), mixed properly, and layered on top of 20mL Lympholyte® Cell Separation 
Media (CEDARLANE Laboratories Ltd., Burlington NC, USA) in 50mL falcon tubes which were 
subsequently centrifuged at 2250rpm for 30 minutes at 10°C on low acceleration and deceleration 
so that phases were not disturbed. After the centrifugation, the phase containing the mononuclear 
cells was carefully aspirated, added to a new falcon tube containing HBSS and washed twice (first 
wash at 1800rpm for 10 minutes and second wash at 1500rpm for 5 minutes) to remove residual 
Lympholyte® Cell Separation Media. The isolated mononuclear layer was used for the further 
separation of monocytes via elutriation. PBMCs were then resuspended in 45mL of HBSS before 
being passed through a cell strainer (BD Bioscience, UK) to remove clumps. PBMCs were 
subjected to centrifugal elutriation in a Beckman JE6 Elutriator (Beckman Coulter, High 
Wycombe, UK) (Figure 2-2) at 2500rpm to obtain enriched monocyte fractions. Elutriation is a 
process that separates a heterogeneous cell population based on size and granularity. Elutriation 
fractionates the cell population based on sedimentation properties of small round particles, with 
minimal perturbation of cellular functions.  
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Figure 2-1 Schematic view of cell synchronisation by centrifugal elutriation 
The centrifugal and the drag forces are acting in opposite directions. (a) Unfractionated cells enter the 
elutriator chamber. (b) Size gradient balanced by centrifugal force and counterflow (drag force) of 
elutriation fluid keeps cells inside the chamber. (c) Increasing flow rate elutes smaller cells first followed by 
larger ones. 
 
 
Figure 2-2 Counterflow centrifugal elutriaton in the JE-6 Beckman elutriator rotor 
The centrifuge is run at 20°C and constant speed (2200rpm). The pump is turned on and the system is 
washed first with 100mL of 70% Ethanol, then with 200mL of physiological buffer (saline or PBS) to 
remove traces of alcohol. The physiological buffer is then replaced by freshly made elutriation fluid at an 
initial flow rate used for the introduction of cells into the chamber. Approximately 100mL of the elutriation 
fluid is collected separately and discarded. The further, still preliminary, run serves to remove bubbles from 
the system. Bubbles tend to left behind in the elutriation chamber, in the sample-mixing chamber, in the 
tubing and inside the manometer. The JE-6 Beckman loading chamber, which also serves as chamber 
mixer, is used in the bypass position to trap bubbles and to compensate for pump pulsation. The bypass 
valve serves to remove bubbles from the sample-mixer chamber. 
Centrifugal force Counterflow
drag force
(a) (b) (c)
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PBMCs were loaded into the specialised elutriator chamber at an increasing flow rate 
where they were subjected to the opposing forces of the centrifugal force and the flow velocity 
(Figure 2-2). Since the centrifugal force is constant, by increasing the flow of the media into the 
centrifuge using a pump, the separation of cells according to their size and granularity is possible. 
Monocytes were ejected when the flow rate was increased to 18-22mL/minute and their purity 
was determined by analysis of cell size and granularity using flow cytometry (FACS). Monocyte 
purity was assessed using directly congregated anti-CD45 and anti-CD14 antibodies and was 
routinely greater than 90%. Only fractions containing more than 90% monocytes and less than 5% 
granulocytes were used for experimental purposes (Krausgruber et al., 2011).  
2.1.2 In vitro differentiation of THP-1 and human monocytes 
For differentiation experiments, THP-1 cells were left untreated, or treated with 10ng/mL 
of phorbol 12-myristate 13-acetate (PMA, Sigma-Aldrich, Poole, UK) a concentration previously 
shown in the literature to induce adherence and subsequent acquisition of a macrophage 
phenotype (Knowles et al., 2006). THP-1 cells, or THP-1 derived macrophages, human 
monocytes, and human monocyte derived macrophages were also stimulated with different 
cytokines (listed in 2.6.1) or LPS (Lipopolysaccharide, Peprotech, UK) for different time points. 
Concentrations used and differentiation periods were chosen from studies previously published in 
the literature (Frede et al., 2006; Krausgruber et al., 2011; Tjiu et al., 2009). 
For human monocytes, upon collection of monocyte-enriched fractions, cells were 
counted and resuspended in RPMI supplemented with 10% FBS, 1% penicillin/streptomycin to a 
concentration of 106 cells/mL. 3mL of this cell suspension was seeded per 60 cm2 tissue culture 
dish. All the dishes and plates were purchased from Becton Dickinson (Falcon, Leuven, 
Belgium). M1 or M2 macrophages were derived from the elutriated monocytes by culturing the 
cells either with 50ng/mL granulocyte macrophage colony-stimulating factor (GM-CSF, 
lyophilized, Peprotech Inc., Rocky Hill, NJ, USA) or 100ng/mL macrophage colony-stimulating 
factor (M-CSF, lyophilized, Peprotech Inc., Rocky Hill, NJ, USA), with differentiation for up to 5 
days (Krausgruber et al., 2011). 
2.1.3 Experimental set-up 
For experiments, cells used in my study (THP-1 cells, THP-1 derived macrophages, 
human monocytes and human monocyte-derived macrophages) were stimulated with different 
cytokines (Table 2-8) (Tjiu et al., 2009) or LPS (Lipopolysaccharide, Peprotech, London, UK) for 
24 hours (Frede et al., 2006). For hypoxic experiments, cells were exposed to 1% oxygen 
(normoxia set up as 20% oxygen) for the indicated times using a hypoxic incubator Galaxy R 
(Biotech, Palo Alto, CA, USA). Alternatively, cells were cultured with the panhydroxylase 
inhibitor and hypoxia mimetic dimethyloxalylglycine (DMOG, made up in ddH2O, Frontier 
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Scientific, Logan, UT, USA) for 16 hours (Muz et al., 2012). THP-1 cells, monocytes and human 
monocyte-derived macrophages MDM were exposed to different conditions, as summarised in 
Table 2-1. RNA and proteins were extracted as detailed in subsequent sections. Cells left either 
untreated, DMOG treated (at a concentration of 1mM overnight) or exposed to 1% O2 for 
different time points (Sivakumar et al., 2008). 
Table 2-1 Experimental set-up 
Culture dishes/plates dimensions and cell number used in the subsequent experiments. All dishes and plates 
were purchased from Becton Dickinson (Falcon, Leuven, Belgium). 
THP-1 cells 
Experiment qPCR Western Blot TransAm assay 
Area of well 2cm2 2cm2 9.6cm2 
Number of cells/cm2 2.5x105 2.5x105 1 x105 
Human MDMs 
Area of well 9.6cm2 3.8cm2 9.6cm2 
Number of cells per/cm2 1 x105 0.5x105 1 x105 
Mouse macrophages 
Area of well 9.6cm2 3.8cm2 9.6cm2 
Number of cells per/cm2 1 x105 0.5x105 1 x105 
 
2.2 RNA STUDIES 
2.2.1 Total RNA Isolation from THP-1 cells 
Cultured cells grown in monolayers (0.5x106 per 1 well/24 well plate) were washed in 
cold phosphate buffered saline (PBS, Merck, Darmstadt, Germany) and then lysed in 500µL of 
RNA-BeeTM (Biozol, Eching, Germany) monophase solution containing phenol and guanidine 
thiocyanate. Addition of 100µL of chloroform (Sigma-Aldrich Co., St Louis, MO, USA) was 
followed by vigorous vortexing for 15-30 seconds and centrifugation at 12,000g for 15 minutes at 
4°C. Centrifugation results in the formation of three distinct phases, the lower blue phenol-
chloroform phase, interphase and the upper colourless aqueous phase. RNA remains exclusively 
in the aqueous phase whereas DNA and proteins are in the interphase and organic phase. The 
colourless aqueous phase was isolated and RNA was precipitated from the aqueous phase by 
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adding equal amount of isopropanol (VWR International S.A.S. AnalaR NORMAPUR; VWR 
International, Lutterworth, UK). The RNA pellet was then washed in 500L of 75% ethanol 
(Sigma-Aldrich Co., St Louis, MO, USA) and then solubilised in 20L DEPC water (Diethyl 
pyrocarbonate Sigma-Aldrich Co., St Louis, MO, USA) following air drying of the pellet. 
The concentration of RNA was measured using a NanoDrop2000TM spectrophotometer 
(Eppendorf AG, Hamburg, Germany) by measuring the optical density at 260nm and 280nm. An 
OD260 nm refers to 40μg/ml RNA. The purity of RNA was evaluated by the ratio of the 
absorbance read at 260nm and 280nm (Abs260/Abs280). This ratio provides an estimation of 
contaminants that absorb the ultraviolet light (UV light), such as protein. The RNA sample was 
considered pure when the Abs260/Abs280 was in between 1.8-2. RNA was stored at -80°C. 
2.2.2 Total RNA Isolation  
RNA was isolated using the Total RNA kit E.Z.N.A.™ EaZy Nucleic Acid Isolation 
(VWR, Batavia, IL, USA). For RNA isolation, cells were cultured in 60 mm plates. Cells were 
washed with 1 x PBS, homogenised using 300µL of provided TRK lysis buffer with addition of 
β-mercaptoethanol (Sigma-Aldrich, Co. St Louis, USA) at a concentration of 20µL added per 
1mL of TRK lysis buffer and RNA was isolated following the manufacturer’s procedure. Cells 
were scraped using cell lifters (Corning Incorporated Costar, 3008 NY14831, Mexico), mixed by 
pipetting, vortexed thoroughly with 300µL 70% absolute ethanol in sterile DEPC-treated water 
and spun using HiBind®RNA Spin Column at 10,000 x g for 1 minute. Genomic DNA 
contamination was removed on-column using RNase-free DNase I Set (VWR, Batavia, IL, USA), 
incubating RNA samples for 15 minutes at room temperature with 75µL of buffer containing 
DNase. The enzyme activity was stopped using RNA Wash Buffer I, followed by washing with 
RNA Wash Buffer II containing ethanol. RNA was eluted with 50µL nuclease-free water, in 
which RNases were inactivated using 0.1% DEPC-treated water. RNA samples were stored at -
80°C. The concentration of RNA was measured as previously described in 2.2.1. 
2.2.2.1  Agarose gel electrophoresis (RNA integrity) 
Total RNA integrity was estimated by fractionating 1µg of samples on a native 1.5% 
agarose gel in TAE buffer (40mM Tris, glacial acetic acid, 1mM EDTA) with SYBR® Green Safe 
DNA gel stain (Invitrogen, Paisley, UK) diluted 1:10,000. 4 x native agarose gel loading buffer 
(60% glycerol, 0.09% xylene cyanol, 0.09% bromophenol blue) was added to the RNA samples to 
a final concentration 1 x. The electrophoresis was run for 30 minutes at 130V and the picture of 
samples separation was taken while the gel was visualised using UV transilluminator (Upland, 
CA, USA). It illustrates an example of RNA integrity assessment for 6 RNA samples. In 
eukaryotic samples intact total RNA run on agarose gel has sharp, clear 28S and 18S ribosomal 
RNA (rRNA) bands. If the 28S rRNA band is approximately twice as intense as the 18S rRNA 
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band, it is a good indication that the RNA is intact. Although RNA secondary structure alters its 
migration pattern and it does not migrate according to its true size, RNA samples were run beside 
1kb Plus DNA ladder (12,000bp - 100bp; Invitrogen, Paisley, UK) as a reference point. 
 
 
 
 
 
 
 
 
Figure 2-3 Agarose gel electrophoresis to test RNA integrity 
An example of agarose gel analysis of RNA samples depicting 28S and 18S rRNA units. 2µL aliquots of 
RNA samples (1 - 6) were mixed with 10µL DEPC water and 4µL loading buffer. 12µL of the mixture was 
loaded onto an 1.5% agarose gel stained with SYBR® Green gel stain next to the 1kb DNA ladder 
(M=marker, 10µL) and the samples were separated by electrophoresis. 
 
2.2.3 cDNA synthesis and Reverse Transcription-Polymerase Chain Reaction 
(RT-PCR) 
Reverse transcription polymerase chain reaction (RT-PCR) is a widely used technique, 
which enables determination of the abundance of specific RNA molecules within a cell or tissue 
as a measure of gene expression. Reverse transcription is a step where complementary DNA 
(cDNA), a template for PCR, is synthesised from a RNA sample and is catalysed by reverse 
transcriptase. Reverse transcriptase, also known as RNA-dependent DNA polymerase is a DNA 
polymerase enzyme that transcribes single-stranded RNA into single-stranded DNA. It also is a 
DNA-dependent DNA polymerase which synthesises a second strand of DNA complementary to 
the reverse-transcribed single-stranded cDNA after degrading the original mRNA with its 
RNaseH activity. Normal transcription involves the synthesis of RNA from DNA; hence, reverse 
transcription is the reverse of this. Reverse transcriptase was discovered by Howard Temin at the 
University of Wisconsin–Madison in RSV virions, and independently isolated by David 
Baltimore in 1970 at MIT from two RNA tumour viruses: R-MLV and again RSV. For their 
achievements, both shared the 1975 Nobel Prize in Physiology or Medicine (with Renato 
Dulbecco). The idea of reverse transcription was very unpopular at first as it contradicted the 
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central dogma of molecular biology which states that DNA is transcribed into RNA which is then 
translated into proteins. However, in 1970 when the scientists Howard Temin and David 
Baltimore both independently discovered the enzyme responsible for reverse transcription, named 
reverse transcriptase, the possibility that genetic information could be passed on in this manner 
was finally accepted. 
Reverse transcription was performed using 500ng of purified RNA diluted in DEPC-
treated in a total volume of 11μL. Addition of 1μL of random primers (Invitrogen, Paisley, UK) 
was followed by incubating the samples at 72°C for 10 minutes in a T Gradient Thermoblock 
(Biometra, Thistle Scientific, UK). The reaction was then cooled down to 4°C (Table 2-2).  
Table 2-2 The amount of reagents used in the first step of reverse transcription 
Reagent Concentration Final concentration Volume 
RNA (X) 500ng  XµL 
DEPC H2O (Y)   Y=11µL-Xl 
Random primers 50ng/µL 4.2ng/µL 1µL 
Final volume 12µL 
 
8µL of a master mix containing 4L 5x reverse transcription buffer, 1L Ribonuclease 
Inhibitor to preserve RNA integrity (RNasin), 1L deoxyribonucleotide triphosphates (dNTPs) 
including a mixture of dATP, dGTP, dCTP, dTTP, 1.5L DEPC water and 0.5L Moloney 
Murine Leukaemia Virus (M-MLV) reverse transcriptase (all purchased from Promega, 
Southampton, UK) was added to each sample. Samples were then incubated using the following 
cycling conditions: 10 minutes at 25°C, 1 hour at 42°C followed by the denaturating stage at 70°C 
for 10 minutes and finally 4°C. Samples were stored at -20°C (Table 2-3). cDNA obtained was 
diluted 5 times (volume) i.e. with 80µL of double distilled (ddH2O) to make a final volume of 
100µL of cDNA solution. 
Table 2-3 The amount of reagents used in the second step of reverse transcription 
Reagent Concentration Final concentration Volume 
RNA + Random primers   12µL 
RT buffer 5 x 1 x 4µL 
DEPC H2O   1.5µL 
RNasin 40units 2units 1µL 
dNTPs 10mM 0.5mM 1µL 
Reverse transcriptase 200u/µL 100u/reaction 0.5µL 
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Final volume 20µL 
 
 
2.2.4 Real-time quantitative Polymerase Chain Reaction (qPCR) 
Real-time polymerase chain reaction, also called quantitative real time polymerase chain 
reaction (qPCR) or kinetic polymerase chain reaction is based on the PCR, which is used to 
amplify and simultaneously quantify a targeted DNA molecule. For one or more specific 
sequences in a DNA sample, Real Time-PCR enables both detection and quantification. The 
quantity can be either an absolute number of copies or a relative amount when normalised to 
DNA input or additional normalising genes. 
The procedure follows the general principle of polymerase chain reaction; its key feature 
is that the amplified DNA is detected as the reaction progresses in real time. This is a new 
approach compared to standard PCR, where the product of the reaction is detected at its end. Two 
common methods for detection of products in real-time PCR are: (1) non-specific fluorescent 
dyes (e.g. SYBR Green I) that intercalate with any double-stranded DNA, and (2) sequence-
specific DNA probes consisting of oligonucleotides that are labeled with a fluorescent reporter 
which permits detection only after hybridization of the probe with its complementary DNA target. 
There are four main phases in the qPCR reaction i.e. linear ground, early exponential, log-
linear (or exponential) and plateau phase (Figure 2-4). The linear ground phase reflects the 
baseline or background fluorescence. During this phase the amount of the PCR product is very 
small and the fluorescence emission at each cycle is not yet raised above background. The early 
exponential phase occurs when the intensity of fluorescence exceeds a threshold where it is 
significantly higher than the background level. The cycle at which this phase occurs is known as 
the cycle threshold (Ct). Consequently, the Ct value is associated with the initial DNA or mRNA 
quantity, i.e. the greater the starting DNA or mRNA, the faster the fluorescent signal significantly 
crossed the background signal threshold, yielding a lower Ct. Therefore, Ct value is representative 
of the starting DNA or mRNA copy number and is used for results analysis. The log-linear phase 
reflects the time when the PCR reaches its optimal amplification with the PCR product doubles 
after every cycle in ideal reaction conditions. Finally, during the plateau phase, the reaction 
components become limited causing the reaction to slow down and eventually stop. The final 
product of the reaction can be confirmed via the dissociation curve analysis, where the presence 
of different PCR products is reflected in the number of first-derivative melting peaks, or gel 
analysis. 
Quantitative PCR can be used for absolute and relative DNA and RNA quantification. 
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Absolute quantification uses serially diluted standards of known concentrations to generate a 
standard curve. The standard curve produces a linear relationship between Ct and initial amounts 
of total RNA or cDNA. Therefore, measuring the Ct values of the study sample in parallel with 
the standards enables the determination of their absolute concentration. This method assumes the 
standards and samples have approximately equal amplification efficiencies. In relative 
quantification, changes in sample gene expression are measured in relation to an external standard 
or a reference sample (untreated control or time zero samples), known as calibrator, and results 
are expressed as a target to reference ration. 
Besides calibration, normalisation of gene expression data is important to correct sample-
to-sample variation. Nucleic acids obtained from different individuals or samples may vary in 
tissue mass or cell number, RNA integrity or quantity. In cell culture works, mRNA levels can be 
standardised to cell number under ideal conditions. When using whole tissue samples, 
normalisation to cell number and type is virtually impossible. Therefore, in most qPCR reactions, 
normalisation of the results against a control gene is needed. The expression of the ideal control 
gene should be unchanged regardless of experimental conditions, tissue or cell types, 
developmental stage, or sample treatment. Examples of commonly used normalisation control 
genes include housekeeping genes or mRNA (e.g. glyceraldehyde 3-phosphate dehydrogenase or 
GAPDH and β-actin), ribosomal RNA (e.g. 18S and 28S), and total RNA. So far, all available 
control genes are not ideal and have their inherent problems. The expression of many commonly 
used housekeeping genes or mRNA could be affected by different experimental conditions or 
treatments, biological processes, and even different tissues or cell types. To overcome these 
problems, multiple control genes are sometimes used although this method may be laborious. The 
18S rRNA has previously been validated against several different reference genes by our 
laboratory in studies related to the effects of hypoxia. Hence, 18S rRNA was used as the control 
gene in this study. 
In this study, the thermocycler Rotor-Gene™ 6000 Multiplexing System (Corbett 
Research Corbett Life Science, Sydney, Australia) was used to perform qPCR reaction. The 
thermocycler used a sensitive camera to detect the fluorescence in each tube during reaction. The 
fluorescence detection chemistry used was the SYBR® Green I which emitted fluorescence when 
bound to dsDNA. The fluorescence intensity increases proportionally to dsDNA concentration. 
SYBR® Green I bound to any dsDNA and therefore was not specific to a particular DNA 
sequence. It has the advantage that one dye could be used for various gene assays. However, its 
non-sequence specific property also has the disadvantage of being prone to false positives. 
Therefore, the end products were checked with dissociation curve analysis, where the presence of 
different PCR products was reflected in the number of first-derivative melting peaks. The 
dissociation curve analysis was programmed into and performed automatically by the 
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thermocycler. 
The qPCR protocol used in this study had previously been validated by our laboratory. In 
each 0.1mL qPCR Qiagen tube (Qiagen Sciences, Maryland, USA), 3µL of cDNA sample was 
mixed with 10µL qPCR mixture containing: SYBR® Green I (Invitrogen, Paisley, UK), Primer 
mix (MWG-Biotech AG, Ebersberg, Germany) and ddH2O was added to a total volume of 13µL 
(Table 2-4). Three replicates of each sample were incubated at 50C for 2 minutes, followed by 
the initial denaturation step at 95C for 5 minutes. 40 amplification cycles were carried out and 
the thermocycling conditions were: denaturation at 95°C for 10 seconds, annealing at 60°C for 15 
seconds and extension at 72°C for 20 seconds. A single peak in the dissociation curve reflects the 
generation of only one product per sample, thus excluding the possibility of contamination. 
Table 2-4 The amount of reagents used in qPCR reaction 
 
Reagent Concentration Final concentration Volume 
cDNA   3µL 
SYBR® Green 2 x 1 x 6.25l 
Forward primer 6.25µM 120nM 0.25l 
Reverse primer 6.25µM 120nM 0.25l 
Nuclease-free H2O   3.25l 
Final volume 13l 
 
Table 2-5 Sequences of primers used in the study  
Genes used in qPCR reactions. 18S=small ribosomal subunit RNA, RPLP0=large ribosomal protein, PHD-
1-3=prolyl hydroxylase domain containing enzymes 1-3, FIH=factor inhibiting HIF, HIF1-2α=hypoxia 
inducible factor 1-2α, STAB1=stabilin1, IRF-5=Interferon regulatory factor-5, HO-1=heme oxygenase-1, 
HEP=hepcidin, ANGPTL4=angiopoietin-like 4, BNIP3= BCL2/adenovirus E1B 19 kDa protein-interacting 
protein 3, CA9= carbonic anhydrase 9, VEGF=vascular endothelial growth factor. h= human, m= mouse 
 
Gene Forward Sequence Reverse Sequence 
HUMAN PRIMERS 
18S gtaacccgttgaacccca ccatccaatcggtagtagcg 
RPLP0 tgcagaaactgctgcctcat tgcccctggagattttagtg 
h PHD-1 cagctagcatcaggacagaaa cagaggcaaagtcagaagca 
h PHD-2 gcacgacaccgggaagtt ccagcttcccgttacagt 
h PHD-3 ttgggatgccaagctaca cgtgtgggttcctacgatct 
h FIH-1 caatgtactggtggcatcacatag ggccactttctgatgagct 
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h HIF-1α cacctctggacttgcctttc ggctgcatctcgagactttt 
h HIF-2α ccttcaagacaaggtctgca ttcatccgtttccacatcaa 
h CD14 ccgctgcctctggaag ggcgagtgtgcttggg 
h CD16 gacagtgtgactctgaa gcacctgtactctccac 
h CD36 gccaaggaaaatgtaacccagg gcctctgttccaactgatagtga 
h IRF-5 cattactgtacaggtggtgc agatgtgatggagctccttg 
h HO-1 ccttcttcaccttccccaac tggcctcttctatcaccctc 
h HEP gcactgagctcccagatctg ctacgtcttgcagcacatcc 
h ANGPTL-4 ttgacccggctcacaatgtc ctgaggtcatcttgcagttc 
h BNIP3 gatatgggattggtcaagtcgg cgctcgtgttcctcatgct 
h VEGF cttgccttgctgctctacct ctgcatggtgatgttggact 
MOUSE PRIMERS 
m PHD2 gcatgggttttactgctacttgatt caggaatgcttgttcatatctgtctt 
m PHD3 ttttggcaaatacaacccttcaga gcagaagatactgtcaccacc 
m -actin catccgtaaagacctctatgccaac atggagccaccgatccaca 
m VEGF gtgcactggaccctggcttta ggtctcaatcggacggcagta 
 
The comparative CT method (2-ΔΔCt) was employed for relative quantitation as follows: 
The calibrator was used to determine the relative amount of gene expression in the unknown 
sample. The threshold cycle (Ct); the cycle number at which the reaction becomes exponential 
and thus the thermocycler is able to discriminate the difference between the amplification 
generated signal and the background was first determined. Relative changes in gene expression 
using the 2 - Ct model the equations used are as follows: 
delta Ct (dCt) value = Ct (target gene)-Ct (housekeeping gene) 
delta delta Ct (ddCt;ΔΔCt) = delta Ct (sample)- delta Ct(calibrator) 
fold change gene expression = 2-ΔΔCt 
To assess the agreement between housekeeping genes used in the study two housekeeping 
genes(18S and RPLP0) were used to measure the same gene and at the same scale of 
measurement. Both of the housekeeping genes gave similar results. For mouse studies β-actin was 
used as a housekeeping gene. 
The graph depicting melting curve of FIH-1 product pin-points the temperature of 
dissociation equal 82°C meaning that 50% of PCR products are dissociated (Figure 2-4) 
corresponding to a specific DNA fragment. 
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Figure 2-4 Representative graphs of Q-PCR analysis 
FIH-1 gene expression represented by amplification curves in (a) a linear view, which depict the increase in 
fluorescence in real-time divided into three phases: exponential, linear and plateau; and (b) a logarithmic 
view of the kinetics of the same reaction. (c) Melting curve shows the dissociation kinetics of the amplified 
FIH-1 products. Coloured lines represent tested samples (every sample in triplicate); black line represents 
the blank control (water); red horizontal line indicates the cycle threshold at 0.05. 
 
2.3 PROTEIN STUDIES 
2.3.1 Cellular protein extraction 
Cellular protein extracts were prepared on ice. Samples were washed in cold 1xPBS and 
then lysed for 20-30 seconds in a denaturing buffer consisting of 8M urea, 1% sodium dodecyl 
sulphate (SDS), 1% glycerol and 10mM Tris (pH 6.8), 0.5mM protease inhibitors cocktail, 1mM 
dithiothreitol (DTT) and phenylmethylsulfonyl fluoride (PMSF) (all purchased from Sigma-
Aldrich, Poole, UK). After being scraped off the dish, samples were transferred in eppendorf 
tubes, sonicated for 5 seconds and kept at -20°C for further use. 
2.3.2 Measurement of protein concentration 
The total protein concentration of the extracted protein was assayed using the BCA™ 
Protein Assay Kit (Thermo Scientific, Rockford, IL, USA). The assay combines the reduction of 
copper ion (Cu2+) to cuprous ion (Cu1+) by protein in an alkaline medium with the highly sensitive 
and selective colorimetric detection of the Cu1+ by bicinchoninic acid (BCA). The first step is the 
chelation of copper with protein in an alkaline environment to form a light blue complex known 
 (a)
(b) (c)
exponential
linear plateau
exponential
Chapter 2 
77 
as the biuret reaction. In biuret reaction peptides, containing three or more amino acid residues 
form a coloured chelate complex with cupric ions in an alkaline environment containing sodium 
potassium tartrate. The second step involves BCA reacting with Cu1+ formed in the first step. The 
chelation of two molecules of BCA with one Cu1+ produces an intense purple product. The water 
soluble BCA/copper complex exhibits a strong linear absorbance at 562nm with increasing 
protein concentrations. The detection of the purple product is approximately 100 times more 
sensitive than the pale blue product formed from the first reaction. 
Protein concentration was determined with a reference to a serially diluted standard of 
known concentrations and a blank standard to generate a standard curve. Serially diluted bovine 
serum albumin (BSA, PAA Laboratories, Pasching, Austria) starting at 2% with urea/SDS lysis 
buffer was used a standard. The blank standard used contained urea/SDS lysis buffer. The BCA™ 
Protein Assay Kit was carried out according to the manufacturer’s protocol. Briefly, 200µL of 
BCA working reagent (50 parts of BCA™ Reagent A mixed with 1 part of BCA™ Reagent B) 
was added to 5µL of sample which was diluted 1/5 volume with urea/SDS lysis buffer, standards 
and blanks in a Costar® 96 well EIA/RIA plate (Corning, Incorporated, NY, USA). Each sample, 
standard and blank was assayed in duplicates. The plate was then covered, gently mixed on a plate 
shaker (Orbit 300, Labnet International Incorporation, Woodbridge, NJ, USA) for 30 seconds. 
The plate was then incubated in dark at 37°C for 30 minutes. Absorbance was read at 540nm on a 
plate reader (Multiscan Ascent model 354, Thermo Labsystem, Finland). The standard curve and 
protein concentration of each unknown sample was determined based on the standard curve 
automatically plotted using the Ascent Software Version 2.6 for Multiscan Ascent photometric 
microplate reader. 
2.3.3 Western blotting 
Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE) separates 
proteins according to their size. Negatively charged SDS-coated proteins migrate in 
polyacrylamide gel towards the lower positive anode. Protein lysates were adjusted with PBS to 
contain the same total protein concentration of 30-50µg in a total volume of 25ul and 5ul of 4x 
loading buffer (250mM Tris/HCl/SDS pH 6.8, 20% glycerol, 20mM DTT, 4% SDS, 0.01% 
bromophenol blue and distilled H2O) was then added into the samples to a maximal volume of 
30ul that is allowed to load on to the gel. The samples were boiled for 5 minutes to denature 
proteins, spun and loaded onto 4-12% Bis-Tris NuPage Ready Gels (Invitrogen, Paisley, UK). 
Gels were immersed in 1x MOPS (3-N-morpholino propane sulfonic acid)/SDS running buffer 
(NuPage Invitrogen, Paisley, UK). A constant voltage of 130V was applied across the gel for 90 
minutes. A pre-stained protein standard Full-Range Rainbow Marker (12,000-225,000Da; 
Amersham, GE Healthcare, UK) was run on each gel to assess protein molecular weight. The gel 
was then equilibrated in cold transfer buffer consisting of 10% methanol, 10mM Tris base, 
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0.005% SDS and 100mM glycine. 
To transfer the separated proteins Immobilon-P transfer membranes (filter type: PVDF, 
Millipore, Watford, UK) were used. Membranes were activated in methanol for 10 seconds, 
placed in water for 2 minutes and finally equilibrated in cold transfer buffer for 10 minutes. 
Transfer of proteins was performed using the Bio-Rad system (Bio-Rad, Hemel Hempstead, UK) 
at 100 V for 90 minutes at 4°C. To reduce non-specific binding membranes were incubated in 
blocking buffer PBS-T (PBS, 1% Tween20 Sigma-Aldrich, Poole, UK) containing 5% non-fat 
milk powder (Premier Brands UK, Spalding, UK) and 1% BSA (Bovine Serum Albumin, Sigma-
Aldrich, Poole, UK) for 1 hour at room temperature. Proteins were detected with monoclonal or 
polyclonal antibodies (Table 2-6) reconstituted in blocking buffer and incubated overnight at 4°C. 
After three times 10 minutes washing steps with PBS/0.1%Tween20, membranes were incubated 
for another hour with rabbit anti-mouse (RAM) or swine anti-rabbit (SAR) polyclonal 
immunoglobulin conjugated with HRP (Dako Cytomation, Glostrup, Denmark) diluted in 
blocking buffer, followed by another five times 5 minutes washing steps with PBS/0.1%Tween20. 
Binding of the antibodies was visualized using enhanced chemiluminescence system, ECL Plus 
(GE Healthcare, Amersham, UK). 
1ºAb Company Concentration 
1ºAb 
dilution 
2ºAb 2ºAb dilution 
Size 
(kDa) 
MoAb anti-
HIF-1 
Becton Dickinson, 
Oxford, UK 
20mg/ml 1:250 RAM 1:3000 120 
MoAb anti-
EPAS-1 
(HIF-2) 
Santa Cruz 
Biotechnology, 
Heidelberg, 
Germany 
20mg/ml 1:250 RAM 1:3000 115 
MoAb anti-
-tubulin 
Sigma-Aldrich, 
Poole, UK 
2.5mg/ml 1:5000 RAM 1:3000 50 
PoAb anti-
PHD-1 
Abcam, 
Cambridge, UK 
1μg/ml 1:500 SAR 1:3000 43.6 
PoAb anti-
PHD-2 
Abcam, 
Cambridge, UK 
20mg/ml 1:2000 SAR 1:3000 46 
MoAb anti-
PHD-3 
Millipore, CA 
1μg/ml 
1:1000 RAM 1:3000 27.3 
PoAb anti-
FIH-1 
Abcam, 
Cambridge, UK 
1.25mg/ml 1:1000 SAR 1:3000 40.6 
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Table 2-6 Details of antibodies used for western blotting 
Antibodies used in the study. Ab=antibody, MoAb=monoclonal antibody, PoAb= polyclonal antibody, 
RAM=rabbit anti mouse, SAR=sheep anti rat. 
 
2.3.4 Cytosolic and nuclear protein extraction  
Nuclear protein extraction was performed using the Active Motif nuclear extraction kit, 
according to the manufactures protocol. Briefly, the medium was removed and cells were washed 
in 1.5mL PBS/Phosphatase Inhibitor solution. The washing solution was aspirated and added 
0.5mL ice-cold PBS/Phosphatase Inhibitor buffer. Cells were removed from the dish by gently 
scraping, transferred to a pre-chilled 1.5mL eppendorf, and centrifuged at 13,000rpm for 1 minute 
at 4°C. The resulting cell pellet was resuspended in 125µL 1x Hypotonic Buffer by pipetting up 
and down several times and left on ice for 15 minutes. 6.25µL of the detergent were added and 
vortexed for 10 seconds at highest setting. The suspension was centrifuged at 14,000g for 0.5 min 
at 4°C and the supernatant (cytoplasmic fraction) was transferred to a pre-chilled 1.5mL 
eppendorf and stored at -80°C for further use. The pellet was used for nuclear fraction collection. 
Nuclear pellet was resuspended in 25 µL of Complete Lysis Buffer and vortexed vigorously for 
10 seconds. The suspension was incubated for 30 minutes on ice on a rocking platform set at 
150rpm. The suspension was then vortexed vigorously for 30 seconds and centrifuged at 14,000g 
for 10 minutes at 4°C. Supernatant (nuclear fraction) was finally transferred into a pre-chilled 
1.5mL eppendorf and stored at -80°C for further use Protein concentration of cytosolic and 
nuclear extracts was measured using the BCA assay kit as described earlier in Section 2.3.2.  
 
 
 
 
MoAb anti-
BNIP3 
Abcam, 
Cambridge, UK 
2.4mg/ml 1:1000 RAM 1:3000 30 
MoAb anti-
lamin 
Abcam, 
Cambridge, UK 
0.25mg/ml 1:50 RAM 1:3000 70 
PoAb anti-
65 (anti-
NFκB) 
Abcam, 
Cambridge, UK 
20mg/ml 1:250 RAM 1:3000 40 
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2.4 STUDIES USING ODD-LUCIFERASE MICE 
A fusion protein was created with a human HIF-1α sequence coding for amino acids 530-
652 (HIF1a [aa 530-652]; this includes the C-terminal portion of the ODD fused to the firefly 
luciferase (luc) gene. This "ODD-Luc" fusion protein was preceded by a loxP-flanked PGK-neo 
cassette and followed by a bovine polyadenylation stop sequence. This targeting construct was 
incorporated into the Gt(ROSA)26Sor locus via electroporation into 129S6/SvEvTac-derived TC1 
embryonic stem (ES) cells. Correctly targeted ES cells were microinjected into C57BL/6 
blastocysts. Chimeric mice were bred to EIIA-Cre transgenic mice (on the FVB genetic 
background) to remove a loxP-flanked neomycin cassette. The resulting mice (with a single loxP 
site ahead of the "ODDLuc" fusion gene) were bred with wild-type FVB mice (and selected 
against the Cre transgene) for 6 generations prior to arrival at The Jackson Laboratory. 
Mice heterozygous for this "ODD-luc" knock-in are viable and fertile with no gross 
phenotypic or behavioural abnormalities. These mice have the C-terminal portion of the HIF-1α 
ODD fused to the firefly luciferase (luc) gene. This region of the ODD also contains a proline 
residue (amino acid 564) that, when hydroxylated, will serve as a binding site for pVHL. Under 
normal oxygen concentrations, prolyl hydroxylation by PHD proteins leads to pVHL-dependent 
polyubiquitylation and proteasomal degradation (thus, little or no luciferase fluorescence). Under 
hypoxia, proline hydroxylation is impaired and ubiquitination is attenuated, resulting in 
stabilisation of the fusion protein and high levels of luciferase fluorescence in the hypoxic 
tissue(s). These "ODD-Luc" bioluminescent reporter mice are useful in researching transcriptional 
regulation of hypoxia-inducible genes, cancer, ischemia, cardiovascular, myocardial infarction, 
stroke, pharmacokinetics, or other studies where imaging/reporting the development of tissue 
hypoxia and the action of small molecule inhibitors of HIF prolyl hydroxylase activity are 
appropriate. 
2.4.1 Fluorescence Reflectance Imaging Device 
Optical imaging experiments were performed using a fluorescence reflectance imaging 
(FRI) device (Kodak In-vivo Multispectral System FX Pro). This utilises a 175W Xenon 
illumination source coupled to an automated multi-wavelength series of excitation filters with a 
range of 390-770nm and emission filters between 480-830nm. This allows a wide range of 
fluorescent dyes of varying wavelengths to be tested. Fluorescence emission is captured using a 
monochrome interlined cooled CCD with a pixel density of 2048x2048 pixels (Figure 2-5). Image 
acquisition and analysis has been performed using proprietary Kodak software (version 5.0). 
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Figure 2-5 Fluorescence Reflectance Imaging: Kodak In Vivo Imaging System FX Pro  
The above photograph describes the experimental set up described in the text. Light source (a) and 
excitation filters (b) Emission filters and CCD (c) Animal chamber and anaesthetic apparatus (d) X-ray 
device.  
 
2.4.2 In vivo Imaging 
The following relates to general details regarding preparation of mice for in vivo imaging 
and principles of image capture. An appropriate anaesthetic regime using isofluorane was utilised 
to ensure mice can be imaged in vivo for multiple time points and prolonged periods. The 
anaesthetic circuit for the Kodak imager has been redesigned for effective and safe anaesthetic 
use. It was necessary to design and build an oxygen/gas delivery circuit that effectively balances 
administration of anaesthetic gases as well as safely scavenged used or excess anaesthetic gas. 
The circuit is housed within the pre-existing imaging box and is capable of regulating the supply 
of anaesthetic gas for up to three animals. It is also capable of providing a warm air supply for 
prolonged anaesthesia as demonstrated in Figure 2-6. 
 
 
 
 
Figure 2-6 Anaesthetic device for small animal imaging 
Images of prototype design for anaesthetic housing (panel 1) and animals anesthetised prior to whole body 
luminescence imaging (panel 2). Isofluorane and Oxygen is delivered and scavenged via nose cones (as 
indicated by arrows). Multiple animals (n=3) animals can be imaged at any one time point and positioning 
of animals can be reproduced for sequential imaging studies. For knee imaging purposes, mice are sitting on 
a piece of black-coloured paper, and knees are extended and imaged (panel 3).   
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Prior to anaesthetic induction, mice were given an intraperitoneal injection of 50mg/kg 
luciferin (VivoGlo™ Luciferin, In vivo Grade,Promega, Madison, WI), a concentration 
previously shown to generate bioluminescence (Goldman et al., 2011). For imaging purposes, 
mice were then anaesthetised with a mixture of isofluorane (2-3%) and Oxygen (2-4l/min). 
Optical imaging was performed using the Kodak Multispectral FX Pro fluorescence reflectance 
imaging device (Carestream Molecular Imaging, Rochester, USA) as described above. Filters for 
excitation and emission were set to 730nm and 770nm respectively. An identical imaging protocol 
(for bioluminescence exposure time: 2.5 minutes, 4x binning, f-stop: 2.50, field of view: 187.12, 
focal plane: platen) was maintained for all images. When required comparative X-ray images 
were taken using the following image settings: (exposure time: 30 seconds, 4xbinning, f-stop: 
2.50 field of view: 187.12, focal plane 9.4mm). 
Images were analysed using the Kodak Molecular Imaging software program (Version 
5.0, Carestream Molecular Imaging, Rochester, USA). A region of interest (ROI) created by an 
automated tool was determined around the inflamed or control knees. Mean ROI signal intensities 
are expressed as arbitrary fluorescent signal intensity units. Bioluminescence gray scale images 
were artificially coloured for depiction purposes according to a colour scale set to the highest and 
lowest levels of mean bioluminescence intensity (red and purple indicate maximum and minimum 
light intensity respectively). The bioluminescence images were co-registered onto X-ray images 
taken concurrently, when anatomical localisation was required. Nephrectomies were also 
performed as previously described in literature (Patschan et al., 2013), and kidney capsules were 
assessed for bioluminescence detection by imaging. Isolation of RNA from a small amount of 
kidneys (1-10 mg) was also accomplished by homogenizing the sample in RNA-Bee as described 
in 2.2.1. The effect of DMOG in vivo was also studied using the above mentioned animal model. 
2.5 IN VIVO MOUSE MODELS OF ARTHRITIS 
2.5.1 Laboratory animal care and regulatory approval 
Male DBA/1 mice 8-12 weeks old were purchased from Harlan Laboratories UK 
(Blackthorn, Bicester, UK). Mice were housed in groups of 6, and were maintained at 21°C ± 2°C 
on a 12-hour light/dark cycle with food and water ad libitum. Male "ODD-Luc" bioluminescent 
reporter mice (strain name: FVB.129S6-Gt(ROSA)26Sortm2(HIF1A/luc)Kael/J) aged 8-12 weeks were 
purchased from The Jackson Laboratory (Sacramento, CA, USA). They were maintained under 
standard conditions at the Biological Service Unit (BSU) of the Kennedy Institute of 
Rheumatology. All studies were performed in accordance with the UK Animals (Scientific 
Procedures) Act 1986 regulations for the handling and use of laboratory animals and performed 
under PPL 70/7335: Identifying and targeting mediators of inflammation. 
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2.5.2 Induction of antigen-induced arthritis (AIA) in ODD-Luc and DBA/1 mice 
To induce arthritis in male ODD-Luc or DBA/1 mice, animals 8-12 weeks old were 
administered a combination of Isofluorane (4%) and Oxygen (1 L/minute) by a gaseous 
anaesthetic delivery device (Vetech, UK). Each mouse was immunised receiving a subcutaneous 
injection in 2 points at tail base of 100μl total (100μg) of 400μl CFA, 380μl PBS and 20μl 
methylated BSA (Sigma-Aldrich, Poole, UK, 40mg/ml mBSA in ddH2O) (Immunisation day, Day 
-7). 7 days post immunisation, disease was induced in mice (Day of Induction, Day 0). Mice were 
first sedated using an intra-peritoneal injection of Hypnorm™ (VetalPharma Ltd, Sherburn in 
Elmet, Leeds UK) (1:10 dilution in ddH2O and inject 150μl per mouse) and shaved around their 
knee areas. Each mouse received an intra-articular injection at their left knee of 10μl (200μg) of 
the following: 50μl mBSA (40mg/ml) and 50μl sterile PBS. Right knees were either left 
unimmunized/untreated (used as controls) or have been immunised (Day -7) and injected (Day 0) 
with just 1×sterile PBS (used as vehicle control). 
2.5.3 Evaluation of AIA 
In order to determine onset and development of arthritis in the AIA model, mice were 
examined daily starting from the day of the intra-articular injection (Day of Induction, Day 0). 
Arthritis was characterised by evaluation of joint properties and inflammation of surrounding 
tissues. For clinical monitoring of AIA development, knee swelling was assessed by measuring 
the thickness of the knees using callipers (see below) (Krœplin, Wessexmetrology, Bournemouth, 
Dorset, UK). Knee measurements made the day before the induction (Day 0) were used as the 
basal levels. Finally, differential weight distribution was assessed by Linton Incapacitance Tester 
(MJS Technology Ltd., Hertfordshire, UK) (see below). 
2.5.3.1 Knee diameter measurement 
To assess the severity of AIA, joint swelling was determined daily until day 3 by 
measuring the transverse diameter of the knee joint using a calliper in units of 0.1 mm as shown 
in the upper left panel of Figure 2-7. As an example to illustrate how mouse knees are measured 
using these callipers, a healthy human finger was used (Figure 2-7, upper right panel). After taring 
it, cursor was adjusted in the middle of the two lines and reading was measured (Figure 2-7, 
bottom left panel). An example of the diameter of a mouse knee joint with no arthritis using the 
calliper is shown in Figure 2-7, bottom right panel). 
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Figure 2-7 Knee measurement using callipers 
Starting from upper left panel and clockwise: First panel corresponds to a picture showing a calliper used to 
measure knee thickness; second panel corresponds to an example of a measurement a human finger; third 
panel corresponds to the actual reading of a normal human finger measurement; fourth panel corresponds to 
the reading of a mouse knee without arthritis incidence. 
 
2.5.4 Haematocrit measurement 
Experimental mice after having been placed in restriction tube (Figure 2-8 panel 1) were 
bled from tail tips and blood was obtained directly into heparinised microhaematocrit capillary 
(75 μL, Andreas Hettich, GmbH &Co KG, Fohrenstr, Germany). Hematocrit determination with 
standard capillaries was carried out with 24-place rotor (Haematocrit Centrifuge 210, Andreas 
Hettich, GmbH &Co KG, Fohrenstr, Germany). Each capillary is secured within its own chamber 
and supported by a holding tray. This holding tray serves to contain glass shards and any leakage 
should a tube break. The rotor comes to a braked standstill (Figure 2-8 panel 2). When 
heparinised blood (heparin is an anticoagulant) is centrifuged, the red blood cells become packed 
at the bottom of the tube, while the plasma is left at the top as a clear liquid. The ratio of the 
volume of packed red cells to the total blood volume is called the haematocrit. Haematocrit 
measurement is described in Figure 2-8. 
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Figure 2-8 HTC measurement 
Mouse placed in a restriction tube (panel 1). The rotor of the haematocrit centrifuge (panel 2). Heparinised 
blood is transferred from a heparinised eppendorf tube to a microhaematocrit capillary. The tube is filled to 
at about 3/4 capacity by capillary action (panel 3). Then the blood-filled end is sealed with clay, and placed 
in a slot in the haematocrit centrifuge (panel 4). In order to obtain a value of haematocrit from the 
centrifuged blood sample in the capillary tube, one must refer to a scale plate, which is located directly 
under the samples in the centrifuge at 13,000 rpm for 7 minutes. The bottom of the packed red cell column 
is first lined up with the "0" line on the scale plate, and then the scale is moved under the sample until the 
top of the plasma column lines up with the"100%" line.  
 
 
2.5.5 Purification of type II collagen 
Experimental arthritis can be induced in susceptible mouse strains by immunisation with 
either heterologous (e.g. bovine, chicken) or homologous type II collagen. Type II collagen is the 
most abundant collagen found in hyaline cartilage (e.g. in synovial joints, sternum, respiratory 
tract), comprising 80-90% of the total collagen content. Therefore, type II collagen was purified 
from bovine articular cartilage, obtained from the femoral heads of 2-3 month old calves, 
following the method by Miller.  
Bovine articular cartilage was powdered using a liquid nitrogen freezer-mill (Spex 
Industries Inc, Metuchen, NJ, USA). To remove proteoglycans, 5 volumes of 4M guanidine 
hydrochloride in 0.05M Tris (pH 7.5) were added to the powdered cartilage and left stirring over 
night at 4°C. The cartilage was pelleted by centrifugation. The proteoglycan removal step was 
repeated and the pellet washed in 0.5M acetic acid to eliminate the remaining guanidine. 
Afterwards the cartilage was digested with pepsin to release the soluble type II collagen. 
Therefore, a solution of 1 mg/mL pepsin (Sigma-Aldrich, Gillingham, UK), in 0.5M acetic acid 
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was added to the pellet. The solution was kept stirring at 4°C for 36 hours. In between the 
incubation period, the viscosity of the solution was checked and more pepsin containing acetic 
acid added, if needed. The insoluble material was removed by centrifugation. To the supernatant 
NaCl was added to a final concentration of 0.9M. The salt precipitates the dissolved type II 
collagen. The precipitate was spun down in a centrifuge and then dissolved in 0.05M Tris 
containing 0.5M NaCl (pH 7.5) by stirring to inactivate residual pepsin. After overnight 
incubation at 4°C, the solution was dialysed (Dialysis Tubing – Visking, size 3, Inf Dia 20/32; 
Medicell International Ltd., London, UK) exhaustively at 4°C against 0.5M acetic acid to remove 
the salt. After dialysis the collagen was lyophilised. The purified bovine or murine type II 
collagen was dissolved in 0.1M acetic acid at a concentration of 4 mg/ml or 2 mg/mL, 
respectively, and stored frozen at -70°C. All centrifugation steps in this protocol were carried out 
at 12,000 rpm for one hour at 4°C. 
2.5.6 Induction of acute collagen-induced arthritis (CIA) in DBA/1 mice 
To induce arthritis in male DBA/1 mice, animals 8-12 weeks old were administered a 
combination of Isofluorane (4%) and Oxygen (1 L/minute) by a gaseous anaesthetic delivery 
device (Vetech, UK). In- house prepared bovine type II collagen as previously described in 2.5.5 
dissolved in 0.1M acetic acid at 4 mg/ml, was emulsified with an equal volume of complete 
Freund’s adjuvant (CFA; DIFCO, Detroit, MI, USA). Each mouse received an intradermal 
injection of 200 µg bovine type II collagen (bCII) emulsified in CFA into the base of their tail.  
2.5.7 Evaluation of CIA 
2.5.7.1 Paw thickness measurement 
In order to determine onset and development of arthritis in the chronic CIA model, mice 
were examined daily beginning two weeks after immunisation. Arthritis was characterised by 
evaluation of joint properties and inflammation of surrounding tissues. Disease onset was 
considered as the day that paw swelling or erythema in the paws could be observed. The disease 
severity was recorded for each paw daily using the following scoring system based on the visual 
signs of arthritis: 0 = normal paw, 1 = mild swelling and/or erythema of the joint or individual 
digits; 2 = moderate swelling and erythema, 3 = moderate swelling and erythema accompanied 
with joint rigidity (Figure 2-9). An arthritis score (range 0 - 12) was assigned to each mouse by 
summing up the score of each paw. For clinical monitoring of CIA development in conjunction 
with the arthritis score, paw swelling was assessed by measuring the diameter of the hind paws 
using POCO 2T callipers (Krœplin Längenmesstechnik, Schlüchtern, Germany). 
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Figure 2-9 Representative clinical scores of mice with CIA 
Starting from upper left panel and clockwise: First panel corresponds to normal hind paw (clinical score 0); 
second panel corresponds to hindpaw with mild swelling (clinical score 1); third panel corresponds to 
hindpaw with pronounced oedematous swelling (clinical score 2); fourth panel corresponds to hindpaw with 
ankylosis (clinical score 3). 
 
2.5.7.2 Liberating cells from arthritic paw  
Before removing the paw from the leg, skin was cut around the ankle with scalpel. Then a 
cut was made vertically down the paw towards the toes. Using gripping forceps, the skin was 
peeled off and pulled over hell to the toes. Toes were then cut off as well as the attached skin 
using scissors. Finally the remaining foot was cut off at the ankle and put in 5 ml sterilin pots 
(Sterilin, UK) containing 1ml RPMI with no additives. The paw was cut off in 3 small pieces so 
the digestion would be easier and quicker. 10µl of DNase I (Roche, UK) and 25µl of Liberase (TL 
Research Grade Roche, UK) were added for each paw, and the steriling pots containing paws in 
the Liberase mix were placed in in humidified incubator at 37°C and 5% CO2 for 90 minutes.  
Media was passed through cell strainer and remaining pieces of the paw were crushed through 
strainer. Strained paws were then spinned at 1500rpm for 5 minutes and pelleted cells were 
counted and made up to a final volume of 500µl of FACS Wash Buffer (FWB) consisting of 
1×PBS, 5% FCS and 0.01% sodium azide (GBiosciences, St Louis, USA). Samples were now 
ready for FACS staining. 
2.5.7.3 Flow cytometry (FCM) analysis 
For staining of mouse cell surface antigens, cells were washed 3 times in 500µl FWB and 
centrifuged each time at 3,000 rpm for 2minutes. Next cells were incubated with Fc Block to 
eliminate non-antigen specific binding for 10 minutes at R.T. The antibody cocktail was prepared 
according to the Table 2-7. Cells were incubated with the antibody cocktail at 4º C for 20 minutes. 
Finally cells were washed three times in 500µl FWB and processed for FACS analysis. Samples 
were run on a FACS Canto II (BD Bioscience, UK) and analysed using the FlowJo software 
(TreeStar, USA). Haematopoietic cells were first gated using the CD45 PerCp antibody. 
Following this, CD11b APC Cy7 was used to subgate myeloid cells and the F4/80 PE-Cy7 
antibody to subgate further the macrophage population. The final subcategorisation toward the 
0 1 
 
2 3 
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M1 and M2 lineage was performed utilising the MHCII FITC (M1-like cells) and CD206 
AlexaFluor 647 (M2-like cells) respectively. 
Table 2-7 Details of antibodies for FACS analysis 
Antibodies used for FACS analysis. CD45 PerCp stains for haematopoietic cells, CD11b APC Cy7 stains 
for myeloid cells, F4/80 PE-Cy7 stains for macrophages, CD206 AlexaFluor 647 stains for M2-like cells, 
MHCII FITC stains for M1-like cells and Fc Block blocks non-specific antigen binding. 
 
 
 
 
2.5.7.4 Histological paw examination (Haematoxylin and Eosin specimen 
preparation) 
At the end of an experiment, paws were dissected post-mortem and fixed overnight at 4ºC 
in 1% phosphate buffered PFA. Paws were then decalcified in a 0.3M EDTA solution for 12-14 
days. Placing the slides in standard histology cassettes and an excess of EDTA ensured an 
adequate volume and circulation of the decalcificant. Decalcificant was intermittently manually 
agitated and changed on two occasions. In order to further facilitate the decalcification process, 
paws were sagitally divided to the proximal metatarsal joint. Decalcification of the inflamed 
mouse paws is necessary for subsequent cutting of the specimens. If calcified bone remains in the 
tissue it will splinter and fracture when cut on the microtome. Tissue blocks were sectioned to 4 
μm thicknesses using a microtome. The tissue sections were allowed to adhere onto Snowcoat X-
tra glass microscope slides (Surgipath, Peterborough, UK) and stained using Mayer’s 
modification of Harris haematoxylin and eosin method. Used with a mordant, haematoxylin stains 
Antibody Cell type Concentration Dilution Company 
CD45 PerCp 
Haematopoietic 
cells 
0.2mg/ml 1:200 
BD 
Bioscience, 
CD11b APC Cy7 Myeloid cells 0.2mg/ml 1:200 
BD 
Bioscience 
F4/80 PE-Cy7 Macrophages 0.2mg/ml 1:200 eBioscience 
CD206 AlexaFluor 
647 M2-like cells 0.5mg/ml 1:200 eBioscience 
MHCII FITC M1-like cells 0.2mg/ml 1:200 eBioscience 
Fc Block 
Blocks non-
antigen specific 
binding 
0.5mg/ml 1:100 
BD 
Bioscience 
Chapter 2 
89 
nuclei blue. Eosin is used to counterstain other cellular components red-pink. For the staining, 
tissue sections were first deparaffinised in xylene and re-hydrated in absolute alcohol. After 
washing in distilled water, sections were stained in Harris haematoxylin solution for 3 minutes. 
Excess stain was washed away with water, and the staining differentiated in 1% acid alcohol for 
30 seconds. Following washing in water, sections were dipped into 0.2% ammonia water for 30 
seconds for blueing the haematoxylin dye. Sections were washed in water and counterstained in 
eosin solution for 30 seconds. Slides were washed with water, dehydrated through 95% and 
absolute alcohol. Before the tissue sections were mounted with xylene based mounting medium, 
they were cleared with xylene. The stained sections were assessed microscopically to evaluate 
arthritic changes in the tibia tarsus joint (TTJ), metatarsophalangeal joint, proximal phalangeal 
joint (PPJ) and the distal phalangeal joint (DPJ). Images were captured with a digital camera 
(ProgRes CF Scan, Jenoptik, Jena, Germany) connected to an Olympus BH-2 microscope 
(Olympus, Tokyo, Japan) and analysed using (ProgRes Capture Pro camera control software, 
version 2.11 Jenoptik, Germany). 
 
2.6 CHEMICAL COMPONENTS AND EQUIPMENT 
2.6.1 Chemicals 
Table 2-8 Reagents used in the study 
Reagent Company details Application 
RPMI 1640 
PAA Laboratories GmbH, 
Pasching, Austria 
Tissue culture 
HBSS (Hank’s Balanced Salt Solution)  
Invitrogen Crp., Carlsbad, Ca., 
USA 
Tissue culture 
Lympholyte® Cell Separation Media  
CEDARLANE Laboratories 
Ltd., Burlington NC, USA 
Tissue culture 
Penicillin-streptomycin 
BioWhittaker, Cambrex Bio 
Science, Verviers, Belgium 
Tissue culture 
FBS (foetal bovine serum) BioSera, Sussex, UK Tissue culture 
PMA (phorbol 12-myristate 13-acetate) Sigma-Aldrich, Poole, UK Tissue culture 
VD3 (1,25-dihydroxycholecalciferol or 
calcitriol) 
Sigma-Aldrich, Poole, UK Tissue culture 
LPS (Lipopolysaccharide) Peprotech, UK Tissue culture 
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GM-CSF (granulocyte macrophage 
colony-stimulating factor)  
lyophilized, Peprotech Inc., 
Rocky Hill, NJ 
Tissue culture 
M-CSF (macrophage colony-stimulating 
factor)  
lyophilized, Peprotech Inc., 
Rocky Hill, NJ 
Tissue culture 
DMOG (Dimethyloxalylglycine) 
Frontier Scientific, Logan, UT, 
USA 
Tissue culture 
DMSO (Dimethyl sulfoxide) Sigma-Aldrich, Poole, UK Tissue culture 
DEPC (Diethyl pyrocarbonate)  
Sigma-Aldrich, Co. St Louis, 
USA 
RNA isolation 
TNF (Tumor necrosis factor) 
lyophilized, Peprotech Inc., 
Rocky Hill, NJ 
Tissue culture 
IL-4 (Recombinant Human) 
lyophilized, Peprotech Inc., 
Rocky Hill, NJ 
Tissue culture 
IL-1 (Recombinant Human) 
lyophilized, Peprotech Inc., 
Rocky Hill, NJ 
Tissue culture 
IFN-γ (Interferon gamma) 
lyophilized, Peprotech Inc., 
Rocky Hill, NJ 
Tissue culture 
M-MLV Reverse Transcriptase, RNase 
H (-), Point Mutant, purified from E.coli 
strain (200units/µL) 
Promega, Southampton, UK 
Reverse 
transcription 
RNasin® Plus RNase Inhibitor 
(10,000units) 
Promega, Southampton, UK 
Reverse 
transcription 
Random primers 300µg (3µg/µL) Invitrogen, Paisley, UK 
Reverse 
transcription 
dNTPs (set of dATP, dCTP, dGTP, 
dTTP 40µmol each) 
Promega, Southampton, UK 
Reverse 
transcription and 
PCR 
1kb Plus DNA ladder (12,000bp – 
100bp) 
Invitrogen, Paisley, UK PCR 
SYBR® Green Safe DNA gel stain Invitrogen, Paisley, UK PCR 
SYBR® Green Safe DNA gel stain Invitrogen, Paisley, UK PCR 
NuPAGE® MOPS/SDS running buffer 
(20x) 
Invitrogen, Paisley, UK western blot 
NuPAGE® 4-12% Bis-Tris Gel 1mmx10 Invitrogen, Paisley, UK western blot 
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Full Range Rainbow™ Recombinant 
Protein Molecular Weight Marker 
GE Healthcare, Amersham, UK western blot 
Protease inhibitor coctail Sigma-Aldrich, Poole, UK western blot 
DTT (DL-Dithiotreitol) Sigma-Aldrich, Poole, UK western blot 
Bovine serum albumin (BSA) 
PAA Laboratories, Pasching, 
Austria 
 western blot 
Primer sets MWG, Ebersberg, Germany Q-PCR 
SYBR® Green JumpStart™ Taq Ready 
MIX™ 
Sigma-Aldrich, Poole, UK Q-PCR 
Hypnorm™  
VetalPharma Ltd, Sherburn in 
Elmet, Leeds UK 
in vivo work 
methylated Bovine serum albumin 
(mBSA) 
Sigma-Aldrich, Poole, UK in vivo work 
DNase I   Roche, UK in vivo work 
Liberase  TL Research Grade Roche, UK in vivo work 
Sodium Azide GBiosciences, St. Louis, USA FACS 
Luciferin  VivoGlo™ Luciferin, In vivo 
Grade, Promega, Madison, WI),  
in vivo work 
 
2.6.2 Mechanical devices 
Table 2-9 The apparatus used in the study 
Apparatus Company details Technique 
Laminar Flow Hood, ESCO, 
Class II 
Airstream ® cell culture 
Digital CO2 Incubator 6500 Napco, Hong Kong cell culture 
Incubator Galaxy R CO2 for cell 
culture in hypoxic conditions (Nr 
300-2453) 
Wolf Laboratories, York, UK cell culture 
Centrifuge 5415D 
Eppendorf AG, Hamburg, 
Germany 
cell culture 
Multi-function Centrifuge 2028R Napco, CA, USA cell culture 
Beckman JE6 Elutriator  Beckman Coulter, High elutriation 
Chapter 2 
92 
Wycombe, UK 
Haematocrit Centrifuge 210 
Andreas Hettich, GmbH &Co KG, 
Fohrenstr, Germany 
in vivo work 
heparinised microhaematocrit 
tubes  
75 μL, Andreas Hettich, GmbH 
&Co KG, Fohrenstr, Germany. 
in vivo work 
Hawksley BS748, cell counting 
chamber 
Improved Neubauer, Sussex, UK cell counting 
ELISA Plate Reader, Multiskan 
Ascent 
Thermo Labsystems, Finland 
protein 
measurement 
Eppendorf AG, BioPhotometer Hamburg, Germany RNA measurement 
T Gradient Thermoblock Biometra, Thistle Scientific, UK 
Reverse 
transcription 
Horizontal Gel Electrophoresis 
Apparatus, Horizon®11,40 
Life Technologies™, Gibco BRL, 
Gaithersburg, MD, USA 
PCR – 
electrophoresis 
UV Transilluminator M-20, UVP 
BioDoc-It™System 
Upland, California, USA 
PCR – 
electrophoresis 
Rotor-Gene™6000 Multiplexing 
System (thermocycler) 
Corbett Life Science, Sydney, 
Australia 
Q-PCR 
Techne Dri-block DB-2A 
(heating block) Model FDB02AD 
Cambridge, UK 
western blot - 
boiling samples 
X Cell Sure Lock™, Novex Mini-
Cell 
Invitrogen, Paisley, UK 
western blot - 
electrophoresis 
Western blot equipment 
Bio-Rad Laboratories, Hemel 
Hempsted, UK 
western blot - 
transfer 
Hypercassette™  Amersham, Life Science, UK western blot 
Fuji Medical X-ray Film, Super 
RX 
Fujifilm Corporation, Tokyo, 
Japan 
western blot 
POCO 2T callipers for paw 
thickness measurement 
Krœplin,Längenmesstechnik, 
Schlüchtern, Germany 
in vivo work 
Callipers for knee swelling 
measurement 
Krœplin,Wessexmetrology, 
Bournemouth, Dorset, UK 
in vivo work 
Linton Incapacitance Tester  MJS Technology Ltd., 
Hertfordshire, UK 
in vivo work 
FACS Canto II BD Bioscience, UK ex vivo work 
Fluorescence reflectance imaging 
(FRI) device (Kodak In-vivo 
Carestream Molecular Imaging, in vivo work 
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Monocytes (THP-1 or human primary monocytes)
+PMA
+VD3
+GM-CSF/M-CSF
M1 or M2 macrophages
+Normoxia
HIF-α PHDs HIF targets
+Hypoxia/DMOG
HIF targets PHDs HIF-α
In vitro
In vivo
+CIA/AIA models of arthritis
+/- DMOG
arthritis
progression
HTC levels macrophage 
polarisation status
Multispectral System FX Pro). Rochester, USA 
 
 
 
 
 
2.6.3 Experimental design of the study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-10 Cytokine-mediated activation of THP-1 cells does not affect HIF-α isoform 
protein levels. 
THP-1 monocytes or human primary monocytes have been left either undifferentiated or differentiated with 
agents described in the figure. The responses of M1/M2 macrophages have also been studied together with 
the expression levels of the HIF-α isoforms, PHDs and the HIF target genes under normoxic and hypoxic 
conditions. Animal models of arthritis (CIA and AIA) have been utilised to study the impact of PHD 
inhibition on RA progression, with a specific focus on HTC levels and macrophafe polarisation status. 
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2.7 STATISTICAL ANALYSES 
Graph Pad Prism 5.02 software package (Graph Pad Software, La Jolla, CA, USA) was 
used in the analyses of the data. Student’s t-test was applied if two groups were analysed. The 
figure legends indicate the comparisons made. 1-way analysis of variance (ANOVA), followed by 
a Dunnett’s Multiple Comparison Test was used where there were more than two groups to 
compare. 2-way ANOVA was used to analyse in vivo data from CIA and AIA studies. Results are 
expressed as the mean ± standard error of the mean (SEM) as indicated. P values less than 0.05 
were considered significant (*p<0.05, **p <0.01, ***p≤0.001). n numbers are described in each 
individual experiment. 
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3 INVESTIGATION OF THE MECHANISMS OF REGULATION OF HIF 
HYDROXYLASES DURING MONOCYTE TO MACROPHAGE 
DIFFERENTIATION OF THP-1 CELLS 
3.1 Introduction 
Previous preliminary studies in our laboratory have shown that PHD-2 protein expression 
is decreased during monocyte to macrophage differentiation. It was also known that pro-
inflammatory cytokines activate the HIF pathway under normal oxygen levels. These 
observations led to the hypothesis that pro-inflammatory cytokines or the monocyte-macrophage 
differentiation process may affect PHD levels and subsequently lead to HIF stabilisation and 
activation. Cytokines regulate a broad range of inflammatory processes that are implicated in the 
pathogenesis of RA. In rheumatoid joints, it is well known that an imbalance between pro- and 
anti-inflammatory cytokine activities favours the induction of autoimmunity, chronic 
inflammation and thereby joint damage. Because of their phagocytic activity and their ability to 
differentiate into antigen-presenting cells, monocytes participate in both innate and adaptive 
immune responses. They derive from bone-marrow progenitor cells, circulate in the blood as 
monocytes and differentiate into tissue macrophages or myeloid dendritic cells in the periphery. 
After activation by an antigenic challenge in the tissues they can contribute to the local resolution 
of the injury or can migrate further to secondary lymphoid organs. While they are circulating in 
the blood stream, they are attracted to inflammatory sites by chemical substances through 
chemotaxis, where they are then differentiating into macrophages. Macrophages are known to 
release cytokines, and cytokines induce HIF (Hellwig-Burgel et al., 1999), thus contributing 
further to the hypoxic conditions. However the precise mechanism by which cytokines induce 
HIF is unknown. 
3.2 Objectives 
The following objectives were assessed in Chapter 3: 
1) To investigate how HIF and HIF hydroxylases are regulated in response 
to proinflammatory cytokine stimulation, and also during monocytes to 
macrophage differentiation in normoxia. 
2) To investigate how HIF stabilisation during the differentiation process 
activates downstream effects, focusing on angiogenesis. 
3) To characterise monocyte/macrophage responses to normoxia/hypoxia 
and how this affects the HIF pathway, focusing on angiogenesis. 
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3.3 Results 
To fully understand how monocyte to macrophage differentiation affects the HIF pathway 
and the way HIF hydroxylases are being regulated over the differentiation time period, the human 
monocytic THP-1 cell line was used as a model system. THP-1 cells were either left as monocytes 
or differentiated to macrophages using a well-established differentiation inducing agent, PMA. 
Investigation of the expression levels of HIF hydroxylases was followed as well as 
characterisation of HIF downstream target gene expression. Finally, responses of 
monocytes/macrophages to hypoxia were assessed, using 1% O2 to mimic hypoxia. 
3.3.1 Characterisation of THP-1 monocytic cell responses to cytokine stimulation 
Study Design: 
THP-1 cells were left untreated (used as control), or treated with 10ng/ml of TNFα, IL-1β 
(lyophilized, both purchased from Peprotech Inc., Rocky Hill, NJ) and 10ng/ml of the bacterial 
stimulus LPS (Lipopolysaccharide, Peprotech, UK) for time points indicated. Concentrations used 
and incubation times were chosen from previously published studies (Frede et al., 2006; 
Krausgruber et al., 2011; Muz et al., 2012; Tjiu et al., 2009). 
I was first interested to see how THP-1 monocytic cells respond to cytokines in terms of 
the HIF pathway. For this purpose, THP-1 monocytic cells were stimulated with TNFα, IL-1β or 
LPS for the indicated time points, with monocytes plated for 30 minutes used as a control 
(Krausgruber et al., 2011). As shown in Figure 3-1, cytokine-mediated activation of 
undifferentiated THP-1 cells did not affect either HIF-1α or HIF-2α mRNA expression, an 
observation also mirrored by HIF-α protein data (Figure 3-2). With regard to the HIF-regulating 
enzymes, cytokine-induced activation of THP-1 cells did not affect mRNA expression of PHD-1 
however TNFα and LPS stimulation significantly reduced PHD-2 mRNA expression (Figure 3-3). 
FIH-1 remained unaffected, whereas an interesting change was noticed in case of PHD-3 mRNA, 
levels of which were significantly reduced throughout the stimulation period (Figure 3-4). PHD-3 
protein levels were not detected in this experiment, whereas PHD-2 protein was constantly 
expressed after stimulation with all cytokines (Figure 3-2). 
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Figure 3-1 Cytokine-mediated activation of THP-1 cells: effect on HIF-α isoform 
mRNA. 
THP-1 cells were stimulated with 10ng/ml of TNFα, IL-1β, and LPS for the time points indicated. 
Expression levels of (a) HIF-1α and (b) HIF-2α isoforms were assessed using RT-PCR analysis as 
previously described. Changes in gene expression are represented relative to expression levels of untreated 
THP-1 cells at time 0 (dashed line). Statistical analysis was performed using 1-way ANOVA with 
Dunnett’s post-hoc test for multiple comparisons versus untreated and all comparisons were found to be not 
significant. Data are from three (n=3) individual experiments. Each individual experiment was performed in 
triplicate and mean values were used for statistical analysis. 
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Figure 3-3 Cytokine-mediated activation of THP-1 cells does not affect PHD-1 and 
PHD-2 mRNA expression. 
THP-1 cells were stimulated with 10ng/ml of TNFα, IL-1β, and LPS for the time points indicated. 
Expression levels of (a) PHD-1 and (b) PHD-2 isoforms were assessed using RT-PCR analysis as 
previously described. Changes in gene expression are represented relative to expression levels of untreated 
THP-1 cells at time 0 (dashed line). Statistical analysis was performed using 1-way ANOVA with 
Dunnett’s post-hoc test for multiple comparisons versus untreated: * p<0.05. Data are from three (n=3) 
individual experiments. Each individual experiment was performed in triplicate and mean values were used 
for statistical analysis. 
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Figure 3-4 Cytokine-mediated activation of THP-1 cells does not affect PHD-3 and FIH-
1 mRNA expression. 
THP-1 cells were stimulated with 10ng/ml of TNFα, IL-1β, and LPS for the time points indicated. 
Expression levels of (a) PHD-3 and (b) FIH-1 isoforms were assessed using RT-PCR analysis as previously 
described. Changes in gene expression are represented relative to expression levels of untreated THP-1 cells 
at time 0 (dashed line). Statistical analysis was performed using 1-way ANOVA with Dunnett’s post-hoc 
test for multiple comparisons versus untreated: * p<0.05. Data are from three (n=3) individual experiments. 
Each individual experiment was performed in triplicate and mean values were used for statistical analysis. 
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3.3.2 Characterisation of PMA-treated THP-1 cells: expression of cell surface 
markers  
Study Design: 
THP-1 cells were left untreated (used as control), or treated with 10ng/ml of PMA 
(Sigma-Aldrich, Poole, UK) for time points indicated. Concentrations used and incubation times 
were chosen from studies previously published in the literature (Knowles et al., 2006; Kohro et 
al., 2004; Oda et al., 2006; Park et al., 2007). 
Having shown that THP-1 monocytic cells do not respond to cytokines or LPS to activate 
the HIF pathway, I next looked at the effect of differentiation on the HIF pathway as well as on 
HIF hydroxylases. Before investigating the effect of differentiation on the HIF pathway, the 
extent of differentiation status was assessed. 
PMA treatment resulted in a significant loss of expression of the monocyte marker CD14 
as early as 6 hours, and CD14 was reduced even more 24 hours after PMA differentiation. CD14 
mRNA levels were slightly increased (compared to 6 hours) after 48 hours of differentiation. 
Downregulation of the CD14 expression observed in that study is in agreement with previous 
studies looking at the PMA-mediated differentiation of THP-1 cells (Mahnke et al., 1997; 
Steinbach and Thiele, 1994). Similarly, CD16 mRNA levels were reduced over the differentiation 
time course. Interestingly, the macrophage marker CD36 was shown to be upregulated as early as 
6 hours following PMA induced differentiation of THP-1 cells to macrophages, a trend which 
remained unchanged until the end of the differentiation period as shown in  
Figure 3-5. FACS analysis was also used to characterise the PMA-treated THP-1 cells for 
the above mentioned antibodies (Figure 3-6). PMA differentiation of THP-1 cells for 3 and 5 days 
resulted in an increased expression of CD14, whereas the CD16 monocytic marker remained 
unchanged. In agreement with the qPCR data CD36 expression was upregulated throughout the 
differentiation period. 
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Figure 3-5 PMA-mediated THP-1 differentiation results in a reduction of monocyte 
markers and increase of macrophage markers. 
RT-PCR analysis of (a) CD14, (b) CD16 or (c) CD36 expression levels in THP-1 cells either left untreated 
or treated with PMA (10ng/ml) for time points indicated. Results are presented relative to THP-1 
monocytes, set as 1 (dashed line). Statistical analysis was performed using 1-way ANOVA with Dunnett’s 
post-hoc test for multiple comparisons versus untreated: * p<0.05, ** p<0.01, *** p<0.001. Data are from 
three (n=3) individual experiments. Each individual experiment was performed in triplicate and mean 
values were used for statistical analysis. 
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Figure 3-6 Characterisation of PMA-treated THP-1 cells by FACS. 
Representative FCM plots are shown. Cells have been stained as described in 2.5.7.3. THP-1 cells either 
left untreated (panel a) or treated with PMA (10ng/ml) for 3 days (panel b) and 5 days (panel c). 
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3.3.3 The M1/M2 paradigm 
Study Design: 
THP-1 cells were left untreated (used as control), or treated with 10ng/ml of PMA 
(Sigma-Aldrich, Poole, UK) for time points indicated. Interferon regulatory actor 5 (IRF-5, M1 
marker), oxygenase (HO-1, M2 marker), and hepcidin (HEP, M2 marker) were chosen to evaluate 
the polarisation status of the macrophage population (Cairo et al., 2011; Krausgruber et al., 2011; 
Sierra-Filardi et al., 2010). 
Because of the distinct and very specific roles of the M1/M2 macrophage subsets within 
the context of various inflammation-related diseases, the next step was to characterise the PMA-
treated THP-1 cells with regard to the classical and alternative activation markers. To evaluate the 
polarisation status, THP-1 cells were differentiated as previously for the time points indicated and  
RT-PCR analysis was performed for markers expressed by M2 macrophages, namely heme 
oxygenase (HO-1), and hepcidin (HEP), whereas interferon regulatory actor 5 (IRF-5) was used 
as an M1 marker. IRF5 expression was shown at the KIR to define commitment to the 
macrophage lineage by driving M1 macrophage polarisation by promoting Th1-Th17 responses 
(Krausgruber et al., 2011). Macrophages are considered to be storage sites of iron at inflamed 
sites (Escribese et al., 2012a). M1 macrophages are supposed to restrict iron release to the 
extracellular milieu, as a mean to potentiate their bactericidal and cytotoxic properties (Cairo et 
al., 2011). Additionally, the expression of proteins like ferroportin 1 (involved in cellular iron 
export) and HEP or HO-1 (both involved in reducing iron donation to the plasma) are 
differentially expressed in the different states of macrophage polarisation (Cairo et al., 2011). In 
particular, the expression of HEP and HO-1 is much higher in anti-inflammatory M2 
macrophages, contributing to the generation of an immunosuppressive environment (Sierra-
Filardi et al., 2010). In my study, IRF-5 mRNA expression levels remained relatively low 
throughout the differentiation period. By contrast the M2 polarisation markers HO-1 and HEP 
exhibited higher mRNA levels as early as 6 hours. HO-1 levels dropped after 6 hours and 
remained low until 72 hours, whereas HEP expression was further increased after 6 hours and 
remained unchanged until 72 hours of differentiation (Figure 3-7). Therefore it is proposed that 
PMA treatment skews THP-1 cells towards a more M2-like, rather than an M1-like, phenotype.  
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Figure 3-7 PMA-treated THP-1 cells exhibit an M2-like phenotype. 
RT-PCR analysis of (a) IRF-5, (b) HO-1 or (c) HEP expression levels in THP-1 cells either left untreated or 
treated with PMA (10ng/ml) for time points indicated. Results are presented relative to THP-1 monocytes, 
set as 1 (dashed line). Statistical analysis was performed using 1-way ANOVA with Dunnett’s post-hoc test 
for multiple comparisons versus untreated: * p<0.05, ** p<0.01, *** p<0.001. Data are from three (n=3) 
individual experiments. Each individual experiment was performed in triplicate and mean values were used 
for statistical analysis. 
 
 
 
Experiments in this study conducted on M2-like THP-1 macrophages were carried out on 
either 24 hours differentiation or 72 hours of differentiation. Therefore, a comparison was made 
between 24 and 72 hours of PMA-induced differentiation with regard to the expression levels of 
the M1/M2 differentiation markers. In either case PMA-treated THP-1 cells exhibited a more M2-
like phenotype as shown by the increased expression levels of the M2 markers  CD36, HO-1 and 
HEP, whereas the M1 marker IRF-5 did not  show such a dramatic increase (Figure 3-8). 
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Figure 3-8 Comparison of the differentiation status acquired by THP-1 cells after PMA 
differentiation for 24 and 72 hours. 
RT-PCR analysis of IRF-5, CD36, HO-1 or HEP expression levels in THP-1 cells either left untreated or 
treated with PMA (10ng/ml) for (a) 24 hours or (b) 72 hours. Results are presented relative to THP-1 
monocytes, set as 1 (dashed line). Statistical analysis was performed using Student’s t-test: *** p<0.001 
versus untreated THP-1 cells. Data are from three (n=3) individual experiments. Each individual 
experiment was performed in triplicate and mean values were used for statistical analysis. 
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3.3.4 The effect of PMA-mediated differentiation of THP-1 cells on the HIF 
pathway and HIF regulating enzymes 
Study Design: 
THP-1 cells were left untreated (used as control), or treated with 10ng/ml of PMA 
(Sigma-Aldrich, Poole, UK) for time points indicated. 
In vivo studies have shown HIF-1α expression to be essential for normal macrophage 
function. Conditional ablation of HIF-1α in murine myeloid cells greatly inhibited motility and 
invasion of ex vivo peritoneal macrophages (Cramer et al., 2003). Even though it was known that 
HIF-1α was essential for myeloid cell activation in response to inflammatory stimuli, what was 
not established was whether HIF-1 activity was affected during the differentiation from 
monocytes to macrophages and if so what was the involvement of the HIF hydroxylases in this 
process. Therefore, to investigate the effect of PMA-induced differentiation on the expression of 
HIF-α isoforms, THP-1 cells were treated with PMA as before either for 24 hours or 72 hours and 
mRNA expression was measured by RT-PCR analysis. PMA differentiation for 24 hours 
increased both HIF-α isoforms although significant changes were only observed in case of HIF-1α 
(Figure 3-9a). Of note is that 72 hours following PMA differentiation HIF-2α mRNA expression 
was significantly higher compared to HIF-1α as shown in Figure 3-9b.  
 
 
 
 
 
Figure 3-9 PMA differentiation of THP-1 cells upregulates HIF-α mRNA: comparison 
of 24 hours and 72 hours incubation. 
RT-PCR analysis of HIF-1α and HIF-2α expression levels in THP-1 cells either left untreated or treated 
with PMA (10ng/ml) for (a) 24 hours or (b) 72 hours. Results are presented relative to THP-1 monocytes, 
set as 1 (dashed line). Statistical analysis was performed using Student’s t-test: **p<0.01 versus untreated 
THP-1 cells. Data are from three (n=3) individual experiments. Each individual experiment was 
performed in triplicate and mean values were used for statistical analysis. 
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I found that monocytes do not express HIF-1α but following PMA differentiation for 24 
hours HIF-1α protein became stabilised. The amount of stabilised HIF-1α appeared to be 
decreased over differentiation time probably owing to the presence of oxygen which allowed 
PHDs to be active and hydroxylate and degrade HIF-α subunits. HIF-2α mRNA upregulation was 
not mirrored by protein data as it was difficult to detect it (Figure 3-10).  
 
 
 
 
 
 
 
Figure 3-10 PMA differentiation of THP-1 cells upregulates HIF-α protein. 
THP-1 cells were either undifferentiated or differentiated with 10ng/ml of PMA for the time points 
indicated. Immunoblot analysis of total protein extracts for HIF-1α and HIF-2α. α-tubulin is shown as a 
loading control.  
 
In a study of HIF-1α and HIF-2α in different tumour types, it was found that HIF-2α 
surprisingly was commonly upregulated in stromal cells rather than tumour cells (Talks et al., 
2000) . These cells were TAMs, and normal tissue macrophages did not express HIF-2α, which is 
a major phenotypic difference between tumour and normal macrophages. The absence of HIF-2α 
expression demonstrates the differential expression of key members of this pathway between 
various myeloid lineage cells (Walmsley et al., 2004). Having shown that PMA-mediated 
differentiation of THP-1 cells resulted in increased HIF-α isoform transcriptional activation and 
protein stabilisation of HIF-1α, the next question to be answered was why HIF-1α becomes 
stabilised during PMA differentiation despite the presence of oxygen. To investigate this, THP-1 
cells were treated with PMA for 6, 24, 48 and 72 hours to become M2-like macrophages, and the 
effect of PMA differentiation on the mRNA expression of the HIF hydroxylases was studied first. 
PMA-mediated differentiation of THP-1 to macrophages resulted in little or no discernible change 
in PHD-1 mRNA expression whereas FIH-1 mRNA expression was induced 72 hours after PMA 
differentiation (Figure 3-11a and Figure 3-12b). Interestingly, after 6 hours of PMA, PHD-2 
mRNA levels were reduced and begun to restore after 72 hours probably reflecting a HIF-
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dependent effect (Figure 3-11b). PHD-3 mRNA levels also appeared to be gradually decreased 
over PMA differentiation as shown in Figure 3-12a in agreement with the preferential PHD-3 
expression in M1 polarised macrophages (Escribese et al., 2012b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-11 The effect of PMA-mediated differentiation on the HIF hydroxylases PHD-1 
and PHD-2. 
RT-PCR analysis of (a) PHD-1 and (b) PHD-2 expression levels in THP-1 cells either left untreated or 
treated with PMA (10ng/ml) for time points indicated. Results are presented relative to THP-1 monocytes, 
set as 1 (dashed line). Statistical analysis was performed using 1-way ANOVA with Dunnett’s post-hoc test 
for multiple comparisons versus untreated: * p<0.05, ** p<0.01. Data are from three (n=3) individual 
experiments. Each individual experiment was performed in triplicate and mean values were used 
for statistical analysis. 
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Figure 3-12 The effect of PMA-mediated differentiation on the HIF hydroxylases PHD-3 
and FIH-1. 
RT-PCR analysis of (a) PHD-3 and (b) FIH-1 expression levels in THP-1 cells either left untreated or 
treated with PMA (10ng/ml) for time points indicated. Results are presented relative to THP-1 monocytes, 
set as 1 (dashed line). Statistical analysis was performed using 1-way ANOVA with Dunnett’s post-hoc test 
for multiple comparisons versus untreated: * p<0.05. Data are from three (n=3) individual 
experiments. Each individual experiment was performed in triplicate and mean values were used 
for statistical analysis. 
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The expression profile of HIF hydroxylases mRNA in THP-1 cells treated with PMA for 
24, 48 and 72 hours was also mirrored by the protein levels. In particular, PHD-1 and FIH-1 
remained unchanged throughout the differentiation time period whereas PHD-2 protein levels 
were reduced as monocytes were differentiated to M2-like macrophages, a reduction which might 
well account for HIF stabilisation after PMA differentiation for 24 hours. Of notice, PHD-2 
protein levels (which are themselves HIF-sensitive) were restored following 72 hours of PMA 
differentiation implying a HIF-feedback loop. PHD-3 was not possible to be detected (Figure 
3-13). Therefore these data suggest that a combination of increased HIF mRNA expression and a 
reduction in both PHD-2 mRNA and protein might be the reason why HIF is capable of escaping 
the pVHL-dependent proteasomal pathway. The absence of PHD-3 protein is probably due to 
decreased transcription and needs further investigation. 
 
 
 
 
 
 
 
 
 
Figure 3-13 PMA differentiation of THP-1 cells downregulates PHD-2 protein. 
THP-1 cells were either undifferentiated or differentiated with 10ng/ml of PMA for the time points 
indicated. Immunoblot analysis of total protein extracts for PHD-1, PHD-2, PHD-3 or FIH-1. α-tubulin is 
shown as a loading control.  
 
 
Several growth factors, hormones, and cytokines were shown to upregulate HIF-1 protein 
levels in normoxia through mechanisms that generally differ from those used under low oxygen 
concentration. These stimuli generally act by increasing HIF-1 gene transcription and/or mRNA 
translation without affecting protein stability (Metzen et al., 2003b; Tacchini et al., 2004; Treins 
et al., 2002) and thus, can cooperate with hypoxia to induce HIF-1 accumulation in an additive 
manner (Richard et al., 2000). So given that PHDs can also be regulated by the availability of co-
factors needed for proper function, we hypothesised that reduced enzymatic activity due to lack of 
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co-factors (i.e. iron, ascorbate and 2-oxoglutarate) and subsequent impaired HIF hydroxylation 
and degradation might be a reason for the observed normoxic HIF stabilisation. This could well 
be in addition to the increased mRNA transcription rates and the reduced PHD-2 protein levels. 
To address this question further and to investigate if HIF hydroxylase activity was impaired, 
THP-1 cells were differentiated with PMA for 24, 48 and 72 hours as before and protein lysates 
were probed for an antibody which recognises hydroxylated HIF subunits (OH-HIF 564). Figure 
3-14 shows again that 24 hours of PMA differentiation leads to normoxic HIF stabilisation; 
however we also observed hydroxylated HIF in THP-1 monocytes, probably due to remaining 
hydroxylase activity possibly driven by PHD-2. This is because as PHD-2 is being reduced over 
time, HIF hydroxylation is also reduced. As PHD-2 levels are restored back to normal levels -due 
to the HIF feedback loop- OH-HIF begins to accumulate again (Figure 3-14). The Oda et al study 
(Oda et al., 2006) also looking at the PMA-mediated differentiation of THP1- cells showed that 
HIF-1α binding to the pVHL remained unaffected thus proposing normal proline hydroxylation, 
whereas the mRNA expression of the HIF-regulating enzymes was shown to be increased (data 
not shown).  
 
 
 
 
 
 
 
Figure 3-14 Impaired hydroxylation leads to HIF-α accumulation during PMA-mediated 
differentiation of THP-1 cells. 
THP-1 cells were either undifferentiated or differentiated with 10ng/ml of PMA for the time points 
indicated. Immunoblot analysis of total protein extracts for OH-HIF 564. α-tubulin is shown as a loading 
control. The smear shown (lanes THP-1 and day 1) for OH-HIF reflects degradation owning to 
oxygenation. 
 
 
The observed normoxic HIF stabilisation caused by PMA differentiation of THP-1 also 
raised the question as to whether the HIF protein induction is reflected by induction of 
downstream HIF-dependent angiogenic genes (VEGF) and genes whose functions might have a 
profound effect on the angiogenic process (EphrinA3 and BNIP3). Therefore THP-1 cells 
differentiated with PMA for 72 hours were analysed by RT-PCR for the above mentioned 
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angiogenic genes. Interestingly, VEGF expression was significantly reduced, whereas expression 
of EphrinA3 and BNIP3 mRNA was not significantly altered (Figure 3-15). These data indicate 
that HIF is not contributing to transcription of these genes perhaps due to the presence of FIH-1 
which controls HIF signaling at a transcriptional level. 
 
 
 
 
 
 
 
 
 
 
Figure 3-15 PMA differentiation of THP-1 cells for 72 hours: effect on angiogenic gene 
expression. 
RT-PCR analysis of VEGF, EphrinA3 or BNIP3 expression levels in THP-1 cells either left untreated or 
treated with PMA (10ng/ml) for 72 hours. Results are presented relative to THP-1 monocytes, set as 1 
(dashed line). Statistical analysis was performed using 1-way ANOVA with Dunnett’s post-hoc test for 
multiple comparisons versus untreated: * p<0.05. Data are from three (n=3) individual experiments. Each 
individual experiment was performed in triplicate and mean values were used for statistical analysis. 
 
 
3.3.5 The effect of VD3-mediated differentiation of THP-1 cells on the HIF 
pathway and HIF regulating enzymes 
Study Design: 
THP-1 cells were left untreated (used as control), or treated with 100nM of 1.25 
dihydroxivitamin D3 (VD3), also known as 1,25-dihydroxycholecalciferol or calcitriol, (Sigma-
Aldrich, Poole, UK) for time points indicated. Concentrations used, incubation times and markers 
used to confirm the differentiation statuses of macrophages were chosen from studies previously 
published in the literature (Hmama et al., 1999; Martin et al., 1994). 
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In an attempt to verify my findings using PMA as a differentiation-inducing agent, I next 
investigated the effect of differentiation of THP-1 cells using another well-known differentiation-
inducing agent 1.25 dihydroxivitamin D3 (VD3), also known as 1,25-dihydroxycholecalciferol or 
calcitriol, on the expression patterns of the enzymes involved in the HIF cascade (PHDs and FIH-
1). While VD3 is known best for its role in regulating plasma calcium homeostasis (Boyle et al., 
1972; Nemere, 1995; Wang et al., 2005) and bone remodeling (Holick et al., 1972; Raisz et al., 
1972), it has also been shown to regulate the activities of myeloid cells and to promote host 
resistance to infection (Crowle et al., 1987; Liu et al., 2006; Rockett et al., 1998; Zasloff, 2006). 
The latter appears to involve activation of innate immunity through effects on mononuclear 
phagocytes (Ustianowski et al., 2005; Wilkinson et al., 2000). VD3 induces the differentiation of 
immature myeloid cells, such as the promonocytic cell line THP-1 along the 
monocyte/macrophage lineage leading to enhanced expression of the monocyte differentiation 
markers CD11b and CD14 (Hmama et al., 1999; Martin et al., 1994). 
To investigate the effect of VD3-induced differentiation on my system, cultured cells 
were treated with VD3 at a final concentration of 100nM for 6, 24, 48 and 72 hours as in the case 
with PMA (Martin et al., 1994). Compared to PMA treatment though, VD3 differentation resulted 
in a less adherent cell phenotype, an observation consistent with previous published studies. As in 
the case of PMA-mediated differentiation, the expression of monocyte/macrophage surface 
markers CD14, CD16 and CD36 was first assessed (Figure 3-16). CD14 expression levels 
appeared to have exactly the opposite trend compared to PMA treatment as they were gradually 
increased over differentiation time period, a trend also observed by other published studies in the 
literature (Collins et al., 1977; Dalton et al., 1988; Kontani et al., 1993; Shinagawa et al., 1995; 
Tanaka et al., 1983) suggesting that different differentiation inducing agents may have different 
effects on the expression of genes. CD16 and CD36 expression levels were induced as early as 6 
hours and then remained low throughout the differentiation period. The failure to obtain 
upregulation of the well-described macrophage marker CD36 in response to VD3 stimulation (in 
contrast to PMA treatment) may reflect a failure to induce fully differentiated macrophages.  
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Figure 3-16 Characterisation of VD3-mediated THP-1 cells: effect on differentiation 
markers. 
RT-PCR analysis of (a) CD14, (b) CD-16 or (c) CD36 expression levels in THP-1 cells either left untreated 
or treated with 100nM VD3 for time points indicated. Results are presented relative to THP-1 monocytes, 
set as 1 (dashed line). Statistical analysis was performed using 1-way ANOVA with Dunnett’s post-hoc test 
for multiple comparisons versus untreated: * p<0.05, ** p<0.01. Data are from three (n=3) individual 
experiments. Each individual experiment was performed in triplicate and mean values were used for 
statistical analysis. 
 
I then studied the effect of VD3 on the HIF hydroxylase expression. In particular, VD3 
differentiation did not significantly affect PHD-1 mRNA expression. With regard to PHD-2, its 
mRNA expression was reduced as early as 6 hours of differentiation and increased 24 hours and 
remained unchanged for the rest of differentiation time (Figure 3-17). Interestingly, PHD-3 
mRNA levels were significantly reduced, a trend also observed in case of PMA differentiation, 
whereas FIH-1 mRNA levels showed no significant changes (Figure 3-18). 
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Figure 3-17 The effect of VD3-mediated differentiation on the HIF hydroxylases PHD-1 
and PHD-2. 
RT-PCR analysis of (a) PHD-1 and (b) PHD-2 expression levels in THP-1 cells either left untreated or 
treated with 100nM VD3 for time points indicated. Results are presented relative to THP-1 monocytes, set 
as 1 (dashed line). Statistical analysis was performed using 1-way ANOVA with Dunnett’s post-hoc test for 
multiple comparisons versus untreated: * p<0.05. Data are from three (n=3) individual experiments. Each 
individual experiment was performed in triplicate and mean values were used for statistical analysis. 
  
 
 
 
 
 
Chapter 3 
118 
P H D -3
6 2 4 4 8 7 2
0 .0
0 .5
1 .0
1 .5
2 .0
T r e a t m e n t  t im e  w ith  V D 3  ( h o u r s )
F
o
ld
 c
h
a
n
g
e
v
e
rs
u
s
u
n
tr
e
a
te
d
**
** **
**
F I H -1
6 2 4 4 8 7 2
0 .0
0 .5
1 .0
1 .5
2 .0
T r e a t m e n t  t im e  w ith  V D 3  ( h o u r s )
F
o
ld
 c
h
a
n
g
e
v
e
rs
u
s
u
n
tr
e
a
te
d
(a)
(b)
ns
ns
ns
ns
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-18 The effect of VD3-mediated differentiation on the HIF hydroxylases PHD-3 
and FIH-1. 
RT-PCR analysis of (a) PHD-3 and (b) FIH-1 expression levels in THP-1 cells either left untreated or 
treated with 100nM VD3 for time points indicated. Results are presented relative to THP-1 monocytes, set 
as 1 (dashed line). Statistical analysis was performed using 1-way ANOVA with Dunnett’s post-hoc test for 
multiple comparisons versus untreated: *** p<0.01. Data are from three (n=3) individual experiments. Each 
individual experiment was performed in triplicate and mean values were used for statistical analysis. 
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3.3.6 Utilisation of PMA-treated THP-1 cells as a tool to investigate the M1/M2 
paradigm 
Study Design: 
I differentiated THP-1 cells with PMA (10 ng/ml for 24 hours) so that they adopt an M2-
like phenotype and then, after washing out the PMA, incubated them either with an M1 stimulus 
(IFN) or an M2 stimulus (IL-4) (both at a concentration of 10ng/ml for overnight) (Krausgruber 
et al., 2011; Tjiu et al., 2009; Watkins et al., 2007). 
A characteristic of macrophages is the huge functional plasticity they exhibit, which 
heavily depends on the relative abundance of the polarising cytokines milieu that in turn allows 
for a continuum of macrophage populations. In this setting I was interested in establishing a M1-
like/M2-like cell model system in order to avoid the time consuming and expensive method of 
elutriation.  The concept that macrophages can change their functional profiles (from M1 to M2 or 
M2 to M1) respectively depending on the cytokines (Th1 or Th2) to which they were exposed is 
well established (Watkins et al., 2007). If M2 macrophages are exposed to Th1 cytokines, they are 
polarised to M1; when M1-polarised macrophages are exposed to Th2 cytokines, they are 
polarized back to M2. I reasoned that establishing this model would enable me to investigate 
whether the HIF hydroxylases can contribute to the plasticity of macrophage polarisation.  
Therefore I attempted to convert one population into another by differentiating THP-1 cells with 
PMA for 24 hours so that they adopt an M2-like phenotype and then, after washing out the PMA, 
incubating them either with a M1 stimulus (IFN) or a M2 stimulus (IL-4) (Krausgruber et al., 
2011; Tjiu et al., 2009). PMA differentiation for 24 hours skewed THP-1 cells to a more M2-like 
phenotype as has been previously shown in this study by enhanced expression of the M2 markers 
CD36 and HEP, whereas the M1 marker IRF-5 expression remained low. Media change of the 
cultures and addition of the M2 polarising cytokine IL-4 induced the M2 phenotype to levels 
comparable to those induced by PMA alone. However, addition of the M1 polarising cytokine 
IFN following media change, reduced the expression of the M2 markers to levels lower than 
those obtained with PMA and/or IL-4 while at the same time IFN modestly increased the 
expression of the M1 marker IRF-5 as shown in Figure 3-19. 
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Figure 3-19 PMA differentiated THP-1 cells: phenotype switching after 24 hours. 
RT-PCR analysis of IRF-5, CD36, or HEP expression levels in THP-1 cells differentiated with 10ng/ml of 
PMA for 24 hours and either left unstimulated or stimulated overnight with 10ng/ml of IL-4 or IFN. 
Results are presented relative to THP-1 monocytes, set as 1 (dashed line). Statistical analysis was 
performed using 1-way ANOVA with Dunnett’s post-hoc test for multiple comparisons versus PMA-treated 
group:  *** p<0.001. Data are from three (n=3) individual experiments. Each individual experiment was 
performed in triplicate and mean values were used for statistical analysis. 
 
  
I next investigated the effect of phenotype switching after 24 hours with regard to the 
expression levels of the HIF-α isoforms and HIF hydroxylases. PMA differentiation of THP-1 
cells for 24 hours upregulated both HIF-α isoforms as previously shown. Figure 3-20a shows that 
phenotype shifting of cells from the original M2 phenotype towards an M1-like phenotype 
resulted in decrease of HIF-1α whereas it did not cause any significant changes on HIF-2α. These 
data are in agreement with the Randal Johnson work where differential activation of the HIF-α 
isoforms in response to Th1 and Th2-type cytokines has been reported for the first time (Takeda 
et al., 2010). With regard to the expression levels of the HIF regulating enzymes, PHD-2 and 
PHD-3 levels remained low in the case of IFN stimulation although IL-4 did induce a modest 
increase as shown in Figure 3-20b. These data were mirrored by protein analysis shown in Figure 
3-21. 
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Figure 3-20 PMA differentiated THP-1 cells: effect of phenotype switching after 24 hours 
on HIF and HIF hydroxylase mRNA. 
RT-PCR analysis of (a) HIF-α isoforms and (b) HIF hydroxylase expression levels in THP-1 cells 
differentiated with 10ng/ml of PMA for 24 hours and either left unstimulated or stimulated overnight with 
10ng/ml of IL-4 or IFN. Results are presented relative to THP-1 monocytes, set as 1 (dashed line). 
Statistical analysis was performed using 1-way ANOVA with Dunnett’s post-hoc test for multiple 
comparisons versus PMA-treated group: * p<0.05, ** p<0.01, *** p<0.001. Data are from three (n=3) 
individual experiments. Each individual experiment was performed in triplicate and mean values were used 
for statistical analysis. 
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Figure 3-21 PMA differentiated THP-1 cells: effect of phenotype switching after 72 hours 
 
THP-1 cells differentiated with 10ng/ml of PMA for 24 hours and either left unstimulated or stimulated 
overnight with 10ng/ml of IL-4 or IFN. Immunoblot analysis of total protein extracts for HIF-1α, HIF-2α 
PHD-2, or PHD-3. α-tubulin is shown as a loading control. 
 
3.3.7 Effect of hypoxia on the HIF/HIF hydroxylases in undifferentiated and PMA-
differentiated THP-1 cells 
Study Design: 
To study the effect of hypoxia on the HIF regulating enzymes the following experiments 
were set up . (i) THP-1 cells were either undifferentiated or differentiated with PMA (10ng/ml, 
for 3 days) and then were exposed to either 1% O2 (16 hours) or 21% O2 (16 hours, used as a 
control).  (ii)THP-1 cells were differentiated with PMA (10ng/ml, for 3 days) and left untreated 
(Normoxia indicated as N), or treated either with DMOG (1 mM, 6 hours, indicated as D) or 
exposed to 1% O2 (6 hours). DMOG concentration and hypoxia incubation time were chosen from 
published studies in the literature (Larsen et al., 2012; Muz et al., 2012). (iii)  THP-1 
undifferentiated cells differentiated were exposed to either 1% O2 (16 hours) or 21% O2 (16 hours, 
used as a control). (iv)THP-1 undifferentiated cells either left untreated (Normoxia indicated as 
N), or treated with DMOG (1 mM, 6 hours, indicated as D) or exposed to 1% O2 (6 hours). 
DMOG concentration and hypoxia incubation time were chosen from published studies in the 
literature (Larsen et al., 2012; Muz et al., 2012). 
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As cells are actively proliferating in situations such as wound healing, atherosclerotic 
plaque formation or in rheumatoid joints, the proliferating tissue mass becomes distant from the 
main blood vessels and the cells enter a phase of oxygen deprivation. Many studies in animals as 
well as in humans have shown that hypoxia can trigger and/or perpetuate the inflammatory 
machinery in diseases such as diabetes, atherosclerosis, RA and cancer (Eltzschig and Carmeliet, 
2011). In all these studies low oxygen levels are associated with accumulation of inflammatory 
cells, enhanced expression of HIF and hypoxia-responsive genes, and increased levels of pro-
inflammatory cytokines. There is thus an intriguing link between hypoxia and inflammation. In 
this context I aimed first to investigate whether sensitivity to hypoxia is different in 
undifferentiated THP-1 monocytic cells and PMA-differentiated M2-like THP-1 cells. For this 
purpose THP-1 cells were either undifferentiated or differentiated with PMA as previously and 
then were exposed to either 1% O2 or 21% O2, (used as a control). Exposure to 1% O2 did not 
affect the M2 marker HO-1 in either untreated THP-1 cells or M2-like THP-1 cells. In contrast, 
low oxygen levels reduced the M1 marker IRF-5 in untreated THP-1 monocytes but not in M2-
like THP-1 cells (Figure 3-22). 
 
 
 
 
 
 
 
 
Figure 3-22 The effect of hypoxia on M1 and M2 markers in THP-1 cells. 
RT-PCR analysis of IRF-5 and HO-1 expression levels in THP-1 cells either left (a) 
undifferentiated or (b) PMA-differentiated for 72 hours (10ng/ml) followed by exposure to 1% 
oxygen for 16 hours. Results are presented relative to normoxia, set as 1 (dashed line). Statistical 
analysis was performed using Student’s t-test versus normoxia (a) and versus THP-1 monocytes 
(b): * p<0.05. Data are from three (n=3) individual experiments. Each individual experiment was performed 
in triplicate and mean values were used for statistical analysis. 
  
 
Although no significant changes in the expression of the M1/M2 markers were observed 
in PMA-treated THP-1 when exposed to 1% O2, cells were able to respond to low oxygen tension 
Chapter 3 
124 
P M A  a lo n e P M A  +  h y p o xia
0
5
10
15
V E G F
E p h r in A 3
B N IP 3
***
**
***
T r e a tm e n t
F
o
ld
 c
h
a
n
g
e
v
e
rs
u
s
u
n
tr
e
a
te
d
P M A  a lo n e P M A  +  h y p o xia
0.0
2.5
5.0
7.5
400
500
600
700
800
P H D - 1
P H D - 2
P H D - 3
F IH -1
*
**
H I F  h y d r o x y la s e
F
o
ld
 c
h
a
n
g
e
v
e
rs
u
s
u
n
tr
e
a
te
d
(a) (b)
ns
ns
ns
ns ns
ns
ns
ns ns
by significantly upregulating the HIF-regulated genes PHD-2 and PHD-3. A significant increase 
in the expression of HIF-dependent angiogenic genes VEGF, EphrinA3, and BNIP3 was also 
observed after exposing PMA-treated THP-1 cells to 1% O2 (Figure 3-23). 
 
 
 
 
 
 
 
 
Figure 3-23 M2-like THP-1 cells respond to 1% O2.  
RT-PCR analysis of (a) HIF hydroxylases and (b) donwnstream HIF target PMA-treated cells for 72 hours 
(10ng/ml) followed by exposure to 1% oxygen for 16 hours. Results are presented relative to normoxia, set 
as 1 (dashed line). Statistical analysis was performed using Student’s t-test: *p<0.05, **p<0.01, ***p<0.001 
versus untreated. Data are from three (n=3) individual experiments. Each individual experiment was 
performed in triplicate and mean values were used for statistical analysis. 
 
Interestingly, 3 days PMA-treated THP-1 cells respond to 1%O2 (6 hours) and to 1mM 
DMOG (6 hours) by stabilising HIF-1α. A certain level of degradation (the smear noticed after 
exposure to Hypoxia) is also observed when THP-1 cells are exposed to hypoxia probably owing 
to reoxygenation (Figure 3-24). 
 
 
 
 
Figure 3-24 THP-1 macrophages 3 days post PMA differentiation stabilise HIF-1α after 
exposure either to 1mM DMOG or 1%O2. 
THP-1 cells were left untreated (Normoxia indicated as N), or treated either with DMOG (6 hours) as 
previously (indicated as D) or exposed to 1% O2 (6 hours). Immunoblot analysis of total protein extracts for 
HIF-1α. α-tubulin is shown as a loading control. 
 
To investigate whether stabilised HIF-1α in DMOG-treated or hypoxic THP-1 
macrophages translocates to the nucleus, cytoplasmic and nuclear fractions were extracted from 
HIF-1α 
 D H 
α tubulin 
 degradation 
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THP-1 cells left in normoxia or treated with DMOG (1mM) or exposed to 1%O2 and probed for 
HIF-1α as shown in Figure 3-25. HIF-1α appears to translocate to the nucleus following exposure 
to hypoxia or treatment with the hypoxia mimetic DMOG, although the DMOG response was not 
as robust as it has been previously observed. α tubulin was shown to be accumulated more in the 
cytoplasmic extracts compared to the nuclear as expected. 
 
 
 
 
 
 
Figure 3-25 HIF-1α translocates to the nucleus when THP-1 macrophages are exposed 
either to 1mM DMOG or 1%O2. 
THP-1 cells left untreated (Normoxia indicated as N), or treated either with DMOG as previously (indicated 
as D) or exposed to 1% O2.Cytoplasmic (indicated as c) and nuclear (indicated as n) fractions were 
extracted as described in 2.3.4 Immunoblot analysis of HIF-1α. α-tubulin is shown as a loading control for 
cytoplasmic extracts, whereas lamin and p65 are shown the loading control for nuclear extracts. 
 
Interestingly, a similar trend was also found after exposure of THP-1 monocytic cells to 
1% O2. With regard to the HIF- regulated enzymes only PHD-3 was found to be significantly 
increased following exposure to 1% O2 -further supporting the notion that THP-1 cells are more 
M1-like- whereas the rest of the HIF-regulating enzymes remained unaffected. As for the HIF-
downstream angiogenic target genes, VEGF and BNIP3 and EphrinA3 were significantly induced 
in a fashion comparable to that of PMA-treated THP-1 cells (Figure 3-26). 
 
 
 
 
 
 
 D H 
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Figure 3-26 THP-1 monocytic cells respond to 1% O2 by upregulating HIF target genes. 
RT-PCR analysis of (a) HIF hydroxylases and (b) donwnstream HIF target THP-1 monocytic cells exposed 
to 1% oxygen for 16 hours. Results are presented relative to normoxia, set as 1 (dashed line). Statistical 
analysis was performed using 1-way ANOVA with Dunnett’s post-hoc test for multiple comparisons versus 
normoxia: * p<0.05, ** p<0.01, ***p<0.001. Data are from three (n=3) individual experiments. Each 
individual experiment was performed in triplicate and mean values were used for statistical analysis. 
 
  
Interestingly, THP-1 monocytes respond to 1%O2 (6hrs) and to 1mM DMOG (6hrs) by 
stabilising HIF-1α, which might well account for the transcriptional upregulation of the 
aforementioned HIF target genes. A certain level of degradation is also observed when THP-1 
cells are exposed to hypoxia probably owing to reoxygenation (Figure 3-27). 
 
 
 
 
 
Figure 3-27 THP-1 monocytic cells respond to 1% O2 by increasing HIF protein. 
THP-1 cells left untreated (Normoxia indicated as N), or treated either with DMOG as previously (indicated 
as D) or exposed to 1% O2. Immunoblot analysis of total protein extracts for HIF-1α. α-tubulin is shown as 
a loading control. 
 
 
 
HIF-1α 
 D H 
α tubulin 
 degradation 
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To investigate whether stabilised HIF-1α in DMOG-treated or hypoxic THP-1 monocytes 
translocate to the nucleus, cytoplasmic and nuclear fractions were extracted from THP-1 cells left 
in normoxia or treated with DMOG (1mM) or exposed to 1%O2 and probed for HIF-1α as shown 
in Figure 3-28. Lamin did not work in this particular setting and p65 was used as an alternative 
control for the nuclear extracts. 
 
 
 
 
 
 
 
 
Figure 3-28 HIF-1α translocates to the nucleus when THP-1 monocytes are exposed 
either to 1mM DMOG or 1%O2. 
THP-1 cells left untreated (Normoxia indicated as N), or treated either with DMOG as previously (indicated 
as D) or exposed to 1% O2.Cytoplasmic and nuclear fractions were extracted as described in 2.3.4 
Immunoblot analysis of HIF-1α. p65 is shown the loading control for nuclear extracts. 
 
 
3.3.8 Effect of LPS on the HIF/HIF hydroxylases in undifferentiated and PMA-
differentiated THP-1 cells 
Study Design: 
To study the effect of LPS in monocyte/macrophages the following experiments were set 
up: (i) THP-1 cells either left undifferentiated or PMA-differentiated for 72 hours (10ng/ml) 
followed by stimulation with 1mM LPS for 16 hours (Blouin et al., 2004; Frede et al., 2006). 
Figure 3-31 (ii) THP-1 cells were PMA-differentiated for 72 hours (10ng/ml) followed by 
stimulation with 1mM LPS for 16 hours (Blouin et al., 2004; Frede et al., 2006). (iii) THP-1 
undifferentiated cells were stimulated with 1mM LPS for 16 hours (Blouin et al., 2004; Frede et 
al., 2006). 
 Bacterial LPS, a compound of the cell wall of Gram-negative bacteria, is a well known 
initiator of the inflammatory response.  Essential components of the cellular response to LPS are 
soluble or membrane-bound CD14 and TLR4 (Guillot et al., 2004) which are strongly upregulated 
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in macrophages. Thus sensitivity to LPS may increase in differentiated cells. To test this 
hypothesis THP-1 cells were either undifferentiated or differentiated with PMA as previously and 
then exposed to LPS or left untreated. LPS stimulation did not affect M1 marker IRF-5 in either 
undifferentiated THP-1 cells or M2-like THP-1 cells. Moreover, LPS did not affect the M2 
marker HO-1 in untreated THP-1 cells except for a modest increase of HO-1 in M2-like THP-1 
cells as shown in Figure 3-29. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-29 LPS does not affect M1 or M2 markers in THP-1 cells.  
RT-PCR analysis of IRF-5 and HO-1 expression levels in THP-1 cells either left (a) undifferentiated or (b) 
PMA-differentiated for 72 hours (10ng/ml) followed by stimulation with 1mM LPS for 16 hours. Results 
are presented relative to untreated cells, set as 1 (dashed line). Statistical analysis was performed using 
Student’s t-test versus untreated and all comparisons were found to be not significant. Data are from three 
(n=3) individual experiments. Each individual experiment was performed in triplicate and mean values 
were used for statistical analysis. 
 
Many studies have already provided evidence formally establishing a close link between 
the extracellular O2 concentrations and inflammatory responses. From that perspective I was 
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interested in investigating the potential role the HIF/HIF hydroxylases might play in this very 
dynamic interplay. In PMA-differentiated M2-like THP-1 cells, but not in untreated THP-1 cells, 
LPS increased expression of PHD-3, thus suggesting an active HIF pathway. The remaining HIF-
regulating enzymes PHD-1, PHD-2 and FIH-1 were unaffected (Figure 3-30). Moreover, in PMA-
differentiated M2-like THP-1 cells, but not in untreated THP-1 cells, LPS increased expression of 
VEGF, although other angiogenic genes including EphrinA3 and BNIP3 remained unaffected 
(Figure 3-31). 
 
 
 
 
 
 
 
Figure 3-30 PMA differentiated THP-1 cells: response to LPS (hydroxylases). 
RT-PCR analysis of HIF hydroxylases expression levels in PMA differentiated THP-1 cells for 72 hours 
(10ng/ml) followed by stimulation with 1mM LPS for 16 hours. Results are presented relative to untreated 
cells, set as 1 (dashed line). Statistical analysis was performed using 1-way ANOVA with Dunnett’s post-
hoc test for multiple comparisons versus untreated: ** p<0.0.  Data are from three (n=3) individual 
experiments. Each individual experiment was performed in triplicate and mean values were used for 
statistical analysis. 
 
 
 
 
 
 
 
 
Figure 3-31 PMA differentiated THP-1 cells: response to LPS (angiogenic genes). 
RT-PCR analysis of HIF target genes in PMA differentiated THP-1 cells for 72 hours (10ng/ml) followed 
by stimulation with 1mM LPS for 16 hours. Results are presented relative to untreated cells, set as 1 
(dashed line). Statistical analysis was performed using 1-way ANOVA with Dunnett’s post-hoc test for 
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multiple comparisons versus untreated: * p<0.05. Data are from three (n=3) individual experiments. Each 
individual experiment was performed in triplicate and mean values were used for statistical analysis. 
 
Undifferentiated THP-1 cells responded to LPS stimulation by downregulating PHD-3 
(Figure 3-32a), whereas none of the angiogenic genes that have been studied in the context of this 
thesis altered their expression levels (Figure 3-32b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-32 Undifferentiated THP-1 cells: response to LPS. 
RT-PCR analysis of (a) HIF hydroxylases or (b) angiogenic genes  in THP-1 cells for stimulated with 1mM 
LPS for 16 hours. Results are presented relative to untreated cells, set as 1 (dashed line). Statistical analysis 
was performed using 1-way ANOVA with Dunnett’s post-hoc test for multiple comparisons versus 
untreated: * p<0.05. Data are from three (n=3) individual experiments. Each individual experiment was 
performed in triplicate and mean values were used for statistical analysis. 
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3.4 Discussion 
The main aim of the studies described in this chapter was to investigate the mechanisms 
of regulation of the HIF hydroxylases during monocyte to macrophage differentiation. Although 
regulation of the HIF-α isoforms has been extensively investigated, little is known about the 
regulation of the oxygen sensors (i.e. HIF hydroxylases) in macrophages and how their expression 
levels affect HIF expression, stability and also genes whose expression is regulated by 
HIF/hypoxia. Monocytes/macrophages constitute critical components of the initial defence of the 
organism against invading microorganisms and extracellular pathogens. Together with the other 
cell types of the innate immune system they manage to quickly eradicate pathogens while 
transmitting signals that amplify the adaptive immune response. Infiltration of inflammatory cell 
types is a common characteristic of many diseases including RA. A very common situation that 
macrophages have to cope with upon entry into a tissue is oxygen-depleted conditions; therefore 
adaptation to the surrounding O2 concentrations is absolutely needed in order for macrophages to 
be able to exert their full spectrum of functions. There is a constantly growing list of evidence 
supporting the notion that oxygen tensions have the ability to shape macrophage polarisation 
status (Escribese et al., 2012a). Interestingly, important components of the Hypoxia/HIF pathway, 
the PHDs, are known to have a direct influence on macrophage polarisation, therefore creating a 
very close link between the O2 extracellular levels and inflammatory immune responses. In this 
context, the current study aimed to shed more light on the influence of monocyte-to-macrophage 
differentiation on the Hypoxia/HIF axis as well as how PHDs are being regulated during the 
differentiation process and influence the HIF pathway. 
Differentiation protocols have been developed by treating monocytic cell lines such as 
U937, HL-60 or THP-1 cells with stimuli such as PMA or VD3 (Fleit and Kobasiuk, 1991; Murao 
et al., 1983; Olsson et al., 1983). The phenotype of the macrophages in these protocols varies with 
the differentiation treatment and duration, reflecting differences in gene transcription (Kohro et 
al., 2004; Park et al., 2007). In my study treatment of THP-1 cells with 10ng/ml PMA for a time 
period between 6 hours to 48 hours resulted in loss of the monocyte cell surface markers CD14 
and CD16 whereas the macrophage marker CD36 was increased. Steinback and Thiele back in 
1994 (Steinbach and Thiele, 1994) investigated the phenotype of mononuclear phagocytes using 
flow cytometry and found CD14 being downregulated over differentiation period. In contrast, 
Kohro et al conducted an oligonucleotide microarray assay in order to characterise the monocytic 
cell line THP-1 and its mature macrophage-like form treated with 100ng/ml PMA for 7 days and 
found CD14 being upregulated after differentiation (Kohro et al., 2004). 
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The time course of all the differentiation experiments conducted in that study ranges from 
6 hours to 72 hours. THP-1 cells in were treated with 10ng/ml PMA for time points indicated and 
expression of widely used cell surface markers CD14, CD16 and CD36 was analysed by RT-PCR. 
CD14 was the first described pattern recognition receptor. It acts as a co-receptor (along with the 
Toll-like receptor 4 -TLR4- and MD-2) for the detection of bacterial lipopolysaccharide (LPS) 
(Kitchens, 2000; Tapping and Tobias, 2000). CD14 can bind LPS only in the presence of 
lipopolysaccharide-binding protein (LBP). Although LPS is considered its main ligand, CD14 
also recognises other pathogen-associated molecular patterns (Thomas et al., 2002).  
CD16 has been identified as Fc receptors FcγRIIIa (CD16a) and FcγRIIIb (CD16b). 
These receptors bind to the Fc portion of IgG antibodies. It is a cluster of differentiation found on 
the surface of natural killer cells, neutrophil polymorphonuclear leukocytes, monocytes and 
macrophages (Janeway and Medzhitov, 2002). The FcγR family consists of at least one high-
affinity receptor (FcγRI or CD64) and two low-affinity receptors (FcγRIIA or CD32 and FcγRIII 
or CD16). Ligation of these surface receptors with the Fc portion of Ig activates the cell signaling 
pathways and triggers various cellular responses, such as production of reactive oxygen species, 
antibody-dependent cellular cytotoxicity, and release of inflammatory cytokines (Daeron, 1997; 
Smith et al., 2006). 
CD36 belongs to the class B scavenger receptor family which includes receptor for 
selective cholesteryl ester uptake, scavenger receptor class B type I (SR-BI), and lysosomal 
integral membrane protein II (LIMP-II). CD36 interacts with a number of ligands, including 
collagen types I and IV, thrombospondin, erythrocytes parasitised with Plasmodium falciparum, 
platelet-agglutinating protein p37, oxidised low density lipoprotein and long-chain fatty acids. On 
macrophages CD36 forms part of a non-opsonic receptor (the scavenger receptor CD36/alphaV 
beta3 complex) and is involved in phagocytosis. CD36 has also been implicated in hemostasis, 
thrombosis, malaria, inflammation, lipid metabolism and atherogenesis (Endemann et al., 1993; 
Febbraio et al., 2000; Nicholson et al., 1995; Ockenhouse et al., 1991; Oquendo et al., 1989; 
Philips et al., 2005; Podrez et al., 2002; Silverstein et al., 1992; Tandon et al., 1989). 
The ability of macrophages to switch between macrophage phenotypes (M1/M2) and the 
distinct roles of the macrophage subsets within the context of various inflammation-related 
diseases is now well appreciated. Evaluation of the polarisation status of THP-1 cells treated with 
10ng/ml of PMA for between 6 to 72 hours led us to the suggestion that PMA treatment skews 
THP-1 cells to a more M2 macrophage phenotype. In an attempt to study the differences between 
PMA-treated THP-1 cells and monocyte-derive macrophages (MDM) Daigneault et al they came 
to the conclusion that despite the morphological similarities between the two model systems, 
PMA-treated THP-1 cells were characterised by greater levels of constitutive and inducible IL-1β 
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and TNF-α production following TLR2 or TLR4 stimulation. Therefore based on this observation 
they proposed that that PMA-treated THP-1 might have a different activation state to MDM. 
Indeed they provided FACS data showing no detectable CD206 - macrophage mannose receptor, 
a marker of alternatively activated macrophages- expression by PMA-treated THP-1 cells. Of 
notice is that they differentiated THP-1 cells using 100 ng/ml for 72 hours and as a mean to 
enhance the differentiation status of PMA-treated cells they removed the PMA containing media 
and they then incubated the cells in fresh media for a further 5 days in the absence of PMA. 
Because of the high degree of plasticity exhibited by macrophages it is possible that when they 
removed the PMA containing media, cultured cells were shifted back to the classical activation 
status and therefore CD206 detection was not feasible (Daigneault et al., 2010). In contrast to the 
Daigneault study and in agreement with my study is the Tjiu et al work where the role of TAMs 
was elucidated in human basal carcinoma (BCC). Differentiating THP-1 cells to macrophages by 
addition of 320nM PMA for 24 hours they found that THP-1 cells stopped proliferating, became 
attached and exhibited significant expression of M2 marker CD206 (Tjiu et al., 2009). This 
controversy -as previously mentioned- highlights that the phenotype macrophages acquire over 
the differentiation period depends on the differentiation conditions and duration and also points 
out that the “M1” and “M2” concepts are ill-defined and most probably experimental models can 
only reflect reality to a limited extent.  
As previously mentioned, a number of non-hypoxic stimuli can strongly increase the HIF-
1 complex in normal oxygen conditions and modulate the transcription of hypoxic genes (Feldser 
et al., 1999; Fukuda et al., 2002; Gorlach et al., 2001; Laughner et al., 2001; Liu et al., 2002; 
Richard et al., 2000; Sandau et al., 2001b; Scharte et al., 2003; Stiehl et al., 2002; Treins et al., 
2002). The main objective of this work was to investigate the effect of monocyte to macrophage 
differentiation on the HIF pathway. My results show that PMA treatment of THP-1 cells for 24 
and 72 hours at a final concentration of 10ng/ml resulted in an increase of both HIF-α isoforms at 
the mRNA level, and in an increase of HIF-1α at the protein level. Changes in HIF-1 activity 
associated with monocytic differentiation were for the first time reported by Oda et al in 2006 
(Oda et al., 2006). They differentiated THP-1 cells using 100nM PMA for 72 hours and found an 
increase for both HIF-1α and HIF-1β, whereas HIF-2 expression was not significantly altered by 
differentiation, thus suggesting an exclusive role of HIF-1α/HIF-1β heterodimers in activated 
macrophages. Interestingly, they provided data showing that unlike hypoxia, differentiation did 
not increase the half-life of HIF-1α protein in THP-1 cells. They also suggest (without showing 
data) that because PHD-2, PHD-3 and FIH-1 mRNA expression was increased during 
differentiation, a reduced availability of these enzymes is unlikely to be the cause of the observed 
normoxic HIF stabilisation. However in our study using a 12.5 times lower concentration of PMA 
it was found that PMA-mediated differentiation of THP-1 cells reduced PHD-2 mRNA and 
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protein levels after 24 hours, a reduction which might well account for the normoxic HIF 
accumulation in agreement with the role of PHD-2 as the main oxygen sensor in regulating HIF 
levels in steady state. As expected, PHD-2 appears to restore its expression levels after 48 hours 
of differentiation thus reflecting a HIF-dependent effect. The slight and not complete reduction in 
the availability of the HIF hydroxylase PHD-2 indicates that although PHD-2 is present, for some 
reason it is unable to exert its hydroxylase activity and impose limitations on HIF accumulation. 
To address the hypothesis of impaired hydroxylation over differentiation time protein lysates from 
PMA-treated THP-1 were probed for the OH-HIF antibody. Indeed impaired hydroxylation 
proved to account for the normoxic HIF stabilisation. The Oda et al study also looking at the 
PMA-mediated differentiation of THP-1 cells showed that HIF-1α binding to the pVHL remained 
unaffected thus proposing normal proline hydroxylation (Oda et al., 2006). Interestingly, Knowles 
et al utilised fluorescence measurements showing that differentiation was associated with a 
marked reduction of the labile iron pool which was responsible for the reduced enzymatic activity 
of the HIF hydroxylases. The HIF-1α stabilisation following the PHD-2 reduction also raised the 
question as to whether HIF-1α is transcriptionally active. In my study expression of angiogenic 
genes BNIP3 and EphrinA3 was not affected by differentiation and surpsingly enough VEGF 
mRNA expression was significantly decreased thus indicating the presence of additional level of 
HIF inhibition perhaps mediated by FIH-1, the levels of which are constantly expressed 
throughout the differentiation period. It has to be mentioned here that given the lower Km values 
of FIH-1 compared to those of PHDs, the latter require higher levels of oxygen for activity 
(Fandrey et al., 2006).  
It is becoming increasingly appreciated that O2 levels critically shape macrophage 
polarisation through modulation of their transcriptional and metabolic programmes (Takeda et al., 
2010; Takeda et al., 2011). Recent data have demonstrated that the PHDs directly influence 
macrophage polarisation, and have formally established a close link between extracellular oxygen 
levels and inflammatory and immune responses (Escribese et al., 2012b). In my study modulation 
of the differentiation status using either IFN- (M1) or IL-4 (M2) increased HIF-α mRNA, 
although protein levels were not found to be further increased. IL-4 addition did not induce 
further the M2 phenotype, although IFNγ reduced significantly the expression of the M2 marker 
HEP to levels lower than those obtained with PMA alone. My data also showed that shifting 
macrophages phenotypes did not have any effect on the expression levels of the PHDs, with the 
exception of IL-4. Overall, further work needs to be done and alternative approaches need to be 
considered to better establish the aforementioned system (discussed later in Future Work). 
Peripheral blood monocytes constitute the early mononuclear phagocyte component of 
the leukocyte infiltrate at sites of inflammation, infection, and tumour growth, where they 
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differentiate into inflammatory and tumour-associated macrophages. Given their critical role in 
the regulation of the initial phases of inflammation, it was of critical importance to study the early 
responses of monocytes to the hypoxic environment (Murdoch et al., 2004). The first 
transcriptome analysis of hypoxic monocytes was performed on primary peripheral blood human 
monocytes exposed to 1% O2 for 16 hours by Bosco et al in 2006 (Bosco et al., 2006). The 
transcriptome analysis revealed expression of known hypoxia-responsive genes including 
adrenomedullin (ADM), BNIP3, IL-1, LDH, PDK1, PGK1, PHD2, TNF, VEGF, VEGFR1. New 
genes involved in immune responses also appeared to be upregulated included scavenger 
receptors, cytokines and chemokines, in particular CCL20/MIP-3, a chemoattractant for immature 
dendritic cells, activated/memory T lymphocytes, and naive B cells (Bosco et al., 2006). In my 
study, undifferentiated THP-1 cells responded to hypoxia by increasing PHD-3, but not PHD-2, as 
well as the angiogenic targets EphrinA3, VEGF and BNIP3. These data are in agreement with 
previous findings in other cell types (del Peso et al., 2003; Hofbauer et al., 2003; Wenger et al., 
2005) and suggest an O2-dependent HIF-1-driven autoregulatory mechanism, needed to ensure 
fast HIF-1α degradation upon reoxygenation, also in monocytes (Bosco et al., 2006). In 
monocytes, hypoxia led to stabilisation of HIF-1, which remained cytoplasmic (Fangradt et al., 
2012). Monocytes upon migrating to inflamed tissue differentiate into macrophages thus 
suggesting that hypoxia induces many phenotypic alterations with subsequent impact on the 
outcome of the inflammatory/immune response. One of the first studies to characterise the 
upregulated genes in such hypoxic areas was performed by Burke et al in 2003 who showed 
induction of VEGF, GLUT-1, MMP-7 in human monocyte derived macrophages after 6 days of 
plating (Burke et al., 2002b). In my study, even though hypoxia did not affect differentiation 
status of M2-like THP-1 cells, cells were found to be capable of responding to hypoxia, 
significantly increasing expression of PHD-3 and angiogenic targets EphrinA3, VEGF and 
BNIP3. M2-like THP-1 cells also upregulated PHD-2, in contrast to undifferentiated THP-1 cells. 
Changes in gene expression caused by hypoxia that ultimately allow macrophages to 
adapt their metabolic activity to anaerobic glycolysis are now well documented and include 
increased production of lactate and pyruvate, and metabolic acidosis (Lewis and Murdoch, 2005; 
Lewis et al., 1999). They also upregulate their release of the important pro-angiogenic growth 
factor VEGF when exposed to hypoxia in vitro and in hypoxic areas of human breast tumours 
(Lewis et al., 2000). Both HIF-α isoforms were shown to play a role in controlling the 
transcriptional response to hypoxia in macrophages. However, there is some degree of 
controversy as to which HIF-α isoform is the most critical mediator in regulating macrophage 
responses to hypoxia. Using PMA-differentiated U937 monocytic cells cells, Talks et al in 2000 
showed that HIF-2α is the predominant transcription factor upregulated by hypoxia (Talks et al., 
2000). Moreover, using adenoviral gene transfer to examine the effects on gene expression of the 
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over-expression of HIF-1α versus HIF-2α in human macrophages, (White et al., 2004) found that 
HIF-2α was the primary mediator of hypoxic induction of macrophage genes encoding angiogenic 
proteins. In contrast, Burke et al provided results showing that human macrophages preferentially 
upregulate HIF-1α after exposure to hypoxia in vitro and in avascular, hypoxic areas of various 
forms of human tumours in vivo (Burke et al., 2002b). 
Hypoxia/HIF is a potent apoptotic stimulus and is an important cause of cell death in 
cancer and ischemia. Although hypoxia is generally proapoptotic, in some situations, brief or 
repetitive exposure to hypoxia may result in cells becoming resistant to apoptosis through the 
mitochondrial Bcl-2 pathway (Weinmann et al., 2004). In the context of ischemia, recurrent 
hypoxia results in a related phenomenon that has been called preconditioning, which may serve to 
protect tissues from ischemic damage (Stone, 2003). Transcription of the gene encoding Nip3, a 
proapoptotic member of the Bcl-2 family of cell death factors is now known to be strongly 
induced in response to hypoxia (Bruick, 2000). BNIP3 and BNIP3L are members of the so called 
BH3-only subfamily of Bcl-2 family proteins (Willis and Adams, 2005) that heterodimerise and 
antagonise the activity of the prosurvival proteins (Bcl-2 and Bcl-XL) (Boyd et al., 1994). Both 
BNIP3 and BNIP3L have been reported to promote cell death in various disease settings (Lee and 
Paik, 2006; Webster et al., 2005). Of relevance to this work, RA synovial hyperplasia is at least 
partially related to a resistance to apoptosis exhibited by fibroblasts-like synoviocytes (FLS). 
Kammouni et al showed that the proapoptotic protein BNIP3 was induced in FLS by hypoxia and 
was widely expressed in the RA synovium, but its proapoptotic effects were inhibited by 
cytokines also being present in the RA synovium namely TNF-α and IL-1β (Kammouni et al., 
2007). However, many studies failed to reproduce the proapoptotic cell death features of 
ectopically expressed BNIP3 or BNIP3L in various cell types, including MEFs, MCF7, PC3 and 
LS174 cells (Papandreou et al., 2005). The cell death function of BNIP3/BNIP3L in a hypoxic 
environment has been put under questioning and postulated a positive role in activating the 
autophagic cell survival process (Pouyssegur et al., 2006). Zhang et al (Zhang et al., 2008) 
demonstrated the hypoxia-induced mitochondrial autophagy via the expression of BNIP3; a 
finding supporting the idea that hypoxia plays a protective role by decreasing ROS. However, the 
precise role of BNIP3-BNIP3L in hypoxia-induced autophagy was not fully elucidated until 2009 
when Gregory Bellot et al showed that the atypical BH3 domains of BNIP3-BNIP3L induce 
autophagy by disrupting the Bcl-2-Beclin1 complex without incuding cell death (Bellot et al., 
2009). 
Endothelial cell receptor tyrosine kinases (RTK) have been recognised as critical 
mediators of angiogenesis. These are the vascular endothelial growth factor (VEGF) receptor, Tie, 
and Eph RTKs. The functions of both VEGF/VEGF receptor and angiopoietins/Tie-2 receptor 
families in vascular development and angiogenesis are well studied, and reviewed elsewhere 
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(Romanovsky et al., 2006). The Eph receptor tyrosine kinase family, however, represents a new 
class of RTKs, and its role in angiogenesis is just beginning to emerge. First, unlike other families 
of RTKs, which bind to soluble ligands, Eph receptors interact with cell surface-bound ephrin 
ligands. Second, distinct from other RTK ligands, ephrins do not promote cell proliferation; 
rather, they mediate cellular repulsion, adhesion, cell attachment to extracellular matrices, and cell 
migration in various cell types. Finally, these receptor–ligand interactions activate signaling 
pathways in a bi-directional fashion, through both the Eph receptors and ephrin ligands. Their 
functions are best studied in the nervous system, where Eph and ephrin molecules are involved in 
patterning the developing hindbrain rhombomeres, axon pathfinding, and guiding neural crest cell 
migration (Cheng et al., 2002). A series of publications has also demonstrated the essential role of 
Eph/ephrin in vascular development during embryogenesis and in adult angiogenesis (Flanagan 
and Vanderhaeghen, 1998). For clarity, the Eph receptors have been divided in two subclasses, 
classesA and B, depending on the type of interaction with the ephrin ligands. In general, Eph class 
A (EphA) receptors bind to GPI anchored ephrin ligands (ephrinA), while Eph class B receptors 
(EphB) bind to ephrin ligands containing transmembrane domains (ephrinB) (Romanovsky et al., 
2006). Stimulation of HEK by EphA3 results in integrin-dependent cell adhesion to laminin as 
well as tyrosine phosphorylation of an unknown 120KD protein (Huai and Drescher, 2001). These 
observations indicate that ephrinA ligands are capable of transducing signals to influence actin 
cytoskeletal changes, attachment, and migration. Expression of ephrin ligands may be induced by 
growth factors and cytokines in various cell types. EphrinA1, the first ephrin ligand identified, 
was shown to be an immediate early gene product induced by TNF-α in cultured human umbilical 
venous endothelial cells (HUVEC) (Holzman et al., 1990). Transcriptional regulators of EphrinA3 
include Sonic Hedgehog and GH6 transcription factor shown to regulate EphA3 expression in the 
retina (Schulte and Cepko, 2000). Aside from its predominant characterisation as a pro-
angiogenic factor in adult mouse tumours, (Easty et al., 1999) ephrinA1 appears to be involved in 
inflammation and apoptosis, two very important facets of infarct progression. It was reported in 
2006 that Eph receptors are differentially expressed at early and late stages of inflammation 
(Romanovsky et al., 2006). For example, at earlier stages of inflammation, EphA2 and ephrinB2 
expression is predominantly localised to epithelial and endothelial cells, promoting disruption of 
the endothelial/epithelial barrier. However, as the inflammatory process progresses, expression of 
EphA1, EphA3, EphB3 and EphB4 on these cells decreases, allowing infiltrating leukocytes to 
adhere to endothelial cells by disrupting endothelial/epithelial barriers (Romanovsky et al., 2006). 
Since my data suggest that the maturation and differentiation of myeloid cells affect the 
HIF pathway we were interested whether the sensitivity to a potent inflammatory stimulus such as 
LPS could affect this process. According to my findings, undifferentiated THP-1 cells did not 
respond to LPS, except for reduction in PHD-3, and expression of angiogenic targets EphrinA3, 
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VEGF and BNIP3 was not significantly affected. In contrast, Frede et al in 2006 provided 
evidence showing that LPS at a concentration of 1µg/ml to THP-1 cells under normoxic 
conditions significantly increased HIF-1α accumulation starting after 2 hours of LPS treatment 
and peaking at 4 h. Treatment of THP-1 cells with LPS under hypoxic conditions further 
enhanced hypoxia-induced HIF-1α accumulation and prolonged the elevation of HIF-1α protein 
content up to 16 h (Frede et al., 2006). LPS did not affect differentiation status of M2-like THP-1 
cells, but cells were able to respond to LPS, significantly increasing expression of PHD-3 and 
angiogenic target VEGF, unlike undifferentiated THP-1 cells. Of interest, THP-1 cells 
differentiated with PMA for 5 days showed increased HIF-1 mRNA and protein in response to 
LPS, with further protein induction by hypoxia, paralleled by expression of ADM. LPS increased 
HIF-1 mRNA expression through activation of NFB site in promoter of HIF-1 gene and an 
increase in p44/42 MAPK (Frede et al., 2006). Nishi et al in 2008 reported that LPS enhanced 
HIF-1 protein through a translation-dependent pathway and HIF-1 transcriptional activity in 
THP-1 human myeloid cells that have undergone macrophage differentiation, but not in 
undifferentiated monocytic THP-1 cells. LPS-induced HIF-1 activation was blocked by treatment 
with antioxidants (N-acetylcysteine or thioredoxin-1), but was independent of NFB activity 
(Nishi et al., 2008). Having investigated how HIF/HIF hydroxylases are regulated during the 
differentiation process as well as the responses of monocytes/macrophages using the THP-1 
monocytic cell line, I was then interested to see to what extend primary cells behave the same way 
as the cell line used in this chapter.  
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4 INVESTIGATION OF THE MECHANISMS OF HIF 
HYDROXYLATION REGULATION DURING MONOCYTE TO 
MACROPHAGE DIFFERENTIATION IN HUMAN MONOCYTE-
DERIVED MACROPHAGES 
4.1 Introduction 
It is important to recognise that the THP-1 model system (as described in Chapter 3) and 
primary monocyte-derived macrophages have significant differences which mainly concern 
mRNA, protein expression of various molecules as well as function, such as lipid accumulation 
(Qin, 2012). Moreover, both cell types have different pathophysiological processes with regard to 
apoptosis. As previously mentioned, THP-1 is an immortalised cell line that grows and divides 
indefinitely in vitro under appropriate culture conditions. By contrast, human primary monocytes 
require inflammatory stimuli, including IL-1β, TNF-α and LPS, which provide all the essential 
surviving factors to inhibit apoptosis (Mangan and Wahl, 1991; Mangan et al., 1991). In my 
study, culturing human primary elutriated monocytes without addition of any of the above 
mentioned inflammatory mediators resulted in non-viable cell cultures, an observation in 
agreement with other published studies in the literature (Mangan et al., 1991). 
The data described in Chapter 3 suggest that monocyte to macrophage differentiation in 
the THP-1 cell model stabilises HIF probably due to decreased PHD-2 availability and reduced 
PHD-2 enzymatic activity. The normoxic HIF stabilisation might be needed as a means to 
precondition monocytes/macrophages to cope with the hypoxic inflammatory 
milieu/microenvironment they face upon migration to an inflamed/injured tissue. The work 
described in the current chapter aims to translate the findings from Chapter 3 to human primary 
monocytes derived macrophages isolated by elutriation from healthy donors as described in 
Section 2.1.1.2. Macrophages demonstrate remarkable plasticity that allows them to efficiently 
respond to environmental signals and change their phenotype and physiology in response to 
cytokines and microbial stimuli (Mosser and Edwards, 2008). These changes can give rise to 
populations of macrophages with distinct functions, which are phenotypically characterised by 
production of pro-inflammatory and anti-inflammatory cytokines (Gordon, 2003). Based on the 
Th1/Th2 polarisation concept (Romagnani et al., 2000), these cells can roughly be classified as 
M1 (classical) macrophages, that produce pro-inflammatory cytokines (IL-12high, IL-23high, IL-
10low) and mediate resistance to pathogens and tissue destruction, and M2 (alternative) 
macrophages, that produce anti-inflammatory cytokines (IL-12low, IL-23low, IL-10high ) and 
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promote tissue repair and remodelling as well as tumour progression (Gordon, 2003; Martinez et 
al., 2008). 
 Macrophages evolve within a specific microenvironment out of monocytes (Volkman 
and Gowans, 1965) and the differentiation of monocytes depends on lineage-determining 
cytokines, with M-CSF and GM-CSF among the most important ones (Verreck et al., 2004). The 
M1 macrophage phenotype is induced by IFN-γ followed by stimulation with bacterial products 
like LPS or by treatment of monocytes with GM-CSF (Fleetwood et al., 2007; Hoeve et al., 2006; 
Lari et al., 2007; Verreck et al., 2004; Verreck et al., 2006). Conversely, the M2 macrophage 
phenotype manifests when monocytes are cultured in the presence of M-CSF (Fleetwood et al., 
2007). The importance of IRF-5 for establishing the pro-inflammatory M1 macrophage phenotype 
and initialising Th1-Th17 responses was for the first time highlighted by Thomas Krausgruber 
(Krausgruber et al., 2011) thus highlighting the potential for therapeutic interventions via 
modulation of the IRF-5/IRF-4 balance.  
4.2 Objectives 
In this context, the current study aimed to shed more light on the influence of human 
primary monocyte-to-macrophage differentiation on the Hypoxia/HIF axis as well as how PHDs 
are being regulated during the differentiation process and influence the HIF pathway. Therefore, 
the key objectives addressed were the following: 
1) To investigate the impact of monocyte to macrophage differentiation on the HIF 
pathway 
2) To investigate how are HIF hydroxylases regulated during the monocyte to 
macrophage differentiation 
3) To investigate whether the  differentiation process affect the sensitivity to 
hypoxia and/or inflammatory stimuli 
 
4.3 Results 
To fully understand how monocyte to macrophage differentiation affects the HIF pathway 
and the way HIF hydroxylases are being regulated over the differentiation time period, human 
primary elutriated cells were used as a model system. Human monocytes were either left 
undifferentiated or differentiated using a well-established differentiation protocol (Krausgruber et 
al., 2011). Investigation of the expression levels of HIF hydroxylases was followed as well as 
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characterisation of HIF downstream target gene expression. Finally, responses of 
monocytes/macrophages to hypoxia were assessed, using 1% O2 to mimic hypoxia. 
4.3.1 Polarisation of human primary monocytes to M1 and M2-like macrophages 
Study Design: 
Human monocytes were either left untreated or treated for time points indicated with 
GM-CSF (50ng/ml) or M-CSF (100ng/ml) to generate M1 and M2 macrophage populations 
respectively and the extent of differentiation was then evaluated using IRF-5 expression levels as 
an M1 marker and HO-1 as an M2 marker (Krausgruber et al., 2011). 
Macrophages are a heterogeneous population of immune cells that are essential for the 
initiation and resolution of pathogen- or tissue damage-induced inflammation (Gordon and 
Taylor, 2005). I first differentiated the elutriated monocytes with the lineage-determining 
cytokines GM-CSF and M-CSF (Krausgruber et al., 2011) to generate M1 and M2 macrophage 
populations respectively and then evaluated the extent of differentiation using IRF-5 expression 
levels as an M1 marker and HO-1 as an M2. I first wanted to establish the best differentiation 
time point that would serve as the starting point to study the responses of differentiated 
macrophages to hypoxia or other inflammatory stimuli. Therefore in a preliminary study, the 
expression of the differentiation markers M1/M2 was studied in a full time course starting from 2 
hours to 120 hours, to identify at which time point I was observing the major differences between 
M1 and M2 polarised macrophages with regard to IRF-5 and HO-1 mRNA expression. As Figure 
4-1 shows, treatment of monocytes with 50ng/ml of GM-CSF resulted in upregulation of IRF-5 
mRNA expression with 2 hours, and appeared to be gradually increasing up to 8 hours of 
differentiation when it reaches its maximum levels. IRF-5 mRNA expression started gradually 
decreasing from 8 hours of treatment until 120 hours. Expression of HO-1 remained lower than 
that of IRF-5 for the differentiation period between 2 to 48 hours but it was slightly increased 
between 72 to 120 hours of treatment. Conversely, treatment of monocytes with 100ng/ml of M-
CSF resulted in upregulation of HO-1 mRNA expression within 48 hours unlike treatment with 
GM-CSF. HO-1 mRNA expression peaked at 72 hours and then was slightly reduced till 120 
hours. 
 
 
 
Chapter 4 
143 
IRF-5
2 4 8 24 48  72 120 2 4 8 24 48  72 120 
0
5
10
15
20
M1 M2
Differentiation time (hours)
F
o
ld
 c
h
an
g
e
ve
rs
u
s 
m
on
oc
yt
es
HO-1
24 48  72 120 24 48  72 120 
0
1
2
3
M1 M2
Differentiation time (hours)
F
o
ld
 c
h
an
g
e
ve
rs
u
s
m
on
oc
yt
es
(a)
(b)
**
**
**
*
**
**
ns
ns
ns ns
ns
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-1 M1-polarised macrophages express IRF-5 and M2 polarised macrophages 
express HO-1. 
Human monocytes were either left untreated or treated for time points indicated with GM-CSF (50ng/ml) or 
M-CSF (100ng/ml). Expression of (a) IRF-5 and (b) HO-1 was assessed by RT-PCR. Results are mean ± 
SD relative to mRNA levels in untreated monocytes, set as 1 (dashed line). Statistical analysis was 
performed using 1-way ANOVA: * p<0.05, ** p<0.01 comparing M1 versus M2 at each time point. Data 
are from three (n=3) individual experiments. Each individual experiment was performed in triplicate and 
mean values were used for statistical analysis. 
 
I then chose to study in more detail the differentiation process at 1 day (early) and 3 days 
(late) of differentiation. Previous studies at our Institute have utilised 3 days differentiated 
macrophages in their studies (Krausgruber et al., 2011). As shown in Figure 4-2, M1 polarised 
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macrophages expressed significantly higher levels of IRF-5 after 1 day of differentiation 
compared to M2 cells, which declines after 3 days. On the other hand HO-1 expression by M2 
cells peaks following 3 days of M-CSF differentiation. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-2 M1 macrophages express significantly higher levels of IRF-5 1 day after 
GM-CSF differentiation and M2 macrophages express significantly higher 
levels of HO-1 3 days after M-CSF differentiation. 
Human monocytes were either left untreated or treated for time points indicated with GM-CSF (50ng/ml) or 
M-CSF (100ng/ml). Expression of (a) IRF-5 and (b) HO-1 was assessed by RT-PCR. Results are mean ± 
SD relative to mRNA levels in untreated monocytes, set as 1 (dashed line). Statistical analysis was 
performed using 1-way ANOVA: *** p<0.001 comparing M1 versus M2 at each time point. Data are from 
three (n=3) individual experiments. Each individual experiment was performed in triplicate and mean 
values were used for statistical analysis. 
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4.3.2 Monocyte to macrophage differentiation leads to normoxic HIF stabilisation 
Study Design: 
Human monocytes were either left untreated or treated for time points indicated with 
GM-CSF (50ng/ml) or M-CSF (100ng/ml) to generate M1 and M2 macrophage populations 
respectively (Krausgruber et al., 2011) and the effect of monocyte to meacrophage differentiation 
on the HIF pathway was studied. 
The effect of PMA-mediated differentiation of the THP-1 monocytic cell line on HIF and 
important components of the HIF pathway namely the PHDs, was discussed in Section 3.3.4. In 
this Chapter, I aimed to also use human primary M1 and M2 macrophages to study the HIF 
pathway and to compare between a cell line and primary cells. Therefore, I first examined the 
effect of M1/M2 differentiation on the expression levels of the HIF-1α and HIF-2α isoforms. 
Human monocytes were differentiated as before for 1 and 3 days. As Figure 4-3 shows, M1 
macrophages appeared to upregulate mRNA levels of both HIF-α isoforms, but HIF-2α to a 
greater extent. Overall no significant differences between M1 and M2 macrophages were 
observed with regard to the HIF-α isoform expression. 
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Figure 4-3 M1 and M2 differentiation upregulates HIF-α mRNA. 
Human monocytes were either left untreated or treated for time points indicated with GM-CSF (50ng/ml) or 
M-CSF (100ng/ml). Expression of (a) HIF-1α and (b) HIF-2α was assessed by RT-PCR. Results are mean ± 
SD relative to mRNA levels in untreated monocytes, set as 1 (dashed line). Statistical analysis was 
performed using 1-way ANOVA comparing M1 versus M2 at each time point and all comparisons were 
found to be not significant. Data are from three (n=3) individual experiments. Each individual experiment 
was performed in triplicate and mean values were used for statistical analysis. 
 
  
The HIF-1α transcriptional upregulation by both M1 and M2 cells was also mirrored by 
protein data. Normoxic stabilisation of HIF-1α protein was observed in both M1 and M2 cells 
following 1 and 3 days of differentiation. Again no differences between M1 and M2 macrophages 
were seen in terms of HIF-1α protein accumulation. Of note is that M1 and M2 cells did not 
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significantly induce HIF-2α protein levels after 1 day of differentiation, but a very weak HIF-2α 
protein band was noticed 3 days following differentiation in both macrophage phenotypes (Figure 
4-4). 
 
 
 
 
 
 
 
Figure 4-4 Monocyte to macrophage differentiation stabilises HIF-1α in both M1 and 
M2 macrophages. 
Human monocytes were treated for time points indicated with GM-CSF (50ng/ml) or M-CSF (100ng/ml). 
Immunoblot analysis of total protein extracts for HIF-1α and HIF-2α compared to freshly isolated 
monocytes. α-tubulin is shown as a loading control. 
 
Donor variability is a characteristic feature of human monocyte derived macrophages, 
posing limitations as a model system. For example in a donor analysed in Figure 4-5, HIF-1α 
mRNA was seen to be gradually increasing only in M1 cells throughout the differentiation period 
compared to M2 differentiation that did not upregulate HIF-1α mRNA expression. HIF-2α mRNA 
was increased in both M1 and M2 cells (in agreement with the THP-1 macrophage data) but to a 
greater extent during M1 differentiation.  
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Figure 4-5 M1 and M2 differentiation upregulates HIF-α mRNA: example of donor 
variability. 
Human monocytes were either left untreated or treated for time points indicated with GM-CSF (50ng/ml) or 
M-CSF (100ng/ml). Expression of (a) HIF-1α and (b) HIF-2α was assessed by RT-PCR. Results are mean ± 
SD relative to mRNA levels in untreated monocytes, set as 1 (dashed line). Statistical analysis was 
performed using 1-way ANOVA: ** p<0.01 **** p<0.0001 comparing M1 versus M2 at each time point. 
Data are from three (n=3) individual experiments. Each individual experiment was performed in triplicate 
and mean values were used for statistical analysis. 
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Interestingly, protein analysis from the same experiment revealed that during M1 
differentiation HIF-1α protein was highly upregulated on day 3 post GM-CSF stimulation and 
remained stable (or slightly reduced) until day 5 as shown in Figure 4-6. HIF-2α protein levels 
were very low in M1 and undetectable in M2 macrophages (not shown). 
 
 
 
 
 
 
 
 
Figure 4-6 Monocyte to macrophage differentiation stabilises HIF-1α to a greater extent 
in M1 macrophages: example of donor variability. 
Human monocytes were either left untreated or treated for time points indicated with GM-CSF (50ng/ml) or 
M-CSF (100ng/ml). Immunoblot analysis of total protein extracts for HIF-1α. α-tubulin is shown as a 
loading control. 
 
4.3.3 Normoxic HIF stabilisation following monocyte to macrophage 
differentiation activates the HIF pathway 
Study Design: 
Human monocytes were either left untreated or treated for time points indicated with 
GM-CSF (50ng/ml) or M-CSF (100ng/ml) to generate M1 and M2 macrophage populations 
respectively (Krausgruber et al., 2011) and the expression of HIF target genes was studied. 
As was the case with the normoxic HIF stabilisation in PMA-treated THP-1 cells, the 
observed HIF-α accumulation in M1 and M2 polarised macrophages raised the question as to 
what extent the HIF-α protein induction is needed for and during the differentiation process. 
Therefore, I aimed to investigate whether the normoxic HIF stabilisation is reflected by induction 
of downstream angiogenic genes such as BNIP3 and EphrinA3. BNIP3, as previously mentioned, 
is not purely angiogenic but by virtue of its involvement in cellular survival it can be 
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characterised as such. Both molecules have been previously identified in angiogenic arrays using 
other cell types including RA synovial fibroblasts and Caco-2 cells (Larsen et al., 2012; Muz et 
al., 2012). Therefore, human monocytes were differentiated towards M1 and M2 phenotypes as 
previously described and RT-PCR analysis was performed for the downstream HIF target genes 
BNIP3 and EphrinA3. Both macrophage phenotypes caused a modest upregulation of BNIP3 one 
day post GM-CSF differentiation, but M2 polarised cells appeared to induce BNIP3 to 
significantly higher mRNA levels compared to M1 3 days after differentiation. The same trend 
was also observed for EphrinA3 which again was significantly upregulated in M2 cells after 3 
days of differentiation. These data imply that M2 polarised macrophages are more responsive in 
expressing these genes compared to M1 macrophages. At the protein level, I have investigated the 
expression of BNIP3 and found that it was expressed only in M2 cells 3 days following 
differentiation, whereas a very weak signal was noticed for all the remaining conditions (Figure 
4-7). 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-7 Monocyte to macrophage differentiation leads to activation of downstream 
HIF pathway. 
Human monocytes were either left untreated or treated for time points indicated with GM-CSF (50ng/ml) or 
M-CSF (100ng/ml). Expression of (a) BNIP3 and (b) EphrinA3 was assessed by RT-PCR. Results are mean 
± SD relative to mRNA levels in untreated monocytes, set as 1 (dashed line). Statistical analysis was 
performed using 1-way ANOVA: *** p<0.001 comparing M1 versus M2 at each time point. (c) 
Immunoblot analysis of total protein extracts for BNIP3. α-tubulin is shown as a loading control. Data are 
from three (n=3) individual experiments. Each individual experiment was performed in triplicate and mean 
values were used for statistical analysis. 
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4.3.4 HIF hydroxylases are differentially regulated during monocyte to 
macrophage differentiation in M1 and M2 macrophages 
Study Design: 
Human monocytes were either left untreated or treated for time points indicated with 
GM-CSF (50ng/ml) or M-CSF (100ng/ml) to generate M1 and M2 macrophage populations 
respectively (Krausgruber et al., 2011) and the expression of the HIF hydroxylases was studied. 
Having shown that during monocyte to macrophage differentiation HIF-1α and HIF-2α 
are transcriptionally upregulated and also stabilised in both macrophage phenotypes, the next step 
was to look at the HIF hydroxylase mRNA expression levels and to study potential differences 
between M1 and M2 macrophages. Therefore, human elutriated monocytes were differentiated as 
previously described for a full time course between 2 hours to 120 hours, and mRNA expression 
levels of the HIF regulating enzymes was analysed. As Figure 4-8 shows, in M1 cells PHD-1 was 
upregulated as early as 24 hours, with mRNA levels being gradually decreased. PHD-1 mRNA 
was upregulated in M2 cells within 4 hours of differentiation and remained activated until the end 
of differentiation period. With regard to PHD-2, 48 hours post M1 polarisation led to an increase 
in mRNA which then appeared to be gradually decreasing until the endpoint of the experiment. 
M2 polarisation increased PHD-2 mRNA expression levels 48 hours post differentiation until 120 
hours (Figure 4-8). My data further suggest that PHD-3 identifies the classically activated M1 
macrophages, in agreement with other studies (Escribese et al., 2012b). As shown in Figure 4-9, 
48 hours following M1 polarisation (but not M2 polarisation), PHD-3 mRNA expression was 
increased and was subsequently decreased by 72 hours. Moreover, FIH-1 mRNA levels did not 
show any significant changes between M1 and M2 cells. Overall, no consistent difference in the 
PHD-1 and FIH-1 mRNA expression levels was observed. However, PHD-2 mRNA levels 
appeared to be upregulated in both M1 and M2 macrophages, whereas PHD-3 was preferentially 
upregulated in M1 cells following 24 hours of GM-CSF differentiation. 
 
 
 
 
 
 
Chapter 4 
152 
P H D -1
2  4  8  2 4  4 8   7 2  1 2 0  2  4  8  2 4  4 8   7 2 1 2 0  
0
1
2
3
4
5
M 1 M 2
D if f e r e n t ia t io n  t im e  ( h o u r s )
F
o
ld
 c
h
a
n
g
e
v
e
rs
u
s
m
o
n
o
c
y
te
s
P H D -2
2  4  8  2 4  4 8   7 2  1 2 0  2  4  8  2 4  4 8   7 2  1 2 0  
0
1
2
3
M 1 M 2
D if f e r e n t ia t io n  t im e  ( h o u r s )
F
o
ld
 c
h
a
n
g
e
v
e
rs
u
s
u
n
tr
e
a
te
d
(a) (b)
ns
ns
ns
ns
ns
ns ns
ns ns
ns
ns
ns
ns
ns
P H D -3
2  4  8 2 4  4 8   7 2  1 2 0  2  4  8  2 4  4 8   7 2  1 2 0  
0
5
1 0
1 5
2 0
M 1 M 2
D if f e r e n t ia t io n  t im e  ( h o u r s )
F
o
ld
 c
h
a
n
g
e
v
e
rs
u
s
m
o
n
o
c
y
te
s
F I H -1
2  4  8  2 4 4 8  7 2  1 2 0  2  4  8  2 4  4 8   7 2  1 2 0  
0
2
4
6
8
1 0
M 1 M 2
D if f e r e n t ia t io n  t im e  ( h o u r s )
F
o
ld
 c
h
a
n
g
e
v
e
rs
u
s
m
o
n
o
c
y
te
s
(a) (b)
ns ns ns
*
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
 
 
 
 
 
 
 
 
 
Figure 4-8 Differential regulation of PHD-1 and PHD-2 during monocyte to 
macrophage differentiation between M1 and M2 macrophages. 
Human monocytes were either left untreated or treated for time points indicated with GM-CSF (50ng/ml) or 
M-CSF (100ng/ml). Expression of (a) PHD-1 and (b) PHD-2 was assessed by RT-PCR. Results are mean ± 
SD relative to mRNA levels in untreated monocytes, set as 1 (dashed line). Statistical analysis was 
performed using 1-way ANOVA comparing M1 versus M2 at each time point and all comparisons were 
found to be not significant. Data are from three (n=3) individual experiments. Each individual experiment 
was performed in triplicate and mean values were used for statistical analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-9 Differential regulation of PHD-3 and FIH-1 during monocyte to macrophage 
differentiation between M1 and M2 macrophages. 
Human monocytes were either left untreated or treated for time points indicated with GM-CSF (50ng/ml) or 
M-CSF (100ng/ml). Expression of (a) PHD-3 and (b) FIH-1 was assessed by RT-PCR. Results are mean ± 
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SD relative to mRNA levels in untreated monocytes, set as 1 (dashed line). Statistical analysis was 
performed using 1-way ANOVA: * p<0.05, comparing M1 versus M2 at each time point. Data are from 
three (n=3) individual experiments. Each individual experiment was performed in triplicate and mean 
values were used for statistical analysis. 
 
 
Given that the greatest difference in M1 and M2 markers was observed at day 1 and day 3 
time points (Figure 4-2), I next studied the HIF hydroxylases expression following 1 and 3 days 
of differentiation in a number of experiments using different donors. M1 and M2 differentiation 
did not seem to affect PHD-1 mRNA expression levels at any time point of the differentiation 
process. By contrast, as shown in Figure 4-10, both macrophage phenotypes induced PHD-2 
expression on day 1 to similar extent, but M2 cells appeared to induce PHD-2 levels significantly 
higher that M1 at day 3 probably reflecting a HIF-dependent effect. PHD-3 was significantly 
upregulated in M1 compared to M2 cells 1 day post GM-CSF differentiation, whereas no 
significant changes were observed in FIH-1 mRNA expression levels between M1 and M2 cells at 
any time point during the differentiation process (Figure 4-11). 
 
 
 
 
 
 
 
 
 
Figure 4-10 Differential regulation of PHD-1 and PHD-2 during monocyte to 
macrophage differentiation between M1 and M2 macrophages:comparison 
between differentiation days 1 and 3. 
Human monocytes were either left untreated or treated for time points indicated with GM-CSF (50ng/ml) or 
M-CSF (100ng/ml). Expression of (a) PHD-1 and (b) PHD-2 was assessed by RT-PCR. Results are mean ± 
SD relative to mRNA levels in untreated monocytes, set as 1 (dashed line). Statistical analysis was 
performed using 1-way ANOVA: *** p<0.001 comparing M1 versus M2 at each time point. Data are from 
three (n=3) individual experiments. Each individual experiment was performed in triplicate and mean 
values were used for statistical analysis. 
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Figure 4-11 Differential regulation of PHD-3 and FIH-1 during monocyte to macrophage 
differentiation between M1 and M2 macrophages: comparison between 
differentiation days 1 and 3. 
Human monocytes were either left untreated or treated for time points indicated with GM-CSF (50ng/ml) or 
M-CSF (100ng/ml). Expression of (a) PHD-3 and (b) FIH-1 was assessed by RT-PCR. Results are mean ± 
SD relative to mRNA levels in untreated monocytes, set as 1 (dashed line). Statistical analysis was 
performed using 1-way ANOVA: *** p<0.001 comparing M1 versus M2 at each time point. Data are from 
three (n=3) individual experiments. Each individual experiment was performed in triplicate and mean 
values were used for statistical analysis. 
 
Analysis of the protein levels from the same experiment revealed no overall significant 
changes in PHD-1 and FIH-1 expression between M1 and M2 macrophages throughout the 
differentiation process. Interestingly, 1 day post M1 and M2 differentiation resulted in a reduction 
of PHD-2 protein levels, a reduction which may well account for the normoxic HIF-1α 
stabilisation shown in Figure 4-4. PHD-2 appeared to restore its protein levels 3 days post M1 and 
M2 differentiation thus reflecting a HIF-α dependent effect (Figure 4-12). PHD-3 was not 
detected in this experiment similar to no expression of PHD-3 from PMA-differentiated THP-1 
cells (Figure 3-10).  
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Figure 4-12 Selective downregulation of PHD-2 during M1 and M2 monocyte to 
macrophage differentiation. 
Human monocytes were either left untreated or treated for time points indicated with GM-CSF (50ng/ml) or 
M-CSF (100ng/ml). Immunoblot analysis of total protein extracts for PHD-1, PHD-2, PHD-3 and FIH-1. α-
tubulin is shown as a loading control. 
 
4.3.5 Shifting between M1 and M2 macrophage phenotypes does not affect the HIF 
pathway 
Study Design: 
After generating M1 macrophages (5 days GM-CSF, 50ng/ml), culture was media changed and 
incubated further with M-CSF (100ng/ml) for 24 hours to skew them to a M2 phenotype. After 
generating M2 macrophages (5 days M-CSF, 100ng/ml), culture was media changed and 
incubated further with GM-CSF (50ng/ml) for 24 hours to skew them to a M1 phenotype 
(Krausgruber et al., 2011; Watkins et al., 2007).  
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The huge functional plasticity that macrophages exhibit is a well-known characteristic 
feature. Of interest to this context was to examine whether HIFs/HIF hydroxylases could 
contribute to the plasticity of macrophage polarisation. As it was previosuly mentioned, the 
concept that macrophages can change their functional profiles (from M1 to M2 or M2 to M1) 
repeatedly depending on the cytokines (Th1 or Th2) to which they were exposed to is well 
established (Watkins et al., 2007). Therefore, I converted one population into the other by 
culturing M2 macrophages with GM-CSF and M1 macrophages with M-CSF for 24 hours 
(Krausgruber et al., 2011). In particular, after generating M1 macrophages following 5 days of 
GM-CSF differentiation I replaced the culture medium with one contrasting M-CSF. In a similar 
way after generating M2 macrophages following 5 days of M-CSF differentiation I then changed 
the media, and cultured them in the presence of GM-CSF. As Figure 4-13 shows, in either case 
switching between macrophages phenotypes did not seem to influence mRNA expression levels 
of the HIF hydroxylases. It should be highlighted here that as cells in Error! Reference source not 
ound. are macrophages generated 5 days following differentiation, expression of PHD-2 is already 
elevated, and thus shifting does not appear to have any further effect on its levels.  
 
 
 
 
 
 
 
 
Figure 4-13 Shifting between M1 and M2 macrophage phenotype does not affect 
hydroxylase expression. 
RT-PCR analysis of HIF hydroxylase expression in (a) M1 macrophages (5 days GM-CSF 50ng/ml) 
followed by M-CSF addition (100ng/ml) for 24 hours. Results are presented relative to 5 day GM-CSF-
treated M1 macrophages, set as 1 (dashed line). (b) RT-PCR analysis of HIF hydroxylase expression levels 
in M2 macrophages (5 days M-CSF 100ng/ml) followed by GM-CSF addition (50ng/ml) for 24 hours. 
Results are presented relative to 5 day M-CSF-treated M2 macrophages, set as 1 (dashed line). Statistical 
analysis was performed using Student’s t-test versus M1 (a) or M2 (b) and all comparisons were found to be 
not significant.Data are from three (n=3) individual experiments. Each individual experiment was 
performed in triplicate and mean values were used for statistical analysis. 
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As previously mentioned, the notion that HIFs critically shape macrophage polarisation 
either directly (through HIF/HIF hydroxylases) or indirectly (through glucose/lipid/iron 
homeostasis or cytokine release) is becoming increasingly appreciated. Therefore, the next 
question to be answered was to what extent HIF-1α mRNA levels were affected during shifting 
between cell phenotypes. Following the same experimental set up as in Figure 4-13, I found that 
both HIF-α isoforms expression levels remained unchanged in either case, although what should 
be noticed again is that starting levels of HIFs are already high enough by the time culture media 
was changed and the opposite differentiation agent was added (Figure 4-14). It is possible that 
after 5 days macrophages are irreversible differentiated towards one phenotype and shifting 
within 24 hours is not possible. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-14 Shifting between M1 and M2 macrophage phenotype does not affect HIF-α 
isoform expression. 
RT-PCR analysis of HIF-α isoform expression in (a) M1 macrophages (5 days GM-CSF 50ng/ml) followed 
by M-CSF addition (100ng/ml) for 24 hours. Results are presented relative to 5 day GM-CSF-treated M1 
macrophages, set as 1 (dashed line). (b) RT-PCR analysis of HIF hydroxylase expression levels in M2 
macrophages (5 days M-CSF 100ng/ml) followed by GM-CSF addition (50ng/ml) for 24 hours. Results are 
presented relative to 5 day M-CSF-treated M2 macrophages, set as 1 (dashed line). Statistical analysis was 
performed using Student’s t-test versus M1 (a) or M2 (b). Data are from three (n=3) individual experiments. 
Each individual experiment was performed in triplicate and mean values were used for statistical analysis. 
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4.3.6 The effect of hypoxia on the HIF pathway in human primary monocytes 
Study Design: 
Human monocytes were exposed to 1% O2 for 16 hours (Bosco et al., 2006; Muz et al., 2012) and 
expression of HIF/HIF hydroxylases and HIF target genes was studied. Normoxic monocytes 
were used as control. 
Mononuclear phagocytes accumulate preferentially in hypoxic/ischemic areas of diseased 
tissues (Murdoch et al., 2004), and hypoxic conditions have been shown to profoundly affect their 
proinflammatory and immunoregulatory responses by modulating the expression of genes coding 
for angiogenic factors, inflammatory cytokines, and extracellular matrix (ECM) 
components/regulators (Murdoch et al., 2004). Recent evidence indicates that hypoxia can also 
strictly control the chemokine network in cells of the monocytic lineage not only by regulating the 
production of specific chemokines but also controlling their action through the modulation of 
their receptors. Upregulation of CCL3 (Bosco et al., 2004), CXCL1 (Murdoch et al., 2004), 
CXCL8 (Murdoch et al., 2004), and CXCR4 (Schioppa et al., 2003), and inhibition of CCL2 
(Bosco et al., 2004) and CCR5 (Bosco et al., 2004) under hypoxia were reported. Given the very 
important role they mediate at the very early stages in inflammation (Murdoch et al., 2004), it is 
important to know how primary monocytes respond to oxygen-depleted conditions. To address 
this question, human primary elutriated monocytes were exposed to 1% O2 and gene expression 
was studied by RT-PCR. Undifferentiated human monocytes responded to hypoxia by 
significantly upregulating the classical HIF–target genes PHD-2 and PHD-3, while PHD-1 and 
FIH-1 being unaffected (Figure 4-15). With the exception of PHD-2, this is in agreement with 
findings using THP-1 monocytes as a model system.  
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Figure 4-15 Undifferentiated human monocytes respond to hypoxia by upregulating 
PHD-2 and PHD-3. 
Human monocytes exposed to 1% O2 for 16 hours. Expression of PHD-1, PHD-2, PHD-3 or FIH-1 was 
assessed by RT-PCR. Results are mean ± SD relative to mRNA levels in normoxic monocytes, set as 1 
(dashed line). Statistical analysis was performed using dCT 1-way ANOVA versus normoxia: *** p<0.001. 
Data are from three (n=3) individual experiments. Each individual experiment was performed in triplicate 
and mean values were used for statistical analysis. 
 
I next studied the effect of 1% O2 with regard to the HIF-α isoform levels. I observed a 
parallel decrease of the mRNAs encoding HIF-α isoforms, it is noticable that both HIF-1α and 
HIF-2α were significantly decreased (Figure 4-16). This finding is consistent with findings 
presented by Bosco et al where they provided evidence for a decrease in HIF-1α/HIF-1β mRNAs, 
accompanied by a decrease in several HIF-1α transcriptional cofactors normally interacting with 
HIF-1α and enhancing transactivation function under hypoxia (Bosco et al., 2006).  
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Figure 4-16 Undifferentiated human monocytes downregulate the HIF-α isoforms in 
response to hypoxia. 
Human monocytes exposed to 1% O2 for 16 hours. Expression of HIF-α isoforms was assessed by RT-PCR. 
Results are mean ± SD relative to mRNA levels in normoxic monocytes, set as 1 (dashed line). Statistical 
analysis was performed using dCT 1-way ANOVA versus normoxia: ** p<0.01. Data are from three (n=3) 
individual experiments. Each individual experiment was performed in triplicate and mean values were used 
for statistical analysis. 
  
Having shown that human monocytes respond to low oxygen tension by upregulating 
some of the typical HIF target genes namely PHD-2 and PHD-3, I next studied the expression of 
genes that could have a potential effect on the angiogenic process. As Figure 4-17shows, exposure 
of human monocytes to hypoxia resulted in an up regulation of the angiogenic genes BNIP3 and 
EphrinA3, whereas VEGF remained unchanged. These findings indicate that mononuclear 
phagocytes respond to hypoxia by regulating the expression of selected target genes, which may 
be critical for their adaptation to the hypoxic environment and ability to function in it, and could 
be representative of the hypoxic transcriptome in cells belonging to the monocytic lineage.  
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Figure 4-17 Undifferentiated human monocytes respond to hypoxia by upregulating HIF 
target genes. 
Human monocytes exposed to 1% O2 for 16 hours. Expression of BNIP3, EphrinA3 or VEGF was assessed 
by RT-PCR. Results are mean ± SD relative to mRNA levels in normoxic monocytes, set as 1 (dashed line). 
Statistical analysis was performed using dCT 1-way ANOVA versus normoxia: **p<0.01, *** p<0.001. 
Data are from three (n=3) individual experiments. Each individual experiment was performed in triplicate 
and mean values were used for statistical analysis. Data are from three (n=3) individual experiments. Each 
individual experiment was performed in triplicate and mean values were used for statistical analysis. 
 
4.3.7 The effect of hypoxia on the HIF pathway in M1 and M2 macrophage 
subtypes 
Study Design: 
Human monocytes were either left untreated or treated for 5 days with GM-CSF 
(50ng/ml) or M-CSF (100ng/ml) (Krausgruber et al., 2011) followed by exposure to 1% oxygen 
for 16 hours (Bosco et al., 2006; Muz et al., 2012). 
Macrophages exhibit great plasticity as they can shift between different modes of 
activation statuses. Driven by various inflammatory stimuli present in their surrounding 
microenvironment, they can perform divergent functions. These include enhanced killing ability 
of invading pathogens (M1 macrophages) and restoring homeostasis after anti-inflammatory 
responses (M2 macrophages). Hypoxia represents an important factor in the macrophage 
environment influencing a wide variety of their functions. Although macrophages have been 
studied in hypoxia, the precise molecular mechanisms by which hypoxia influences the different 
modes of their activation, and how it regulates the shift between them, remains unclear. The 
current knowledge suggests that hypoxic induction of macrophage pro-angiogenic mediators 
suppress M1 macrophage polarisation by post-transcriptionally inhibiting pro-inflammatory 
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mediators, and help shift between phenotypes (Rahat et al., 2011). However, the regulation of HIF 
hydroxylases expression in the above context still remains unclear. Therefore, human primary 
monocytes were differentiated towards the M1 and M2 macrophage phenotypes following 5 days 
of GM-CSF and M-CSF stimulation respectively,  and then exposed to hypoxia and mRNA 
expression levels of the HIF hydroxylases were measured by RT-PCR. As  
Figure 4-18 shows both macrophage phenotypes responded to 1% O2 in a similar manner 
by upregulating the HIF-target gene PHD-3, whereas the remaining HIF regulating enzymes 
PHD-1, PHD-2 and FIH-1 remained unaffected. 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Figure 4-18 Hypoxia up regulates PHD-3 mRNA expression in M1 and M2 macrophages. 
Human monocytes were either left untreated or treated for 5 days with GM-CSF (50ng/ml) or M-CSF 
(100ng/ml) followed by exposure to 1% oxygen for 16 hours. (a) Expression of HIF hydroxylases (PHD1-3 
and FIH) was assessed by RT-PCR in M1 macrophages. (b) Expression of HIF hydroxylases (PHD1-3 and 
FIH) was assessed by RT-PCR in M2 macrophages. Results are presented relative to untreated monocytes, 
set as 1 (dashed line). Statistical analysis was performed using dCT 1-way ANOVA versus normoxia: 
***p<0.001. Data are from three (n=3) individual experiments. Each individual experiment was performed 
in triplicate and mean values were used for statistical analysis. 
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Given that both macrophage phenotypes responded to hypoxia by upregulating PHD-3, I 
then investigated whether M1 and M2 macrophages respond differently to hypoxic conditions 
with regard to the angiogenic genes. As previously mentioned in Section 1.6, angiogenesis 
represents the critical function that restores oxygen levels into inflamed tissues and is mainly a 
characteristic function of M2-polarised macrophages. Macrophages accumulate into hypoxic 
areas, express HIF-α isoforms and also many pro-angiogenic factors with the best studied being 
VEGF. In my study M2 polarised macrophages were shown to be more responsive in terms of 
angiogenic gene expression. Indeed Figure 4-19 shows M2 macrophages upregulated the mRNA 
expression levels of BNIP3, EphrinA3, and VEGF to a much higher degree compared to M1 cells. 
Since hypoxic macrophages express both M1 and M2 markers, their classification in a hypoxic 
environment is not straight forward. There is a possibility that a hypoxic macrophage population 
shares features of both phenotypes. In this respect, exposure to 1% O2 did not seem to have any 
impact on the M1 and M2 differentiation markers IRF-5 and HO-1 (Figure 4-20). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-19 M1 and M2 macrophages respond to hypoxia by up regulating HIF-target 
genes. 
Human monocytes were either left untreated or treated for 5 days with GM-CSF (50ng/ml) or M-CSF 
(100ng/ml) followed by exposure to 1% oxygen for 16 hours. (a) Expression of HIF target genes was 
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assessed by RT-PCR in M1 macrophages. (b) Expression of HIF target genes was assessed by RT-PCR in 
M2 macrophages. Results are presented relative to untreated monocytes, set as 1 (dashed line). Statistical 
analysis was performed using dCT 1-way ANOVA versus normoxia: * p<0.05. Data are from three (n=3) 
individual experiments. Each individual experiment was performed in triplicate and mean values were used 
for statistical analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-20 Hypoxia does not affect M1 and M2 markers in monocyte-derived 
macrophages. 
Human monocytes were either left untreated or treated for 5 days with GM-CSF (50ng/ml) or M-CSF 
(100ng/ml) followed by exposure to 1% oxygen for 16 hours. (a) Expression of M1 and M2 markers was 
assessed by RT-PCR in M1 macrophages. (b) Expression of M1 and M2 markers was assessed by RT-PCR 
in M2 macrophages. Results are presented relative to untreated monocytes, set as 1 (dashed line). Statistical 
analysis was performed using dCT 1-way ANOVA versus normoxia: * p<0.05. Data are from three (n=3) 
individual experiments. Each individual experiment was performed in triplicate and mean values were used 
for statistical analysis. 
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4.3.8 DMOG mediates HIF-α isoform stabilisation and activates the HIF pathway 
Study Design: 
Human monocytes were differentiated with GM-CSF (50ng/ml) or M-CSF (100ng/ml) for 
time points indicated (Krausgruber et al., 2011) and either left untreated ( indicated as -) or treated 
with 1mM DMOG for 16 hours (indicated as +) (Elvidge et al., 2006; Muz et al., 2012). 
DMOG, which is a 2-OG analogue, stabilises HIF- via inhibition of PHDs and FIH-1, 
and was therefore used in this study (Nguyen et al., 2013). Among many available stabilisers of 
HIF- protein, DMOG was chosen for comparison with hypoxia, as a striking concordance 
between gene pattern induced by hypoxia and DMOG was reported in MCF7 and Hep3B cells 
(Elvidge et al., 2006). Therefore, responses of 1 and 3 days differentiated M1 and M2 
macrophages were studied after exposing cells to DMOG. As Figure 4-21 shows, treatment of M1 
and M2 macrophages with DMOG further increases HIF-1α protein levels suggesting that both 
cell phenotypes are responsive to DMOG. Interestingly, DMOG stimulation also activated the 
HIF pathway as it is being shown by upregulation of the HIF-target gene BNIP3.  
 
 
 
 
 
 
 
 
 
Figure 4-21 DMOG mediates HIF-α isoform stabilisation and activates the HIF pathway. 
Human monocytes were differentiated with GM-CSF (50ng/ml) or M-CSF (100ng/ml) for time points 
indicated and either left untreated (-) or treated with 1mM DMOG for 16 hours (+).Immunoblot analysis of 
total protein extracts for HIF-α isoforms and BNIP3. α-tubulin is shown as a loading control.  
 
  
DMOG stimulation also induced mRNA expression of BNIP3 and EphrinA3 with the fold 
change being similar between M1 and M2 macrophages, although the starting levels were higher 
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in M2 macrophages (Figure 4-22). With regard to PHD-2 and PHD-3, exposure of both 
macrophage phenotypes to DMOG upregulated both genes transcriptionally. M2 macrophages 
again appeared to be more responsive to DMOG stimulation 3 days post M2 differentiation, at 
least partially explained by the higher starting expression levels (Figure 4-23). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-22 DMOG induces transcription of the HIF-target genes BNIP3 and EphrinA3. 
Human monocytes were differentiated with GM-CSF (50ng/ml) or M-CSF (100ng/ml) for time points 
indicated and either left untreated or treated with 1mM DMOG for 16 hours. Expression of (a) BNIP3 and 
(b) EphrinA3 was assessed by RT-PCR. Results are presented relative to normoxia, set as 1 (dashed line). 
Statistical analysis was performed using 1-way ANOVA, comparing M1 versus M2 at each time point and 
all comparisons were found to be not significant. Data are from three (n=3) individual experiments. Each 
individual experiment was performed in triplicate and mean values were used for statistical analysis. 
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Figure 4-23 DMOG induces transcription of the hypoxia-regulated genes PHD-2 and 
PHD-3. 
Human monocytes were differentiated with GM-CSF (50ng/ml) or M-CSF (100ng/ml) for time points 
indicated and either left untreated (-) or treated with 1mM DMOG for 16 hours (+). (a) Immunoblot 
analysis of total protein extracts for PHD-3. α-tubulin is shown as a loading control. Expression of (b) 
PHD-2 and (c) PHD-3 was assessed by RT-PCR. Statistical analysis was performed using 2-way ANOVA 
M1 versus M2: *** p<0.001. Data are from three (n=3) individual experiments. Each individual experiment 
was performed in triplicate and mean values were used for statistical analysis.  
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4.4 Discussion 
My data presented in this chapter suggest that normoxic stabilisation of HIF-1α protein is 
observed in both M1 and M2 monocyte-derived macrophages, and that this may be at least 
partially due to increased HIF-1α mRNA transcription leading to more protein, and/or reduced 
PHD-2 expression. Monocytes/macrophages of the myeloid lineage are the main effectors of the 
innate immunity. In my study the hypothesis was that the observed normoxic HIF-1α stabilisation 
occurred during monocyte to macrophage differentiation was at least partially due to impaired 
hydroxylation and thus reduced activity of the PHD enzymes. PHD-2, as previously mentioned, is 
the key oxygen sensor in regulating the steady state levels of HIF in normoxia and therefore slight 
changes in PHD-2 might play a crucial role in regulating the HIF levels. My data suggest that 
PHD-2 protein levels are decreased during both M1 and M2 monocyte to macrophage 
differentiation and restored 3 days post GM-CSF and M-CSF differentiation, probably reflecting a 
HIF-dependent feedback effect, since PHD-2 is a well-known HIF target gene. As mentioned in 
Section 1.4.3, recent studies have highlighted two post-transcriptional mechanisms that control 
PHD-2 protein levels. First, PHD-2 binds the peptidyl prolyl cis/trans-isomerase FKBP38, and 
siRNA-mediated depletion of FKBP38 leads to increases in PHD-2 protein abundance (Barth et 
al., 2009). TGFβ signaling through the Type I TGFβ receptor is a second mechanism to decrease 
PHD-2 protein levels (McMahon et al., 2006). The Type I TGFβ receptor is a member of the 
activin-like receptor kinase (ALK) family of receptors that bind several distinct ligand families 
including TGFβs, activins, and bone morphogenic proteins (Derynck and Zhang, 2003; Shi and 
Massague, 2003). The cytoplasmic domains of the ALK receptors are serine/threonine kinases 
that are activated when the ligand induces the Type I receptor to dimerise with a Type II receptor. 
Seven Type I receptors (ALK1–7) have been identified and can be grouped based upon the 
homology of their cytoplasmic domains. The high degree of homology between ALK5 (Type I 
TGFβ receptor), ALK4, and ALK7 renders them similarly sensitive to a class of highly selective 
small molecule inhibitors that have very limited effects on other kinases including p38MAPKs 
(DaCosta Byfield et al., 2004). Therefore one of the above mentioned mechanisms might well 
account for the reduction in the PHD-2 protein levels 1 day post M1 and M2 differentiation and 
needs to be investigated. The unpublished data mentioned in the Oda et al study looking at the 
monocytic differentiation showed that HIF-1α binding to the pVHL remained unaffected thus 
proposing normal proline hydroxylation (Oda et al., 2006). Adhesion-induced differentiation of 
PBMC-derived monocytes/macrophages for 7 days also induced normoxic expression of HIF-1α 
that was abrogated by treatment with 25µmol/L ascorbate (Knowles et al., 2006). The authors 
assayed PHD activity directly by analysis of the amount of VHL captured by a bead-
immunopurified HIF-1α construct (Tuckerman et al., 2004). In assays lacking supplementation 
with Fe2+ or ascorbate, monocytic PHD activity was high compared with PMA-treated cells thus 
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suggesting that there might be differences in the ability of supplementary iron to access the 
enzymatic active site in extracts compared with whole cells. They also did not rule out the 
possibility that a decrease in enzyme expression could contribute to the above result. 
Of importance was also to identify whether HIF-α isoforms are differentially regulated 
between the M1 and M2 human polarised macrophages. In my study normoxic HIF-1α protein 
stabilisation was observed in both M1 and M2 monocyte-derived macrophages, with overall no 
significant differences between the two macrophage phenotypes. That HIF isoforms can critically 
shape macrophage polarisation was first shown by Randal Johnson et al in 2010. The HIF-α 
isoforms were shown to be differentially activated: HIF-1α was induced by Th1 cytokines in M1 
macrophage polarisation, whereas HIF-2α was induced by Th2 cytokines during an M2 response. 
This differential response was most evident in polarised macrophages through HIF-α isoform-
specific regulation of the inducible NO synthase gene by HIF-1α, and the arginase1 gene by HIF-
2α. In silico modeling also predicted that regulation of overall NO availability is due to 
differential regulation of HIF-1α versus HIF-2α, acting to, respectively, either increase or 
suppress NO synthesis. They also used an in vivo model of endotoxin challenge confirming the 
above findings; thus, this study revealed that the two homologous transcription factors, HIF-1α 
and HIF-2α, can have physiologically antagonistic functions, but that their antiphase regulation 
allows them to coordinately regulate NO production in a cytokine-induced and transcription-
dependent fashion (Takeda et al., 2010). My findings suggest no significant differences between 
the two macrophage phenotypes. 
The direct influence of the HIF hydroxylases -PHDs- on the macrophage polarisation has 
been recently showed by Escribese et al in 2012 who described the preferential expression of the 
PHD-3 by human pro-inflammatory macrophages in vivo and in vitro and that PHD-3 expression 
was restricted to TAM that exhibit weak or absent levels of typical anti-inflammatory/M2 
markers. Moreover, they demonstrated that activin A regulates the constitutive expression of 
PHD-3 in M1 (GM-CSF) macrophages and its hypoxia-inducible expression in M2 (M-CSF) 
macrophages. Considering that activin A production is an exclusive property of pro-inflammatory 
M1 (GM-CSF) macrophages (Sierra-Filardi et al., 2011), the activin A-PHD3 axis appears to 
constitute a specific signature of pro-inflammatory macrophage polarisation. Moreover, because 
activin A expression was upregulated by hypoxia in M2 (M-CSF) macrophages, the authors 
speculated that activin A-PHD3 axis might also influence macrophage effector functions under 
low oxygen pressures, a condition that is common to solid tumours and tissues undergoing active 
inflammatory responses (Escribese et al., 2012b). In my study, shifting between M1 and M2 
macrophage phenotypes did not affect HIF hydroxylase expression. One possible explanation 
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would be that these were 5 days differentiated macrophages, and expression of PHD-2 was 
already high because of the HIF-α feedback effect.  
Within the scope of this study, it was also possible to investigate whether the 
differentiation process affects the sensitivity to hypoxia. When monocytes were exposed to 
hypoxia both HIF-α isoforms were downregulated at the mRNA level with HIF-1α being 
significantly reduced. This observation was also described and explained in two different studies. 
The first study was by Bosco et al (Bosco et al., 2006) and showed downregulation of several 
HIF-1 transcriptional co-activators, including CBP, C/EBPα, MITF, and NCOA1/SRC-1 in 
hypoxic monocytes. All the above mentioned proteins physically interact with HIF-1α thus 
boosting its transactivation potential under oxygen-depleted conditions (Busca et al., 2005; 
Semenza, 2001; Wenger et al., 2005), and their downregulation suggests the presence of a 
negative feedback mechanism to keep under control the monocytic hypoxic response. This is a 
speculation the authors made based on which they explained the parallel decrease of the mRNAs 
encoding HIF-1α and one of its dimerisation partners, HIF-2α also found in my study. In a second 
study Xu et al investigated the precise role of each of the HIF-α subunits in clear cell renal cell 
carcinoma (CCRCC) tumourigenesis. They proved the hypothesis that VHL inactivation in 
CCRCC cells results in HIF-1α/2α-dependent downregulation of HIF-1α mRNA through direct 
binding of either subunit to a reverse hypoxia-response element in the HIF-1α proximal promoter 
(Xu et al., 2012). 
Although human monocytes did not upregulate HIF-α isoforms in response to hypoxia, 
they appeared to respond to 1% O2 by upregulating PHD-3 in a way comparable to THP-1 
monocytic cells. PHD-2 was also found to be increased following exposure of monocytes to 
hypoxia. Bosco et al also observed hypoxia-mediated upregulation of all three PHDs, namely 
PHD-1, PHD-2 and PHD-3 in agreement with previously published data using other cell types 
(del Peso et al., 2003; Hofbauer et al., 2003; Wenger et al., 2005) implying the presence in 
monocytes of an O2-driven HIF-dependent mechanism required to ensure HIF destabilisation 
when O2 levels are being restored. The same group also studied alterations in molecules mediating 
important roles in angiogenic processes such as VEGF. They found that monocytes exposed to 
normoxic conditions expressed basal levels of VEGF mRNA, which was increased further 
following incubation under hypoxia a finding also reported by other previously published studies 
(Melillo et al., 1999). In my study, exposure of monocytes to hypoxia increased the angiogenic 
genes BNIP3 and EphrinA3. Although monocytes appear to respond to hypoxia, HIF 
translocation to the nucleus has not been demonstrated (Elbarghati et al., 2008). In a very recent 
study published in 2012 by Fangradt et al (Fangradt et al., 2012) it was examined how monocytes 
adapt to hypoxic conditions during their differentiation into macrophages. The localisation of 
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HIF-1α shifted during the differentiation process from the cytosol (in monocytes) to the nucleus 
(in macrophages), apparently as a PKC-a/b1- mediated adaptation to a low oxygen environment is 
their key observation. They propose that in monocytes, it is NFκB1, and not HIF-1α, that is of 
central importance for the expression of hypoxia-adjusted genes thus demonstrating that during 
differentiation crucial cellular adaptation mechanisms are decisively changed; the understanding 
of which is of critical importance to identify the underlying pathophysiological processes of 
diseases such as inflammatory arthritis. Nuclear localisation blots are very good to show 
translocation into the nucleus but they are not the gold standard for nuclear exclusion of proteins. 
Western blots are not the most sensitive and can miss transcriptionally active amounts of HIF 
present in the nucleus, therefore immunofluorescence or confocal data would give more validity 
on the results. Moreover, the suggestion that NFκB is driving the expression of HIF target genes 
without qualifying this by saying it could be a secondary effect, is another weakness of the study. 
In their study, human monocytes were differentiated into macrophages after incubation with 
25nM M-CSF for 7 days and therefore no distinction between M1 and M2 macrophages has been 
made. 
In my study, hypoxia/DMOG upregulated HIF-1α protein levels 1 and 3 days post M1 
and M2 differentiation. However, there is still no clear perspective regarding the role of the 
different HIFs in hypoxic macrophages, and different periods of time of hypoxic exposure or 
different oxygen levels may have different effects on HIFs expression. Increased HIF-1α protein 
levels in hypoxia can be observed without a parallel increase in the mRNA levels. This is 
mediated by the binding of the two RNA-binding proteins (RBP) polypyrimidine-tract-binding 
protein (PTB) and human antigen R (HuR) to the 3-UTR and 5-UTR, respectively, as their knock-
down through RNAi inhibited HIF-1α accumulation (Galban et al., 2008). Iron response proteins 
(IRP) bind to their elements located in the 5-UTR region of the HIF-2α m RNA and inhibit 
translation of the m RNA in normoxia, while hypoxia releases this binding and enhances HIF-2α 
translation (Galban and Gorospe, 2009). The mechanisms for translational control have not yet 
been described in monocytes/macrophages and this needs further investigation. In terms of 
macrophages, expression of both HIF-1α and HIF-2α protein in response to hypoxia has been 
shown (Anand et al., 2007; Burke et al., 2002b; Elbarghati et al., 2008; Fang et al., 2009; Talks et 
al., 2000). Of particular interest to this study was to identify potential differences in terms of the 
hypoxic responses between M1 and M2 macrophages. Both macrophage phenotypes responded to 
hypoxia by upregulating the HIF regulating enzyme PHD-2 whereas the remaining HIF 
hydroxylases remained unchanged. As previously highlighted angiogenesis is mainly a 
characteristic feature of the M2-polarised macrophages. In our study both macrophage phenotypes 
responded to hypoxia by upregulating the angiogenic genes BNIP3, EphrinA3, and VEGF with 
the M2 cells being more responsive compared to M1 cells.  
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Overall, a concordance between the THP-1 macrophage data and MDM data was 
observed in terms of HIF-2α mRNA increased expression in both PMA-treated (M2-like 
macrophages) and in M2 MDM cells from day 1 to day 3 of differentiation. Moreover, HIF-1α 
protein was stabilised in both macrophage phenotypes (day 1 in PMA-treated THP-1, day 3 in 
M1/M2 macrophages), an effect at least partially attributable due to the PHD-2 protein reduced 
levels observed in both cell models. Among the HIF-target genes that appeared to be upregulated 
in THP-1 monocytes and in human monocytes were PHD-3, VEGF, EphrinA3 and BNIP3.The 
same set of genes was also upregulated in case of the PMA-treated THP-1 macrophages and 
M1/M2 macrophages. Certainly, a broader investigation of both phenotypes using PCR based 
array systems or large scale protein identifications (meso scale development) will be necessary to 
be able to identify profound changes in gene expression levels in both phenotypes. Further work 
will be described in more detail in chapter 6. 
 
 
 
 
 
 
 
Chapter 5 
173 
 
 
 
 
 
 
Chapter 5  
Chapter 5 
174 
5 Targeting HIF hydroxylases using in vivo disease models 
5.1 Introduction 
While several TNF inhibitors and other biological therapies are in routine clinical use in 
RA, the fact that not all patients respond adequately, coupled with the increased risk of infections 
such as tuberculosis associated with biological therapies, means that there is still a high unmet 
need in the field, that necessitates the development of new therapeutic treatments able to 
demonstrate alternative modes of action and thus achieve differentiation in RA therapy. 
The concurrent presence of angiogenesis, hypoxia and inflammation in RA synovium 
suggest that modulation of these may have profound effects on disease progression, and this 
underlies the long-standing research interest of the Kennedy Institute of Rheumatology in the role 
of blood vessels and hypoxia in chronic inflammation. Hypoxia and expression of HIFs have been 
described in many chronic inflammatory diseases, including RA (Giatromanolaki et al., 2003a; 
Hollander et al., 2001) and inflammatory bowel disease (IBD) (Giatromanolaki et al., 2003b), and 
as a consequence have been proposed to play key roles in disease pathogenesis. The HIF pathway 
has traditionally been thought to contribute to RA by promoting expression of genes such as 
vascular endothelial growth factor (VEGF) and thereby angiogenesis. In addition, evidence has 
recently emerged supporting a role for HIF in driving the differentiation of T-cells towards the 
disease-promoting Th17 phenotype (Kryczek et al., 2011; Makino et al., 2003; Nakamura et al., 
2005). However, the role of the HIF pathway in disease is not fully understood, and may be more 
complex than initially thought. This is a scenario that mainly comes from a series of studies 
investigating the potential therapeutic benefit of the activation of the HIF pathway in the context 
of many inflammatory diseases including IBD and ischemia.  
Of relevance in the context of hypoxia and RA, one of the best characterised hypoxia-
responsive genes is erythropoietin (EPO), which is required for survival, proliferation, and 
differentiation of erythroid progenitor cells, and inadequate production of which results in 
anaemia. As in many chronic inflammatory diseases, one of the most common extra-articular 
manifestations of RA is anaemia which is estimated to occur in 30-60% of RA patients (Wilson et 
al., 2004). Anaemic patients have more severe RA and also have more affected joints and higher 
levels of functional disability and pain. Studies have shown that treating anaemia in RA patients 
leads to reduced joint swelling and had a positive effect on patients’ quality of life. The 
development of anaemia in RA is related to the effects of chronic pro-inflammatory cytokine 
expression; however other causes also exist, depending on the stage of the disease and treatments 
used (Masson, 2011). Α key mediator of anaemia in RA is hepcidin, a regulatory hormone that 
limits iron availability and suppresses erythropoiesis under conditions of inflammation (Abdel-
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Khalek et al., 2011). Expression of hepcidin is induced by IL-6, a major player in the 
pathogenesis of RA (Hashizume and Mihara, 2011). Under conditions of hypoxia, the expression 
of hepcidin is repressed to permit physiological adaptation to tissue oxygen tension. It has been 
reported that inhibition of the PHD enzymes by deferoxamine (DFO) or DMOG was also able to 
down-regulate hepcidin expression, independently of HIF (Braliou et al., 2008), but the exact 
mechanism still remains unknown.  
Thus, the evidence so far regarding the role of HIFs in inflammation is unclear and often 
controversial. In addition the role of the HIF regulating enzymes (PHD/FIH-1) has only recently 
begun to be elucidated, particularly with the development of mice with global or conditional 
deletion of PHD/FIH-1 genes. Specific inhibitors of the different enzymes have also recently been 
developed, allowing a better understanding of the role of these enzymes. 
5.2 Objectives   
This part of the study aims to investigate the role of HIF hydroxylases in RA, using a 
combination of in vivo disease models utilising commercially available HIF hydroxylase 
inhibitors such as the pan-specific inhibitor DMOG. The potential of this approach to promote 
anaemic correction in RA makes this an attractive therapeutic option. This complementary 
approach will deepen our understanding of the role of hypoxia in promoting and maintaining RA. 
Therefore, the key objectives addressed were the following: 
1) To investigate the effect of modulating HIF hydroxylases in vivo using pre-clinical 
models of RA. 
2)   To investigate the in vivo mechanism of action of HIF hydroxylase inhibitors. 
5.3 Results 
The monitoring and validation of the therapeutic approaches for RA were performed 
following standardised protocols.  Several in vivo arthritis models which can predict effectiveness 
of therapy in RA are available, including collagen-induced arthritis (CIA, induced using bovine 
collagen), and antigen-induced arthritis (AIA), induced using methylated BSA, in DBA/1 mice. 
To build upon the results described in Chapters 3 and 4, the effect of DMOG in vivo was studied 
using the above mentioned animal models of disease. Incidence and severity of arthritis was 
assessed using an established scoring system, together with histological analysis as described in 
2.5. The murine CIA model was also used for analysis of the molecular mechanisms, underlying 
anaemia in RA and investigating the possible use of HIF hydroxylase inhibitors in reversing 
anaemia. My findings suggest that DMOG activates the HIF pathway in vivo and appears to exert 
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a protective role in the setting of murine models of arthritis, followed by amelioration of anaemia 
and expansion of the M2 macrophage population. 
5.3.1 DMOG increases luminescence in vivo: studies using ODD-luciferase 
bioluminescent reporter (ODD-Luc mice) 
Study Design: 
 
 
 
ODD-Luc mice left either untreated (control) or treated with 8mg DMOG (i.p.) for 2 hours as 
shown in the time-line (Cummins et al., 2008; Hams et al., 2011; Milkiewicz et al., 2004). Both 
mice received 50mg/kg luciferin (i.p.) 2 hours post-DMOG injection and 10 minutes later they 
were imaged(Hams et al., 2011; Milkiewicz et al., 2004; Safran et al., 2006). 
A mouse model has been developed in which regions of hypoxia may be imaged via 
bioluminescent imaging (Safran et al., 2006). In this model, Safran et al created a transgenic 
mouse expressing the oxygen-dependent degradation (ODD) domain of the HIF-1α gene fused to 
a luciferase (Luc) bioluminescent reporter gene. The HIF-1α gene is ubiquitously transcribed and 
translated, but under normoxic conditions, PHDs utilises oxygen to hydroxylate the HIF ODD. 
The hydroxylated ODD then recruits pVHL thus leading to poly-ubiquitination of HIF-1α and its 
subsequent degradation by the proteasome. Conversely, under hypoxic conditions, lack of 
hydroxylation of the ODD domain leads to the accumulation of HIF-1α, which acts as a 
transcriptional regulator for a number of hypoxia-induced genes. By universally expressing the 
ODD luciferase gene in mice, Safran et al developed an organism in which luciferase is 
continuously transcribed and translated in all cells, but is also rapidly degraded under normoxic 
conditions. Only under conditions of hypoxia (under which HIF hydroxylases are inactive and can 
therefore not hydroxylate residues in the ODD domain of Luc), luciferase accumulates in the cells 
and thus, by providing the substrate luciferin, regions of hypoxia within these mice may be 
imaged with bioluminescent imaging equipment. I reasoned that activation of the HIF pathway in 
vivo by DMOG should be visible in ODD-luciferase expressing mice and thus hypothesised that 
the ODD-luciferase murine transgenic model could serve as a universal platform for non-invasive 
imaging of hypoxia areas in vivo. I first treated ODD-Luc mice with a single dose of 8mg of 
DMOG (i.p.) and 2 hours later I assessed the luciferase activity in terms of the generated 
bioluminescent signal by imaging. As Figure 5-1a shows, treatment of mice with 8 mg of DMOG 
for 2 hours increases the net signal intensity, thus demonstrating that DMOG is having an effect 
in vivo probably by increasing the HIF-1α levels. In comparison, luciferase activity in untreated-
control mice did not change over this period (Figure 5-1b). 
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Figure 5-1 DMOG enhances the luciferase activity in vivo resulting in increased 
bioluminescent signal in ODD-Luc mice. 
Bioluminescent images of mice (n=2) left either untreated (control) or treated with 8mg DMOG (i.p.) for 2 
hours as shown in the time-line. Both mice received 50mg/kg luciferin (i.p.) 2 hours post-DMOG injection 
and 10 minutes later they were imaged. (a) Luminescence images artificially coloured for depiction 
purposes were adjusted to conform to the same radiance scale. (b) The images were quantified and relative 
net intensity of signal is shown. 
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5.3.2 DMOG treatment reaches the highest fold-increase in ODD-luciferase 
activity 2 hours after PHD inhibition 
Study Design: 
 
 
 
 
 
 
 
 
 
ODD-Luc mice left untreated (control) or treated either with 8mg DMOG (i.p.) or PBS 
(i.p.) for 2, 6 and 24 hours as shown in time-line (Cummins et al., 2008; Hams et al., 2011; 
Milkiewicz et al., 2004). All mice received 50mg/kg luciferin (i.p.) 2 hours post treatment and 10 
minutes later they were imaged (Hams et al., 2011; Milkiewicz et al., 2004; Safran et al., 2006). 
The kinetics of ODD-luciferase activity were next investigated after treatment of mice 
with a single dose of DMOG (8mg. i.p.) during a 24-hour time period. Mice were separated into 
three groups, each consisting of 3 mice (except for the control group which was consisted of 2 
mice). One mouse served as control (untreated), one mouse (vehicle treated) received a PBS 
injection (1xPBS, i.p.) and the third mouse was injected with DMOG. Images were obtained of 
two views: ventral and dorsal. In the ventral view, the abdominal fat pad and teats generate 
relatively high background signals over the abdomen and the thyroid generates a high intensity 
signal in the cervical region, while in the dorsal view, the kidneys generate a marked signal. 
Bioluminescent images were taken at the following time points post DMOG injection: 2 hours 
(Figure 5-2), 6 hours and 24 hours. As Figure 5-2 shows, DMOG treatment results in a 
significantly increased luciferase activity as evidenced by the enhanced bioluminescence observed 
in all three groups tested. In comparison, the net signal intensity remained relatively low in the 
case of control mice (untreated) or PBS-treated mice. Quantification is shown in Figure 5-3. 
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Figure 5-2 DMOG increases luciferase activity as early as 2 hours in ODD-Luc mice. 
Bioluminescent image with co-registered X-ray. Bioluminescent images of mice (n=8) left untreated 
(control) or treated either with 8mg DMOG (i.p.) or PBS (i.p.) for 2 hours as shown in time-line. All mice 
received 50mg/kg luciferin (i.p.) 2 hours post treatment and 10 minutes later they were imaged. The images 
are adjusted to conform to the same radiance scale showing the relative intensity of signalling among all 
images. Images were obtained of two views: ventral (left panel of images) and dorsal (right panel of 
images). 3 different groups of mice are shown. 
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Figure 5-3 Quantification of the net signal intensity in ODD-Luc mice at 2 hours.  
Mice (n=8) left untreated (control) or treated either with 8mg of DMOG (i.p.) or PBS (i.p.) for 2 hours as 
shown in the time-line. Relative net intensity of signal is shown. Lines show mean value and data were 
analysed by 1-way ANOVA with Dunnett’s post-hoc test for multiple comparisons: ** p<0.01 versus PBS-
treated group. 
 
Mice have also been imaged 6 hours after receiving their first DMOG treatment. DMOG-
injected mice did not manage to sustain the robust bioluminescence they exhibited after 2 hours 
thus possibly suggesting that DMOG’s effect on PHD inhibition and HIF stabilisation in vivo is 
short. This effect may result from a feedback mechanism mediated by the HIF-dependent 
activation of PHD-2 after DMOG administration. Newly transcribed and expressed PHD-2 may 
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escape the effect of DMOG and further hydroxylate HIF α leading to its degradation and a 
decreased bioluminescence signal (Figure 5-4). Quantification of the net signal from mice at 6 
hours also suggests that the signal intensity generated by the DMOG-injected mice is not 
significantly different from the signal generated by the other two groups of mice (Figure 5-5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-4 DMOG –induced luciferase activity is gradually decreasing at 6 hours in 
ODD-Luc mice. 
Bioluminescent image with co-registered X-ray. Bioluminescent images of mice (n=8) left untreated 
(control) or treated either with 8mg DMOG (i.p.) or PBS (i.p.) for 6 hours as shown in time-line. All mice 
received 50mg/kg luciferin (i.p.) 6 hours post treatment and 10 minutes later they were imaged. The images 
are adjusted to conform to the same radiance scale showing the relative intensity of signalling among all 
images. Images were obtained of two views: ventral (left panel of images) and dorsal (right panel of 
images). 3 different groups of mice are shown. 
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Figure 5-5 Quantification of the net signal intensity in ODD-Luc mice at 6 hours. 
Mice (n=8) left untreated (control) or treated either with 8mg of DMOG (i.p.) or PBS (i.p.) for 6 hours as 
shown in the time-line. Relative net intensity of signal is shown. Lines show mean value and data were 
analysed by 1-way ANOVA with Dunnett’s post-hoc test for multiple comparisons: versus PBS-treated 
group and all comparisons were found to be not significant. 
 
Imaging 24 hours after mice received 8 mg DMOG revealed that the bioluminescent 
signal generated by the DMOG-injected mice returned back to the basal levels, thus showing no 
difference between the DMOG-treated mice and the mice either left untreated (control) or 
vehicle-treated (PBS-mice) (Figure 5-6). This was further confirmed by quantification of images 
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obtained of both views. The net signal intensity from mice at 24 hours following DMOG-injection 
is not significantly different from the signal generated by the other two groups of mice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-6 DMOG –induced luciferase activity is returned back to the basal levels at 24 
hours. 
Bioluminescent image with co-registered X-ray. Bioluminescent images of mice (n=8) left untreated 
(control) or treated either with 8mg DMOG (i.p.) or PBS (i.p.) for 24 hours as shown in time-line. All mice 
received 50mg/kg luciferin (i.p.) 24 hours post treatment and 10 minutes later they were imaged. The 
images are adjusted to conform to the same radiance scale showing the relative intensity of signalling 
among all images. Images were obtained of two views: ventral (left panel of images) and dorsal (right panel 
of images). 3 different groups of mice are shown. 
 
Chapter 5 
184 
                  V e n tr a l  2 4  h r
U n t re a t e d P B S D M O G
0
2.010 6
4.010 6
6.010 6
8.010 6
S
ig
n
a
l 
In
te
n
si
ty
T r e a tm e n t
                    D o r s a l  2 4  h r
U n t re a t e d P B S D M O G
0
2.010 6
4.010 6
6.010 6
8.010 6
S
ig
n
a
l 
In
te
n
si
ty
T r e a tm e n t
PBS
DMOG
24 hrs
Luciferin
10 mins
Imaging
ns
ns
ns
ns
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-7 Quantification of the net signal intensity in ODD-Luc mice at 24 hours. 
Mice (n=8) left untreated (control) or treated either with 8mg of DMOG (i.p.) or PBS (i.p.) for 24 hours as 
shown in the time-line. Relative net intensity of signal is shown. Lines show mean value and data were 
analyzed by 1-way ANOVA with Dunnett’s post-hoc test for multiple comparisons: versus PBS-treated 
group and all comparisons were found to be not significant. 
 
A time course of the experiment is shown in Figure 5-8. DMOG treatment significantly 
increased the bioluminescent signal as early as 2 hours followed by a gradual decrease over a 24 
hour time period. By contrast mice either left untreated (control) or vehicle-treated (PBS) did not 
exhibit an increase in luciferase activity throughout the time period. 
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Figure 5-8 Imaging luciferase activity after in vivo administration of 8mg DMOG over a 
24-hour time course. 
Mice (n=8) left untreated (control) or treated either with 8mg of DMOG (i.p.) or PBS (i.p.) for time points 
indicated. Relative net intensity of signal is shown. Lines show mean value and data were analysed by 2-
way ANOVA: ** p<0.01 versus PBS-treated group. 
 
5.3.3 DMOG treatment activates the HIF pathway in vivo 
Study Design: 
 
 
 
ODD-Luc mice were left untreated (control) or treated either with 1mg DMOG (i.p.), or 8 
mg DMOG (i.p.) every 24 hours for 4 days (Nagel et al., 2011). All mice received 50mg/kg 
luciferin (i.p.) 2 hours post treatment and 10 minutes later they were imaged. Day 7 represents 
bioluminescent images taken from mice 3 days post last DMOG injection (Hams et al., 2011; 
Milkiewicz et al., 2004; Safran et al., 2006). 
Having shown that DMOG treatment results in enhanced luciferase activity generating a 
robust bioluminescent signal as early as 2 hours, I next investigated the effect of two different 
DMOG concentrations (1 mg/mouse and 8 mg/mouse). The scope of this experiment was to study 
what effect different DMOG treatment regimes have because little is known about DMOG 
pharmacokinetics in terms of activation of the HIF pathway in these mice. For this reason, 9 
weeks old DBA/1 mice were treated with two different DMOG concentrations (i.p.) every 24 
hours for 4 days and were imaged 2 hours post-DMOG injection and 10 minutes after receiving 
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50 mg/kg luciferin (i.p.). As Figure 5-9 shows, treatment with 8 mg DMOG generates a much 
more robust bioluminescent signal than 1 mg DMOG on day 1. On day 2 after treatment the 
mouse that received 1 mg DMOG generated more bioluminescence compared to day 1, whereas 
bioluminescent levels generated by the mouse that received the highest DMOG concentration 
remained unchanged. On day 3 bioluminescent levels generated by both DMOG regimes were 
comparable to that of control levels. On day 4, mouse treated with 1 mg DMOG restored its 
bioluminescent levels compared to mouse treated with 8 mg DMOG which did not alter its 
bioluminescence from day 3. Interestingly, when mice were imaged 3 days post last DMOG 
treatment (day 7) bioluminescent images mirrored those observed on day 1 (Figure 5-9).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-9 Comparison of the effects of two different DMOG concentrations in vivo: 8mg 
DMOG activate the HIF pathway. 
Bioluminescent image with co-registered X-ray. Bioluminescent images of mice left untreated (control, first 
from the top ) or treated either with 1mg DMOG (i.p.) (the one in the middle) or 8 mg DMOG (i.p.) (first 
from the bottom) every 24 hours for 4 days. All mice (n=3) received 50mg/kg luciferin (i.p.) 2 hours post 
treatment and 10 minutes later they were imaged. Day 7 represents bioluminescent images taken from mice 
3 days post last DMOG injection. The images are adjusted to conform to the same radiance scale showing 
the relative intensity of signalling among all images. Images were obtained of two views: ventral (left panel 
of images) and dorsal (right panel of images). 
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At this stage, I reasoned that a possible explanation why treatment with 8 mg DMOG 
does not increase further the bioluminescent levels between days 2 and 4 is probably because of 
the HIF-dependent feedback loop that leads to PHD upregulation which in turn targets HIF for 
degradation. To examine this hypothesis, nephrectomies were performed after mice have been 
imaged on days 1, 2 and 3 and mRNA expression levels of the HIF target genes VEGF, PHD-2 
and PHD-3 were analysed by qPCR as shown in Figure 5-10. Mice treatment with 8 mg DMOG 
resulted in a significant increase in PHD-3 mRNA expression levels on days 1 and 2 whereas 
VEGF and PHD-2 did not show any dramatic increase. The PHD-3 mRNA upregulation might 
account for the absence of any bioluminescence signal on days 2, 3, and 4 given that PHD-3 
targets HIF for degradation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-10 DMOG activates the HIF pathway in vivo. 
mRNA expression levels of the HIF target genes VEGF, PHD-2 and PHD-3 on days 1 (a), 2 (b) and 3 (c). 
Nephrectomies were performed after mice (n=3) have been imaged as it is indicated by the timeline. 
Comparison was made against kidneys that have been removed from mice left untreated 
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5.3.4 Monitoring AIA progression in ODD-Luc mice 
Study design: 
 
 
 
 
 On day –7 prior to the induction of arthritis 10-12 weeks old ODD-Luc mice were 
immunised (each mouse was immunised receiving a subcutaneous injection in 2 points at tail base 
of CFA, PBS and methylated BSA, as previously described in 2.5.2) and arthritis was induced 
(each mouse received an intra-articular injection at their left knee of the following: mBSA and 
sterile PBS, as previously described in 2.5.2) on day 0 as shown in timeline. Control 
animals/knees left either untreated (control) or underwent the same procedure but received only 
equivalent volumes of saline (Brackertz et al., 1977a; Brackertz et al., 1977b).  
Having shown that DMOG has an effect in vivo in terms of activating the HIF pathway, 
in ODD-Luc mice, I then investigated the effect of DMOG administration using an in vivo murine 
AIA model of arthritis in terms of the disease establishment and progression. Immunisation of 
male ODD-Luc mice was performed as described in 2.5.2 and resulted in inflammatory arthritis. 
Figure 5-11illustrates the time course of AIA progression in ODD-Luc mice. Disease onset and 
progression was monitored daily for three days after induction (day 0) for the extent of oedema, 
erythema and deformity. The clinical signs of arthritis appeared on day 1 after induction. For 
clinical monitoring of AIA development knee swelling was assessed by measuring the thickness 
of the knees using callipers as described in 2.5.3.1. Knee measurements made before the induction 
(Day 0) were used as the basal levels. Figure 5-11a shows the time course of changes in knee joint 
diameter in both knees (arthritic and contra-lateral) over the observation time of 3 days after 
arthritis induction. In the untreated knee there was no increase in joint diameter throughout the 
time course (the observed reduction might represent an injection effect or could well be due to 
more movement to compensate for the diseased knee). In contrast, significant swelling of the knee 
joint was observed from day 1 in the methylated-BSA (mBSA) knee. However, the knee diameter 
started decreasing gradually from day 2 after induction and returned to the basal levels on day 3 
(Figure 5-11b). Knees have been also dissected out from experimental mice and pictures have 
been taken to visualise the difference in thickness and vascularity between an arthritic knee and 
the contra-lateral knee. Figure 5-12 shows changes in knee joint diameter in both knees (arthritic 
and contra-lateral) over the observation time of 3 days after arthritis induction. In the contra-
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lateral knee there was no increase in joint diameter throughout the time course. In contrast, 
significant swelling of the knee joint was observed from day 1 in the mBSA- injected knee. 
 
Figure 5-11 Time course of AIA progression in ODD-Luc mice. 
Graph (a) illustrates the disease course of an AIA experiment on 10-12 weeks old ODD-Luc mice. On day –
7 prior to the induction of arthritis mice were immunised and arthritis was induced on day 0 as described in 
2.5.2 and shown in timeline. Control animals/knees left either untreated (control) or underwent the same 
procedure but received only equivalent volumes of saline. The inflammatory response is represented as 
knee thickness in mm measured from day 0. Data are expressed as means ± SEM (n = 11) and were 
analysed by 2-way ANOVA: *** p<0.001 versus contra-lateral knee. Pictures (b) show representative 
images from a healthy skinned knee (left panel) and from an arthritic skinned knee (right panel) 
demonstrating severe oedema and redness of the entire knee. 
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Figure 5-12 AIA disease progression in ODD-Luc mice. 
Pictures (a) show representative images from an arthritic knee (left panel) and from healthy knee (right 
panel) demonstrating severe oedema, swelling and redness of the entire knee. Pictures (b) show the same 
knees as above without the skin. The increased redness and enhanced vessel formation in the case of the 
arthritic knee is observed. 
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5.3.5 Effect of hydroxylase inhibition on AIA in ODD-Luc mice 
Study design:  
 
 
 
 
 On day –7 prior to the induction of arthritis 10-12 weeks old ODD-Luc mice were 
immunised and arthritis was induced on day 0 as previously described in 2.5.2 and as shown in 
timeline (Brackertz et al., 1977a; Brackertz et al., 1977b). Treatment of mice started from day 
minus 1 either with DMOG daily (i.p.) at a dose of 8mg in 100µL in PBS (equivalent to 
400mg/kg) or left untreated (Cummins et al., 2008; Hams et al., 2011; Milkiewicz et al., 2004). 
Having established the AIA model in the ODD-Luc mice, I next investigated the effect of 
HIF hydroxylase inhibition on disease activity. Immunisation of male ODD-Luc mice was 
performed as described in 2.5.2 and resulted in inflammatory arthritis. Treatment of mice started 
from day minus 1 either with DMOG daily (i.p.) at a dose of 8mg in 100µL in PBS (equivalent to 
400mg/kg) or left untreated. Significant swelling of the knee joint was observed from day 1 in the 
mBSA injected knee. However, the knee swelling started decreasing gradually from day 2 after 
induction and returned almost to the basal levels on day 3 (Figure 5-13a). Of note is that DMOG 
treatment significantly reduced the disease progression as early as day 1, and knee thickness 
readings returned to the basal levels from day 2 onwards as shown in Figure 5-13b. 
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Figure 5-13 DMOG reduces the disease progression in an AIA model in ODD-Luc mice. 
Graph (a) illustrates the disease course of an AIA experiment on 10-12 weeks old ODD-Luc mice. On day 
minus 7 prior to the induction of arthritis mice were immunised and arthritis was induced on day 0 as 
described in 2.5.2 and shown in timeline. Control animals/knees either left untreated (control) or underwent 
the same procedure but received only equivalent volumes of saline. The inflammatory response is 
represented as knee thickness in mm measured from day 0. Data are expressed as means ± SEM (n = 11) 
and were analysed by 2-way ANOVA: **** p<0.0001 versus contra-lateral knee. Graph (b) illustrates the 
potentially therapeutic benefit of DMOG administration (8mg/mouse) received every day starting from day 
-1. Data are expressed as means ± SEM (n = 11) and were analysed by 2-way ANOVA: **** p<0.0001 
versus DMOG. 
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After showing that DMOG significantly ameliorated the disease progression in AIA model, I 
expected that arthritic knees would generate a robust bioluminescent signal as a result of the 
possible hypoxia occurring within the diseased area. Showing this would confirm whether HIF 
expression is associated with the disease in the affected knee. As Figure 5-14a shows AIA does 
not lead to significant upregulation of the luciferase activity and therefore the generated 
bioluminescent signal is not dramatically different between the knees of the control mouse and 
those of the AIA mouse. This is also confirmed by quantification of the net signal intensity 
(Figure 5-14b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-14 AIA does not significantly enhance luciferase activity. 
Bioluminescent images (a) with co-registered X-ray. Bioluminescent images of mice left unimmunised 
(control, first from the top ) or immunised and induced AIA (AIA mouse) as descibed in 2.5.2. The images 
are adjusted to conform to the same radiance scale showing the relative intensity of signalling among all 
images. Images were obtained of ventral view. 1 refers to the injected knee of the AIA mouse whereas 2 
refers to the uninjected knee of the AIA mouse. 3 and 4 refer to unmanipulated knees of the control mouse. 
Quantification (b) of the net signal intensity in vivo on day 1 after AIA induction is also shown. 
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5.3.6 Effect of hydroxylase inhibition on AIA in DBA/1 mice 
Study design:  
 
 
 
 
 On day –7 prior to the induction of arthritis 10-12 weeks old DBA/1 mice were immunised and 
arthritis was induced on day 0 as previously described in 2.5.2 and as shown in timeline 
(Brackertz et al., 1977a; Brackertz et al., 1977b). Treatment of mice started from day minus 1 
either with DMOG daily (i.p.) at a dose of either 1mg or 8mg in 100µL in PBS or left untreated 
(Nagel et al., 2011). 
Having shown that DMOG has an effect in vivo in ODD-Luc mice, I then investigated the 
effect of DMOG administration on AIA in the well described DBA/1 mouse strain. Figure 5-15 
illustrates the time course of AIA progression in DBA/1 mice which received DMOG at 
concentrations of either 1 or 8mg/mouse. Figure 5-15 shows the time course of changes in knee 
joint diameter in both knees arthritic (Figure 5-15a) and contra-lateral (Figure 5-15b) over the 
observation time of 3 days after arthritis induction. The arthritic knees that remained untreated 
throughout the disease progression exhibited severe swelling as early as day 1 after disease 
induction and gradually decreased until day 3 of disease. DMOG treatment reduced knee 
thickness although statistical significance was reached only with 8mg DMOG (Figure 5-15a) 
Knee diameter reading of the contra-lateral knee remained relatively low throughout the disease 
progression (Figure 5-15b). 
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Figure 5-15 Comparison of two DMOG treatment regimes on AIA progression in DBA/1 
mice. 
Illustration of the disease course of an AIA experiment on 10-12 weeks old ODD-Luc mice on arthritic 
knees (a) and contralateral knees (b). On day minus 7 prior to the induction of arthritis mice were 
immunized and arthritis was induced on day 0 as described in 2.5.2 and shown in timeline. Arthritic knees 
were treated either with 1or 8mg/mouse starting from day minus 1. Control animals/knees either left 
untreated (control) or underwent the same procedure but received only equivalent volumes of saline. The 
inflammatory response is represented as knee thickness in mm measured from day 0. Data are expressed as 
means ± SEM (n = 11) and were analysed by 2-way ANOVA: ns = not significant, * p<0.05 versus control. 
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5.3.7 Effect of HIF hydroxylase blockade on anaemia in AIA in DBA/1 mice 
Study design:  
 
 
 
 
 
 On day –7 prior to the induction of arthritis 10-12 weeks old DBA/1 mice were 
immunised and arthritis was induced on day 0 as previously described in 2.5.2 and as shown in 
timeline (Brackertz et al., 1977a; Brackertz et al., 1977b). Treatment of mice started from day 
minus 1 either with DMOG daily (i.p.) at a dose of either 1mg or 8mg in 100µL in PBS or left 
untreated (Nagel et al., 2011). Haematocrit measurements were made on days -4 and 3 as 
described in 2.5.4 
Anaemia associated with RA, known as rheumatoid anaemia, is a typical example of 
anaemia of chronic disease (Gomollon and Gisbert, 2010; Masson, 1992). In the absence of 
effective treatment, anaemia is highly prevalent among RA patients. Therefore, I wanted also to 
investigate whether amelioration of the disease following DMOG treatment can be associated 
with amelioration of hematocrit levels. Experimental mice from 5.3.6 were bled at day minus 4 
prior disease induction and on day 3 post disease induction. Hematocrit measurements were 
performed as described in 2.5.4. According to the Figure 5-16 arthritic mice are characterised by 
relatively low haematocrit levels, whereas treatment with 8mg DMOG appeared to restore the 
haematocrit levels. Arthritic mice that received 1 mg DMOG did not receive any therapeutic 
benefit in terms of amelioration of the haematocrit levels. 
 
 
 
 
 
 
 
 
Chapter 5 
197 
Day 1
Immunisation
Record: 1) clinical score
2)  Paw thickness
3)  Animal weight
10 days
post disease onset
Day 14 Day 45
bleed
Cull  
U
n i
n d
u c
e d
U
n t
re
a t
e d
 (a
r t
h r
it
ic
)
D
M
O
G
 8
m
g /
m
o u
se
D
M
O
G
 1
m
g /
m
o u
se
3 5
4 5
5 5
6 5
7 5
D M O G  in je c t e d  i .p .  d a i ly  f r o m
d a y  - 1  ( 1  d a y  b e f o r e  m e t B S A )
R a n g e  o f  H T C  a t  s t a r t  o f
e x p e r im e n t  ( d a y  - 4 )
T r e a t m e n t
H
a
e
m
a
to
c
ri
t 
(%
)
* *
bleed
bleed
Immunisation
7 days
Induction
Days
0                      1                    2           3         
Measurement Cull  
- 4
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-16 DMOG treatment improves the haematocrit levels in DBA/1 arthritic mice. 
Range of haematocrit measurements at start of experiment (day -4). Haematocrit measurements were made 
as described in 2.5.4. Groups of mice being utilised include: arthritic mice that have not been treated with 
DMOG (untreated), mice that disease has not been induced on them and mice treated either with 1 or 8mg 
DMOG. Data were analysed by 1-way ANOVA:  * p<0.05 versus untreated.  
 
5.3.8 Comparison of haematocrit in healthy and DBA/1 arthritic mice using the 
CIA model 
Study design: 
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10-12 weeks old DBA/1 mice were immunised on day 1, as described in 2.5.6. 2 weeks were 
allowed in order for the mice to develop disease. Disease occurred between day14 to day 45 and 
monitored for 10 days post disease onset (Courtenay et al., 1980). Terminal bleedings were 
performed as described in 2.5.4 
 
Subsequent to the AIA studies, a different in vivo model of arthritis were applied namely 
the collagen induced arthritis model (CIA). To induce arthritis, male DBA/1 mice received an 
injection of bovine type II collagen in CFA, and monitoring of the disease was performed as 
described in 2.5.6. Clinical signs of arthritis could be observed from day 14, until day 45 after 
immunisation as shown in timeline Figure 5-17.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-17 Timeline and incidence utilising the CIA-induced arthritis model. 
10-12 weeks old DBA/1 mice were immunised on day 1. 2 weeks were allowed in order for the mice to 
develop disease. Disease occurred at some time point between day14 to day 45 and monitored for 10 days 
post disease onset.  
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Figure 5-18 illustrates a representative graph of clinical score (Figure 5-18a) and 
differential clinical score (Figure 5-18b) throughout the disease progression in arthritic animals 
followed over a period of ten days. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-18 Time course of arthritis progression in DBA/1 mice (clinical 
score/differential clinical score). 
Graphs illustrate a CIA experiment run in this study to demonstrate the disease course. Immunisation of 
DBA/1 mice with bovine CII induced joint inflammation with characteristic oedema and erythema. Mice 
with visual appearance of arthritis (redness and/or swelling of a paw) were monitored daily for 10 days to 
observe disease progression. The inflammatory response was represented as (a) clinical score and (b) 
differential clinical score.  
 
Figure 5-19 illustrates a representative graph of paw thickness (Figure 5-19a) and 
differential paw thickness (Figure 5-19b) throughout the disease progression in arthritic animals 
followed over a period of ten days. 
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Figure 5-19 Time course of arthritis progression in DBA/1 mice (paw 
thickness/differential paw thickness). 
Graphs illustrate a CIA experiment run in this study to demonstrate the disease course. Immunisation of 
DBA/1 mice with bovine CII induced joint inflammation with characteristic oedema and erythema. Mice 
with visual appearance of arthritis (redness and/or swelling of a paw) were monitored daily for 10 days to 
observe disease progression. The inflammatory response was represented as (a) paw thickness and (b) 
differential paw thickness.  
 
Experimental mice have been terminally bled and haematocrit measurements were 
performed as described in 2.5.4. As Figure 5-20 shows, healthy mice (14 weeks old) exhibited a 
median of 52 (percentage of red blood cells in the blood), non-arthritic mice of 22-24 weeks of 
age exhibited a median of 48 (percentage of red blood cells in the blood), whereas arthritic mice 
of the same age showed a median of 44 (percentage of red blood cells in the blood), that is 
significantly lower HCT than the age-matched healthy mice. 
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Figure 5-20 Comparison of haematocrit between healthy and arthritic DBA/1 mice (CIA 
model). 
Haematocrit measurements (a) were made as described in 2.5.4. Groups of mice being utilised include: 
healthy mice (14 weeks old), non-arthritic mice (22-24 weeks old) and arthritic mice (22-24 weeks old). 
Data were analysed with one-way ANOVA: ** p<0.01 versus non-arthritic group, *** p<0.001 versus 
healthy group. 
 
I next investigated the relationship between haematocrit levels and arthritis score. Mice 
upon arthritis disease onset have been analysed in terms of their haematocrit levels throughout the 
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10 day time period. As Figure 5-21 shows, haematocrit levels are reversed correlated to the 
arthritis score. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-21 Haematocrit is reduced in CIA model. 
Haematocrit levels were analysed compared to arthritis severity (a).Haematocrit is inverted correlated with 
arthritis score. Data were analysed (b) with spearman correlation (r) P values (two tailed):* p<0.05 versus 
clinical score. 
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5.3.9 Effect of HIF hydroxylase inhibition on CIA-induced arthritis in DBA/1 mice 
Study design: 
 
 
 
 
 
 
 
 
 
 
 
10-12 weeks old DBA/1 mice were immunised on day 1, as described in 2.5.6. 2 weeks 
were allowed in order for the mice to develop disease. Disease occurred between day14 to day 45 
and monitored for 10 days post disease onset (Courtenay et al., 1980). Mice were either left 
untreated or treated with 8mg DMOG (i.p.) on days 1, 4 or 7 post disease onset. Vehicle-treated 
mice received the same volume of saline (i.p.) for the same time points. 
 
Having shown the effect of DMOG using the AIA model of arthritis, I next investigated 
the effect of HIF hydroxylase inhibition in the CIA model. For that reason, 10-12 weeks old male 
DBA/1 mice were either left untreated or treated with 8mg DMOG (i.p.) on days 1, 4 and 7 post 
disease onset. Vehicle-treated mice received the same volume of saline (i.p.) for the same time 
points. Figure 5-22 shows that all three groups of mice exhibited a sum of clinical score between 
3-4 on day 3 post disease onset. Clinical score of untreated mice remained relatively unchanged 
until day 7 and was followed by a slight increase until the day 10 post disease onset. Vehicle and 
DMOG-treated mice exhibited a lower clinical score compared to untreated between day 4 and 
day 10 post disease onset, however no difference between vehicle and DMOG-treated mice was 
observed on this occasion.  
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Figure 5-22 Clinical score of CIA-induced arthritis progression in DBA/1 mice. 
Graphs illustrate a CIA experiment run in this study to demonstrate the disease course. Immunisation of 
DBA/1 mice with bovine CII induced joint inflammation with characteristic oedema and erythema. Mice 
with visual appearance of arthritis (redness and/or swelling of a paw) were monitored daily for 10 days to 
observe disease progression. The inflammatory response was represented as clinical score. Data are 
expressed as means ± SEM (n = 30) and were analysed with 2 way ANOVA (versus vehicle) and all 
comparisons were found to be not significant.  
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Paw swelling was assessed by measuring the maximal thickness between the dorsal and 
planter surfaces of the paw using microcalipers and calculating the change in thickness for each 
inflamed paw as demonstrated in Figure 5-23. This experiment showed no significant difference 
in paw thickness measurements between experimental groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-23 Paw thickness progression of CIA-induced arthritis in DBA/1 mice. 
Graphs illustrate a CIA experiment run in this study to demonstrate the disease course. Immunisation of 
DBA/1 mice with bovine CII induced joint inflammation with characteristic oedema and erythema. Mice 
with visual appearance of arthritis (redness and/or swelling of a paw) were monitored daily for 10 days to 
observe disease progression. The inflammatory response was represented as paw thickness in mm. Data are 
expressed as means ± SEM (n = 30) and were analysed with 2 way ANOVA and all comparisons were 
found to be not significant.  
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Having shown no significant difference in paw thickness measurements between DMOG-
treated mice and/or vehicle/untreated, when giving DMOG every 3 days, I next investigated the 
effect of HIF hydroxylase inhibition on CIA-induced arthritis progression by using a different 
protocol whereby I was giving DMOG every day post arthritis disease onset. For that reason, 10-
12 weeks old male DBA/1 mice were either left untreated or treated with 8mg DMOG (i.p.) daily 
starting from day 1 post disease onset. Vehicle-treated mice received the same volume of saline 
(i.p.) for the same time points. Figure 5-24 shows that DMOG treated mice exhibited a 
significantly lower clinical score compared to untreated or vehicle treated mice. Paw thickness is 
shown in Figure 5-25.  
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Figure 5-24 Clinical score of CIA-induced arthritis progression in DBA/1 mice (DMOG 
given daily). 
Graphs illustrate a CIA experiment run in this study to demonstrate the disease course. Immunisation of 
DBA/1 mice with bovine CII induced joint inflammation with characteristic oedema and erythema. Mice 
with visual appearance of arthritis (redness and/or swelling of a paw) were monitored daily for 10 days to 
observe disease progression. The inflammatory response was represented as clinical score. Data are 
expressed as means ± SEM (n = 30) and were analysed with 2 way ANOVA: ** p<0.01, **** p<0.0001 
versus vehicle. 
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Figure 5-25 Paw thickness progression of CIA-induced arthritis in DBA/1 mice (DMOG 
given daily). 
Graphs illustrate a CIA experiment run in this study to demonstrate the disease course. Immunisation of 
DBA/1 mice with bovine CII induced joint inflammation with characteristic oedema and erythema. Mice 
with visual appearance of arthritis (redness and/or swelling of a paw) were monitored daily for 10 days to 
observe disease progression. The inflammatory response was represented as paw thickness in mm. Data are 
expressed as means ± SEM (n = 30) and were analysed with 2 way ANOVA: **** p<0.0001 versus 
vehicle. 
 
Histological analysis was used to confirm the clinical assessments. Paws were harvested 
at indicated time points and processed for histological evaluation. No clinical or histological 
evidence of arthritis was seen in control animals receiving DMOG. Sections of healthy joints 
revealed well defined joint spaces (indicated with a single asterisk *), with the articular surface of 
bones covered with cartilage of uniform thickness and smooth surface. The synovial lining is 
barely perceptible and is only one to two cell layers thick. Soft tissues surrounding the joints are 
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normal. The histological examination of affected paws revealed a good correlation between the 
clinical and the histological findings. Sections of severely arthritic paws, however, exhibited 
widespread infiltration of inflammatory cells throughout the joint tissue, extensive proliferation 
and vascularisation of the synovium (indicated with a double asterisk **), as well as invasion and 
erosion of cartilage and subchondral bone by pannus tissue, leading to complete disorganisation 
of the joint architecture and in some areas to the development of fibrous or bony ankylosis. Figure 
5-26a presents typical histopathological features of a severely arthritic paw compared to a healthy 
paw. Quantification is shown in Figure 5-26b. 
 
 
 
 
 
 
 
 
 
Figure 5-26 Histological changes in joints of mice with CIA. 
Paws were harvested at the end of an experiment and processed for histological examination. Images (a) 
present haematoxylin and eosin stained sections of metatarsophalangeal joints from arthritic mice left either 
untreate or treated with vehicle or DMOG 8mg (i.p.) A subchronic inflammation with fibrous thickening of 
the synovium (S) and moderate infiltration of inflammatory cells (I) could be observed in arthritic joints. 
Compared to untreated, articular cartilage (C) and the underlying bone were rarely or only mildy eroded in 
DMOG treated mice. 
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5.3.10 Effect of DMOG on haematocrit levels in arthritic DBA/1 mice during the 
CIA model 
Study design: 
 
 
 
 
 
 
 
 
 
 
 
10-12 weeks old DBA/1 mice were immunised on day 1, as described in 2.5.6. 2 weeks 
were allowed in order for the mice to develop disease. Disease occurred between day14 to day 45 
and monitored for 10 days post disease onset (Courtenay et al., 1980). Mice were either left 
untreated or treated with 8mg DMOG (i.p.) on days 1, 4 or 7 post disease onset. Vehicle-treated 
mice received the same volume of saline (i.p.) for the same time points. Terminal bleedings were 
performed as described in 2.5.4. 
 
Experimental mice from 5.3.9 have also been bled at the end of the disease course and 
their haematocrit levels have been analysed as described in 2.5.4. As Figure 5-27a shows, 
haematocrit levels were significantly upregulated following DMOG treatment. Moreover, 
untreated mice exhibited significantly lower haematocrit levels compared to mice that have been 
immunised but did not develop disease (non-arthritic). Arthritic mice left untreated showed a 
median of 50 (percentage of red blood cells in the blood), whereas DMOG-treated mice exhibited 
a median of 58 (percentage of red blood cells in the blood). Similar trend was also observed in the 
case of mice that have been immunised but did not develop disease (non-arthritic) with a median 
of haematocrit level of 56 (percentage of red blood cells in the blood), (Figure 5-27b). 
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Figure 5-27 DMOG ameliorates anaemia in arthritic DBA/1 mice. 
Haematocrit measurements (a) were made as described in 2.5.4. Groups of mice being utilised include: 
arthritic mice, DMOG-treated mice and non-arthritic mice .Data were analysed with one-way ANOVA: 
** p<0.01 versus non-arthritic group, ns=non significant, * p<0.05, ** p<0.01 versus healthy group. 
Quantification is shown in (b). 
 
5.3.11 DMOG reduces arthritis severity probably by skewing macrophage 
phenotypes from M1 to M2 
In an attempt to investigate a possible mechanism by which DMOG treatment results in a 
significant reduction of the paw swelling and oedema throughout the CIA disease course I 
characterised the macrophages derived from paws from experimental mice used in 5.3.9 in terms 
of M1/M2 markers. Cells have been liberated by paws as described in 2.5.7.2 and analysed with 
regard to M1/M2 macrophage markers by FACS analysis. As shown in Figure 5-28a, M2 
macrophages was the predominant macrophage population in the case of a healthy paw compared 
to M1 macrophages verifying the role of M2 cells in guarantying the homeostasis within a tissue. 
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Arthritic mice that have been left untreated exhibited an increase in their M1 macrophage 
population compared to the healthy paws, whereas their M2 cell population was significantly 
decreases. Interestingly, DMOG treatement mice appeared to restore homeostasis by increasing 
the M2 macrophage population. As FACS analysis shows in Figure 5-28b, M2 cells constitute for 
a 56.2% of the whole cell population, whereas the M1 cells only for 10.7%. The opposite trend is 
observed in arthritic mice that have been left untreated in which case there is a significant 
decrease in the M2 cell population down to 23.5% and a concomitant slight increase in the M1 
macrophage population to 18.3%. The percentages of the cell population observed in a healthy 
paw are similar to those observed within a DMOG-treated paw in which case the M2 cell 
population is restored back to 67.1% and the M1 cell population decreases to 4.11%. 
 
 
 
 
 
 
 
 
 
 
Figure 5-28 DMOG shifts macrophage phenotypes from M1 to M2 phenotype. 
Quantification is shown in (a) M1 macrophage population is shown in white bars and M2 macrophage 
population is shown in black bars. Representative FCM plots (b) are shown. Macrophages have been 
stained as described in 2.5.7.3. All three panels represent the M1 versus M2 macrophage populations 
existing within a healthy (non-arthritic) paw, a vehicle-treated paw (PBS) and a DMOG-treated paw. 
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5.4 Discussion  
This part of the study aims to investigate the role of HIF hydroxylases in RA, using a 
combination of in vivo disease models utilising commercially available HIF hydroxylase 
inhibitors such as the pan-specific inhibitor DMOG. The advent of sophisticated and analytical 
methods including positron emission tomography, magnetic resonance imaging (MRI), and 
optical imaging, has made possible the identification of anatomical and functional differences 
between a normal and a diseased tissue (Weissleder and Ntziachristos, 2003). Optical imaging is 
the most widely used technique due to the low costs of the above mentioned facilities. Regardless 
of the modality used, it is increasingly appreciated that non-invasive imaging represents a very 
important part of basic and translational research as well as drug development and medical care 
by enabling the detection of molecular signatures indicative of specific disease states or the 
actions of particular therapeutics in real time. A number of bioluminescent and fluorescent 
reporters have been used for optical imaging including firefly luciferase, green fluorescent 
protein, and caged near infrared probes (Gross and Piwnica-Worms, 2005; Weissleder and 
Ntziachristos, 2003). Bioluminescent and fluorescent proteins can be genetically reengineered so 
that particular enzymes affect their abundance or specific activity. For example, such proteins can 
be rendered unstable by fusion to polypeptides that are recognized by specific ubiquitin ligases 
complexes, which act to target proteins for proteasomal degradation (Gross and Piwnica-Worms, 
2005). The resulting fusion proteins can then be used to interrogate molecular events that affect 
their respective ubiquitin ligases. Bioluminescent reporters, such as luciferases, have the 
advantage that they do not require excitation by an external source, and, hence, problems related 
to tissue autofluorescence are minimized (Safran et al., 2006). 
 With regard to Hypoxia/HIF, Safran et al fused a fragment of HIF that is subject to 
oxygen-dependent degradation, to firefly luciferase and showed that the resulting fusion protein 
(ODD-Luc) is responsive to hypoxia and hypoxia mimetics in live cells grown in culture. 
Moreover, they engineered a mouse that ubiquitously expresses the ODD-Luc reporter and 
showed that this mouse strain, ROSA26 ODD-Luc/+, can be used to image the development of 
tissue hypoxia and the action of small molecule inhibitors of HIF prolyl hydroxylase activity. The 
authors have used several HIF agonists with which they have treated the ROSA26 ODD-Luc/+ 
mice. Administration of FG-4383 to ROSA26 ODD-Luc/+ mice by oral gavage caused a dose-
dependent increase in light emission, especially in the regions of the kidneys and liver. Induction 
of ODD-Luc in these two organs, and to a much lesser extent in the lungs, was confirmed by 
immunoblot analysis and was associated with activation of a subset of HIF target genes as 
determined by real-time PCR. The authors comment that they failed to observe ODD-Luc 
stabilisation in mice treated with DFO or the hydroxylase inhibitor DMOG, suggesting that these 
agents are far less potent than FG-4383. However, those data were not shown in the study. The 
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decision on DMOG doses used in my study was based on published studies showing that 
inhibition of endogenous HIF inactivation by DMOG induces angiogenesis in ischaemic skeletal 
muscles of mice (Milkiewicz et al., 2004).  
For my study purposes, I followed the same protocol as Safran et al However, in contrast 
to the above mentioned study, DMOG treatment in my experiments enhanced the luciferase 
activity, as evidenced by the increased bioluminescent signal as early as 2 hours which then 
gradually decreased within a time period of 24 hours. Having shown that DMOG has indeed an 
effect in vivo I was interested to study the pharmacokinetics of DMOG in vivo. The only study to 
investigate the pharmacokinetics and pharmacodynamics of DMOG in vivo in a disease setting 
was conducted by Nagel et al (Nagel et al., 2011) who investigated the effect of DMOG on the 
outcome of ischemia after permanent and transient middle cerebral artery occlusion (p/tMCAO) 
in the rat. Before and after pMCAO, rats were treated with 40 mg/kg, 200mg/kg DMOG, or 
vehicle, and with 40 mg/kg or vehicle after tMCAO. Serial magnetic resonance imaging (MRI) 
was performed to assess infarct evolution and regional cerebral blood flow (rCBF). Both doses 
significantly reduced infarct volumes, but only 40 mg/kg improved the behavior after 24 hours of 
pMCAO. Animals receiving 40mg/kg were more likely to maintain rCBF values above 30% from 
the contralateral hemisphere within 24 hours of pMCAO. DMOG after tMCAO significantly 
reduced the infarct volumes and improved behavior at 24 hours and 8 days and also improved the 
rCBF after 24 hours. A consistent and significant upregulation of both mRNA and protein levels 
of VEGF and eNOS was associated with the observed neuroprotection, although this was not 
consistently related to HIF-1α levels. The authors suggested that the absence of a simple 
relationship between outcome and HIF levels at the end of the experiment is probably reflecting 
the complex dynamics of this pathway with its multiple feedback loops (Nagel et al., 2011). There 
are some interesting confounds to the current study that lead to the conclusion that the biological 
effects seen in this model might not entirely be explained by HIF-mediated changes in gene 
expression. Protection was observed with only a moderate increase in HIF-1α, and despite a 
further increase in HIF-1α protein levels, as well as raised expression levels of VEGF, eNOS, and 
EPO, the higher DMOG dose failed to improve behavior. It is possible that a bigger sample size 
would reveal a protective effect of higher doses of DMOG on behavior or that an early peak in 
HIF-1α was missed.  
My findings suggest that treatment with 8 mg DMOG increases the net intensity more 
than treatment with 1 mg DMOG. However, continuous DMOG treatment does not increase 
further the bioluminescent signal probably due to the HIF-dependent feedback loop which 
enhances PHD activity (as shown by increased PHD-3 mRNA expression levels) and thus does 
not allow HIF to become stabilised and the subsequently luciferase gene to be expressed. An 
illustration is shown in Figure 5-29. 
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transfer of CII-reactive T-cells, passively transferred IgG anti-CII antibodies induce a severe 
arthritis in naïve mice (Holmdahl et al., 1990). The importance of B-cells has further been proven 
by the fact that B-cell deficient mice are protected from CIA (Svensson et al., 1998). 
Pro-inflammatory cytokines like TNFα are crucial in the regulation of joint inflammation 
and tissue destruction. The administration of TNFα has been shown to accelerate severity of CIA 
in rats (Brahn et al., 1992). In contrast, disease is inhibited when mice are treated with anti-TNF 
antibody (Williams et al., 1992). Using the CIA model in the context of my PhD study, I found 
that DMOG treatment (8mg/mouse, i.p.) at days 1, 4 and 7 post-disease onset did not result in any 
significant reduction in paw thickness measurement compared to untreated mice. However, when 
I was administering mice DMOG every day post disease onset for the whole disease course I 
found that arthritic mice treated with DMOG received a significant therapeutic benefit compared 
to untreated mice suggesting that more frequent dosage is required to reach the beneficial effect of 
DMOG. 
AIA is another model of rheumatoid arthritis that has been established by using 
methylated bovine serum albumin (mBSA) 3 as antigen (AIA) (Brackertz et al., 1977a). The main 
advantage of AIA in comparison to other established animal models is that arthritis is induced in 
the knee joint which lends itself for microscopic observations. The knee joint is the only joint 
which can be accessed for intravital microscopy without inducing major trauma (Veihelmann et 
al., 1998).  
 In my study the AIA disease model was implemented using both DBA/1 and ODD-Luc 
mouse strains. I first ran an AIA disease model using ODD-Luc mice and found that DMOG 
treatment significantly reduced the disease progression as early as day 1 (post induction), and 
knee thickness readings returned to the basal levels from day 2 onwards. Unfortunately, arthritic 
knees did not generate a robust bioluminescent signal and therefore I was unable to correlate HIF 
expression with the diseased site. The effect of hydroxylase inhibition using DMOG was also 
confirmed on AIA in DBA/1 mice. The absence of a link between HIF expression/Hypoxia and 
the diseased site might be either due to the failure of the imager to capture hypoxia 
(bioluminescent signal not strong enough) or some non-HIF-related effects of DMOG might also 
be responsible for the observed effects. For instance, it has been described that DMOG can 
activate antioxidant gene expression through the nuclear factor erythroid 2-related factor 2 
pathways in microvascular endothelial cells, which induces the expression of various antioxidant 
proteins with critical roles in the adaptive responses to oxidative stress (e.g., HO1 or glutathione 
peroxidase 2). Thereby, DMOG resulted in significant reduction of apoptosis in the postischemic 
myocardium (Natarajan et al., 2009). 
Chapter 5 
217 
Another point also to keep in mind is that DMOG is a nonselective PHD inhibitor 
expected to interfere with all 2-OG-dependent oxygenases affecting a number of important 
cellular processes such as DNA repair, carnitine biosynthesis, and collagen modifications, and 
most likely many other functions within the cell, including the Krebs cycle (Schofield and 
Ratcliffe, 2004). Of major importance, different levels of HIF might affect different targets: 
targets we may not know yet and some of which may not be beneficial. However, this should not 
necessarily stop us from finding therapeutic utility at this point. It is evident that the right amount 
of HIF is needed at the right time, as it has been shown that sustained hypoxia/ischemia and HIF 
activation may trigger negative feedback loops (Webb et al., 2009). The recent failure of the EPO 
trial in human stroke, however, may illustrate the theory that the upregulation of a whole 
protective cellular environment rather than the increase of one potentially protective downstream 
player is necessary (Ehrenreich et al., 2009). Therefore, it is possible that HIF PHD inhibition is 
protective independent of HIF activation, and thus using HIF target gene expression is not a 
sensitive or specific proxy for HIF PHD inhibition.  
Cummins et al (Cummins et al., 2008) investigated the effects of the hydroxylase 
inhibitor DMOG on Caco-2 intestinal epithelial cell in vitro and in a dextran sodium sulphate 
(DSS)-induced model of murine colitis. DMOG induced both HIF-1α and NFκB activity in 
cultured intestinal epithelial cells, and was profoundly protective in dextran- sodium sulphate 
colitis in a manner that was at least in part reflected by the development of an anti-apoptotic 
phenotype in intestinal epithelial cells, which the authors proposed to reduce epithelial barrier 
dysfunction. In this study female C57BL/6 strain mice were treated with 8mg of DMOG injected 
i.p. every second day, a regimen previously shown to cause HIF-1 activation in vivo (Milkiewicz 
et al., 2004). The mechanism by which hydroxylase inhibition activates the NFκB pathway was 
less clear, however, the same group generated evidence that hydroxylation of key members of the 
NFκB pathway may also impact on overall NFκB activity (Cummins et al., 2006). Thus the 
inhibition of hydroxylase activity may be an efficient way to target both the HIF-1 and NFκB 
pathways for simultaneous activity. However, the authors make the point that whether reduced 
epithelial cell apoptosis or indeed cytokine expression is the cause or consequence of the 
protective effects conferred by DMOG, needs further investigation. It is speculated that it is 
possible that these effects are a result of amelioration of inflammation rather than a direct effect of 
DMOG on epithelial cells. The authors also draw the attention to the possibility that using 
pharmacological activation of HIF and NFκB pathways in tissues may lead to pro-tumourigenic 
effects of the activation of these pathways (Karin, 2006; Sen, 2006). However, that temporary 
hydroxylase inhibition promotes mucosal healing, suggests that there is a window of therapeutic 
opportunity in gastrointestinal (GI) inflammatory diseases.  
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In contrast to previous studies (Cummins et al., 2008; Karhausen et al., 2004; Robinson et 
al., 2008; Tambuwala et al., 2010) Marchbank (Marchbank et al., 2011) focused on the earliest 
stages of repair, namely restitution and proliferation. They, therefore, examined the effect of 
DMOG on influencing gut injury and repair using a rat gastric (indomethacin, 20 mg/kg and 3 h 
restraint) damage model. DMOG stimulated migration in a dose-dependent manner, increasing 
migration twofold when added at 25 mM. Additive effects were seen when DMOG was added to 
cells in hypoxic conditions. Both oral and subcutaneous administration of DMOG decreased 
gastric injury without influencing intragastric pH (50% reduction in injury when 1ml gavaged at 
0.57 mM). Indomethacin reduced tissue HIF and VEGF levels but this was prevented if DMOG 
was present. Therefore they concluded that DMOG stimulates the early phases of gut repair and 
VEGF-dependent processes appear relevant, implying that non-peptide factors such as this may 
be useful to stabilise or repair gut mucosa. Interestingly, it is again emphasized by the authors that 
although DMOG appears to be well tolerated, caution needs to be shown due to the fact that 
prolonged modification of NFκB levels may result in pro-tumourigenic effects (Cummins et al., 
2008) with a short exposure being more advantageous.  
Anaemia associated with RA, known as rheumatoid anaemia, is a typical example of 
anaemia of chronic disease (Gomollon and Gisbert, 2010; Masson, 1992). In the absence of 
effective treatment, anaemia is highly prevalent among RA patients. The mechanisms involved in 
rheumatoid anaemia include shortening of the erythrocyte lifespan, inadequate bone marrow 
erythropoiesis in response to the anaemia, and iron metabolism abnormalities. The development 
of rheumatoid anaemia is related to the effects of the proinflammatory cytokines, including TNF, 
IFN-γ, IL-1, and IL-6. IL-6, in particular, exerts major effects on the iron-lowering hormone 
hepcidin (Means, 2004). Polymorphisms in the TNFRSF1A and TNFRSF1B genes may also 
affect the expression of rheumatoid anaemia (Glossop et al., 2005).  
Although anaemia in a patient with RA is usually rheumatoid anaemia, other causes exist, 
depending on the stage of the disease and treatments used. Among them, the most common is iron 
deficiency anaemia due to malabsorption or, more often, iron loss. Patients with RA may have 
folate deficiency anaemia (usually counteracted in patients taking the anti-folate agent 
methotrexate); vitamin B12 deficiency anaemia (although concomitant Biermer’s anaemia is 
rare); hemolytic anaemia; anaemia related to myelodysplastic syndrome; or anaemia induced by 
medications such as methotrexate, salazopyrine, or leflunomide, via various mechanisms (Chan et 
al., 2010). Cytokines affect erythropoiesis in three ways: by diminishing the production of 
erythropoietin, by decreasing the amount of iron available for erythropoiesis, and by exerting 
direct toxic effects on early-stage erythropoietic cells. TNFα and IFNγ inhibit erythroid colony 
formation in vitro. The apoptotic Fas/Fas-ligand system inhibits the proliferation of burstforming 
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unit-erythroid (BFU-E) and colony-forming unit-erythroid (CFU-E) progenitors. Some of the 
ligands of the Fas/Fas-ligand system, produced by mature erythroblasts and inflammatory cells, 
exert a negative feedback effect on the development of less mature erythroblasts. Erythropoietin is 
a 30.4 kDa glycoprotein composed of 165 amino acids. Erythropoietin inhibits erythroid 
progenitor apoptosis and induces clonal proliferation of normoblasts. In adults, the kidneys 
produce 90 to 95% of the erythropoietin found in the bloodstream. The remainder is produced by 
the liver. Hypoxia activates erythropoietin production. Erythropoietin was first purified in 1977 
and the gene was cloned in 1983. The first clinical studies were started in 1986. The introduction 
of erythropoietin therapy has virtually eliminated the need for blood transfusions in chronic 
hemodialysis patients. In RA, the high proinflammatory cytokine levels usually inhibit the 
production of erythropoietin mRNA to some extent, leading to a decrease in endogenous serum 
erythropoietin (Raj, 2009). However, this pathogenic mechanism is not consistently present in 
rheumatoid anaemia (Papadaki et al., 2002). Another mechanism of interest is EPO signaling 
pathway alteration due to increased production of suppressor of cytokine signaling/cytokine 
inducible SH2 protein (SOCS/CIS). The result is resistance to the effects of erythropoietin 
(Moreno Lopez et al., 2009). The best means of correcting rheumatoid anaemia is to ensure 
systemic disease control by administering synthetic or biologic disease-modifying antirheumatic 
drugs such as methotrexate (Bijlsma and Jacobs, 2009), TNFα antagonists (Doyle et al., 2009), 
rituximab, abatacept, and tocilizumab (Emery et al., 2008; Genovese et al., 2008; Jones et al., 
2010; Maini et al., 2006; Smolen et al., 2008). A pooled analysis of data from three randomized 
clinical trials comparing infliximab to placebo, with methotrexate, in RA patients showed that the 
infliximab-methotrexate combination was associated with a greater than 1-g increase in serum 
hemoglobin levels in 40% of patients and produced normal hemoglobin level in 43% (Doyle et 
al., 2009).  
Animal models have been helpful in the study of the mechanisms of anaemia associated 
with inflammatory conditions since mice have a hematologic and inflammatory system similar to 
humans (Rivera and Ganz, 2009). Nevertheless, it is important to recognise that there are 
important differences between human and murine pathophysiology that could lead to profound 
differences in the anemic response to inflammation. For instance, the lifespan of the mouse 
erythrocyte is much shorter than that of humans (Anosa, 1976) so consequently they have a more 
active erythropoiesis and higher reticulocyte counts at baseline. Moreover, mice mount a much 
more intense reticulocyte response to some inflammatory stimuli and are capable of extensive 
extramedullary hematopoiesis (Wallner et al., 1987). My findings suggest that the median 
haematocrit level of healthy mice is 52, whereas arthritic mice exhibit significantly lower 
haematocrit levels with the correlation between the haematocrit levels and arthritis severity being 
reversed correlated. Of note is that DMOG treatment significantly ameliorated the haematocrit 
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levels by restoring them back to 58. Therefore, it can be concluded that correction of anaemia 
might well contribute to the reduction of RA. 
Furthermore, my findings suggest that the predominant macrophage population within a 
healthy paw is the anti-inflammatory M2 macrophage subtype in striking contrast to the arthritic 
paw in which the pro-inflammatory M1 macrophages seem to be the main macrophage 
population. This can be at least partially attributed to the nature of the M2 cells being responsible 
for the maintenance of tissue homeostasis while the M1 cells are the key role players in 
orchestrating the inflammatory response (Krausgruber et al., 2011). Of note is that DMOG 
treatment appears to bring back the equilibrium by restoring the M2 macrophage population and 
decreasing the M1 cell population, thus partially explaining the amelioration of the disease in both 
murine models of arthritis, CIA and AIA. Findings supporting the beneficial role of DMOG also 
come from Hams et al (Hams et al., 2011) who demonstrated in vivo that pre-treatment of male 
C57BL/6 mice with DMOG, 2 hours prior to LPS treatment attenuated systemic LPS-induced 
activation of the NFκB pathway. Furthermore, mice treated with DMOG had significantly 
increased survival in LPS-induced shock. Conversely, in models of polymicrobial sepsis, DMOG 
exacerbated disease severity. DMOG treatment of mice also promoted M2 polarisation in 
macrophages within the peritoneal cavity, resulting in the downregulation of pro-inflammatory 
cytokines such as TNFα. In addition, in vivo DMOG treatment upregulated IL-10 expression, 
specifically in the peritoneal B-1 cell population thus demonstrating cell type specific roles for 
hydroxylase inhibition in vivo and providing insight into the mechanism underlying the protection 
conveyed by DMOG in models of endotoxic shock. Their data suggest two mechanisms through 
which DMOG is working in preventing endotoxemia: first, through tolerising the peritoneal 
macrophages to NFκB activation and promoting the generation of M2 macrophages thereby 
attenuating the pro-inflammatory responses to LPS and, secondly, direct upregulation of IL-10 
production, involving CREB activation as an example, specifically from peritoneal B-1 cells. 
They speculated that CREB is just one possible mechanism linking hypoxia and IL-10, and to 
fully delineate the signaling underlying this response it would also be necessary to assess 
activation of other transcription factors such as AP-1 and Erk. The upregulation of NFκB 
observed in response to DMOG treatment was likely to be direct activation of the p50 subunit. 
Pretreatment with DMOG has the effect of tolerating the mice to be refractory to subsequent 
challenge with LPS. In addition, recent work has shown that activation of the p50 NF-κB subunit 
actually inhibits M1 and drives M2 macrophage activation, a phenotype also associated with LPS 
tolerance (Nizet and Johnson, 2009). This has been demonstrated in that study through the ability 
of DMOG to enhance M2 polarisation by chitin, a known inducer of M2 activation. Overall, my 
data suggest that DMOG activates the HIF pathway in vivo, and appears to exert a protective role 
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in the setting of arthritis (reduced paw/knee swelling), possibly by promoting the expansion of the 
anti-inflammatory M2 macrophage population and ameliorating the haematocrit levels. 
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6 CONCLUDING REMARKS 
6.1 Discussion 
Hypoxia-inducible factor (HIF) is a heterodimeric transcription factor composed of a 
hypoxia-inducible α-subunit and a constitutively expressed β-subunit. Under hypoxic conditions, 
stabilisation of HIF-α results in formation of an active complex that regulates expression of genes, 
including angiogenic factors, glycolytic enzymes, and survival factors (Harris, 2002). Under 
normoxic conditions, HIF-α is post-translationally hydroxylated by the prolyl hydroxylase domain 
enzymes (PHD1-3), targeting it for interaction with the pVHL E3 ubiquitin ligase complex and 
rapid proteasomal degradation (Bruick and McKnight, 2001; Epstein et al., 2001). An additional 
level of regulation is mediated by the asparagine hydroxylase enzyme FIH-1, that under the same 
conditions silences HIF transcriptional potential. Myeloid cells are important players mediating 
key-roles in many inflammation-related diseases which are characterised by hypoxia and 
enhanced expression of HIF-α isoforms, such as RA (Hollander et al., 2001). Myeloid cells have 
developed HIF-α dependent ways of surviving and functioning within oxygen-depleted conditions 
(Cramer et al., 2003), and it is now well appreciated that hypoxia/HIF-α isoforms can either 
directly or indirectly influence many aspects of monocyte/macrophage functions (Takeda et al., 
2010; Takeda et al., 2011). Therefore, the main objective that was assessed in the context of this 
PhD Thesis was the investigation of HIF/HIF hydroxylases regulation during monocytes to 
macrophage differentiation in normoxia. Moreover, the effect of HIF stabilisation during the 
differentiation process on downstream effects, from the perspective of angiogenesis, has also been 
studied. Finally, I investigated the effect of modulating HIF expression in vivo, using murine 
models of arthritis. 
Limitations related to isolation and use of primary monocytic cells prompted me to first 
use the THP-1 monocytic cell line as an experimental cell model system to study the mechanism 
by which HIF/HIF hydroxylase are regulated during the monocyte to macrophage differentiation. 
In my study, treatment of THP-1 monocytes with PMA led to the acquisition of a M2-like 
macrophage phenotype, based on alterations in the expression of markers such as CD36 (M2) and 
IRF-5 (M1). There is currently some argument in the literature as to whether PMA differentiation 
of THP-1 cells leads to acquisition of a M1-or M2-like macrophage phenotype (Tjiu et al., 2009). 
Nevertheless, characterising the macrophage phenotype that predominates is crucial in 
understanding the role of the different macrophage subtypes present at different stages of the 
disease, and under the conditions used in my study, THP-1 cells were M2-like, rather than M1-
like. With regard to the effect of monocyte to macrophage differentiation on the HIF pathway, 
PMA differentiation of THP-1 monocytes led to transcriptional upregulation of both HIF-α 
isoforms, namely HIF-1α and HIF-2α, although statistical significance was reached only with the 
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HIF-2α isoform. Interestingly, HIF-2α protein has not been detected in the context of this study 
throughout the differentiation time period, despite HIF-2α being more resistant to oxygen-
dependent degradation than HIF-1α (Lofstedt et al., 2007). A variety of reasons may explain the 
absence of HIF-2α protein expression in my system. One reason may be that HIF-1α and not HIF-
2α plays key roles during the differentiation process, a notion consistent with the observations of 
Cramer’s study (Cramer et al., 2003). The possibilities that cells in my system do not express the 
HIF-2α isoform to the extent they express HIF-1α, or antibody quality issues that make the HIF-
2α detection difficult, should also be kept in mind. With regard to the HIF-1α isoform, the 
differentiation process appeared to stabilise its levels one day post PMA differentiation and then 
levels were gradually decreasing probably due to oxygen-dependent hydroxylation/degradation. 
These data suggest that despite adequate oxygen conditions, the differentiation process stabilises 
the HIF-1α isoform, thus drawing the attention to the expression levels of the HIF hydroxylases. 
Indeed, my data show that PMA-mediated differentiation of THP-1 cells reduced PHD-2 mRNA 
and protein levels after 24 hours, a reduction which might well account for the normoxic HIF 
accumulation in agreement with its role as the main oxygen sensor in regulating HIF levels in 
steady state. As expected, PHD-2 appears to restore its expression levels after 48 hours of 
differentiation thus reflecting a HIF-dependent effect. The hypothesis of impaired hydroxylation 
over differentiation was proven by probing protein lysates from PMA-treated THP-1 using the 
OH-HIF antibody. Furthermore, in my study modulation of the differentiation status using either 
IFN- (driving cells potentially towards an M1-like phenotype) or IL-4 (M2) increased HIF-α 
mRNA, although protein levels were not found to be further increased. Interestingly, PMA 
differentiation of THP-1 cells for 24 hours followed by stimulation with IL-4 increased more HIF-
2α than HIF-1α, in agreement with the preferential expression of HIF-2α isoform in response to 
Th2-type cytokines (Takeda et al., 2010). Shifting macrophages phenotypes did not have any 
effect on the expression levels of the PHDs when IFN- was used, but IL-4 upregualted both 
PHD-2 and PHD-3.  
My findings suggest that normoxic HIF stabilisation during the differentiation process 
was not followed by upregulation of downstream HIF targets that could play a role in the 
angiogenic responses. This might be due to either cytoplasmic localisation of HIF or due to the 
constitutive presence of FIH-1 thus imposing limitation on HIF-mediated gene transcription. In 
the context of characterising monocytes/macrophages responses to hypoxia, I found that even 
though hypoxia did not affect differentiation status of M2-like THP-1 cells, cells responded to 
hypoxia, by significantly increasing expression of PHD-3 and angiogenic targets EphrinA3, 
VEGF and BNIP3.  
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Since my data suggest that the maturation and differentiation of myeloid cells affect the 
HIF pathway I was then interested to examine whether the sensitivity to a potent inflammatory 
stimulus -such as LPS- could affect this process. My findings suggest that undifferentiated THP-1 
cells do not respond to LPS, except for reduction in PHD-3, and expression of angiogenic targets 
EphrinA3, VEGF and BNIP3 was not significantly affected either. Although, LPS did not affect 
differentiation status of either THP-1 cells or M2-like THP-1 cells, cells were capable of 
responding to LPS bysignificantly increasing expression of PHD-3 and angiogenic target VEGF, 
unlike undifferentiated THP-1 cells. 
As with any study employing THP-1 cells, the conclusive remarks coming from this study 
required further verification using primary cells and/or in vivo models to be translated to 
monocytes and macrophages. Therefore, I next investigated the mechanisms of HIF hydroxylase 
regulation during monocyte to macrophage differentiation using human primary monocyte-
derived macrophages. Elutriated human monocytes were utilised to address questions related to 
the impact of monocyte to macrophage differentiation on the HIF pathway, the regulation of HIF 
hydroxylases during the differentiation process, as well as if the differentiation process affects the 
sensitivity to hypoxia. 
Normoxic stabilisation of HIF-1α protein was observed in both M1 and M2 MDM at days 
1 and 3, likely at least in part due to transcriptional upregulation previously observed. Again no 
significant differences were seen between M1 and M2 macrophages. A very weak up-regulation 
of HIF-2α protein was observed, thus suggesting in my experimental system the HIF-2α isoform 
expression levels appear to be relatively low. According to my data the observed normoxic HIF-
1α stabilisation occurred in both M1 and M2 cells was at least partially due to impaired 
hydroxylation and thus reduced activity of the PHD enzymes. 
In contrast to the PMA-treated THP-1 cells where normoxic HIF stabilisation was not 
followed by downstream HIF-dependent gene expression, BNIP3 and EphrinA3 were increased in 
my study throughout the differentiation process although M2 responses were significantly greater.  
My data also suggest that undifferentiated human monocytes responded to 1% O2 by upregulating 
PHD-2 and PHD-3 whereas HIF-α isoform mRNA expression was reduced under the same 
conditions. These findings indicate that mononuclear phagocytes respond to hypoxia by 
regulating the expression of selected target genes, which may be critical for their adaptation to the 
hypoxic environment and ability to function in it, and could be representative of the hypoxic 
transcriptome in cells belonging to the monocytic lineage. Whether or not upregulation of these 
targets is mediated by the HIF pathway or other pathways are involved namely the NFκB remains 
to be investigated. With regard to the M1 and M2 cells responses to the hypoxia/hypoxia mimetic 
DMOG both HIFs were stabilised leading to transcription of target genes BNIP3 and EphrinA3. 
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In terms of responsiveness, PHD-2 and PHD-3 were found to be increased more in M2 cells 
compared to M1 cells. 
Having shown the normoxic HIF stabilisation during monocyte to macrophage 
differentiation and the subsequent effect of hypoxia to the HIF/HIF hydroxylases and HIF targets, 
I then interrogated the role of HIF hydroxylases in RA, using a combination of in vivo disease 
models utilising a commercially available HIF hydroxylase inhibitor, namely the pan-specific 
inhibitor DMOG. Briefly, utilisation of a transgenic mouse expressing the ODD domain of the 
HIF-1α gene fused to a luciferase bioluminescent reporter gene has enabled me to investigate 
whether DMOG has any effect in vivo, particularly if DMOG increases HIF-1α levels (or if 
DMOG has non-HIF related effects). Use of the aforementioned model would also enable me to 
study whether HIF expression is associated with the diseased site. In this context, the effect of 
DMOG on arthritis was also studied.  
My data suggest that DMOG enhanced the luciferase activity in vivo resulting in 
increased bioluminescent signal. Moreover, DMOG treatment reached the highest fold-increase in 
ODD-luciferase activity 2 hours after PHD inhibition while in parallel activated the HIF pathway 
in vivo as evidenced by PHD-3 upregulation. Even though DMOG resulted in a significant 
reduction of knee swelling using an AIA model of arthritis in ODD-Luc mice, I was unable to 
detect luciferase activity in the knee. Using a different mouse strain, DBA/1 mice, DMOG-
mediated knee swelling reduction in AIA was also accompanied by amelioration of the 
haematocrit levels which I found to be reduced in arthritic mice. The potential therapeutic benefit 
of DMOG administration was further confirmed using the CIA model. Of note is that DMOG-
dependent paw thickness swelling reduction was also accompanied by a shift of the macrophage 
phenotype from a M1 toward a more M2-like phenotype, something that has also previously 
described in other disease models. However, it remains to be investigated, if this effect involves 
the HIF/PHD pathway.  
6.2 Study Limitations 
In this PhD study, two cell model systems were used: THP-1 derived macrophages after 
differentiating THP-1 cells with PMA, and monocyte-derived macrophages (MDMs). MDMs 
were obtained by treatment of human elutriated monocytes with GM-CSF and M-CSF, which 
have been widely described to differentiate monocytes to M1 and M2 phenotypes respectively 
(described in Chapter 4). All experiments conducted in Chapter 3 refer to the THP-1 cell type as a 
model system to study macrophages. Since their establishment thirty years ago, THP-1 cells have 
become one of the most widely used cell lines to study the function and regulation of monocytes 
and macrophages (Tsuchiya et al., 1982).  
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Technically, THP-1 cells have some advantages over human primary monocytes–
macrophages. First, their homogeneous genetic background minimises the degree of variability in 
the cell phenotype (Cousins et al., 2003; Rogers et al., 2003). This trait is particularly important 
when studying the biological function of chemicals with high variability, such as oxidised low 
density lipoprotein (LDL), because oxidised LDL is a biochemical assembly with high variation 
and requires a large number of replica experiments; the most reliable findings are usually obtained 
using a cell line with relative minimal variability in the cell phenotype (Cousins et al., 2003; 
Rogers et al., 2003). Second, transfection efficiency is a common problem in human primary 
monocytes and macrophages (Burke et al., 2002a), whereas genetic modification of THP-1 by 
small interfering RNAs (siRNAs) to downregulate the expression of a specific protein is relatively 
easy. Third, THP-1 cells can be stored indefinitely in liquid nitrogen. Following an appropriate 
procedure, this cell line can be recovered without obvious detrimental effect on monocyte–
macrophage features and cell viability. Thus, this ability to store cells guarantees sufficient cells 
for DNA, RNA, and protein studies. In contrast, the availability of primary human monocytes–
macrophages is limited; accounting for only 3–9% of all leukocytes. Additional challenges for the 
use of primary cells include donor variability and accessibility, contamination with other blood 
components such as platelets (Altieri and Edgington, 1988a), and a limited survival period in 
culture.  
The limitations regarding the use of THP-1 cells is that it remains still an open question T 
to what  extent THP-1 cells are able to mimic monocyte and macrophage function. This is 
because this cell line was originated from the peripheral blood of a 3 years old male patient 
suffering from acute monocytic leukemia. In an attempt to address this question many seminal 
recent publications provided evidence describing the interactions between THP-1 cells and 
various vascular cells (such as endothelial cells, smooth muscle cells, adipocytes, and T cells) 
thus shedding more light into the roles of the interconnection of monocytes–macrophages with 
other vascular cells during many inflammatory diseases, including atherogenesis, obesity and - of 
relevance to this study - to RA. The responses of monocytes/macrophages to various 
inflammatory stimuli such as LDL and LPS were further characterised by transcriptome analysis, 
profile, and histone modifications using THP-1 cells thus giving answers to many questions 
regarding the regulatory mechanisms of monocytes/macrophages. These studies confirm that 
under certain circumstances, THP-1 cells not only can mimic human primary 
monocytes/macrophages isolated from either healthy donors or donors with disease, but also 
mirror the in situ alteration of macrophages in the adipose tissue of obese subjects and in 
atherosclerotic lesions. Nevertheless, the conclusive remarks of studies employing THP-1 cells 
require further verification using primary cells and/or in vivo models to be translated to 
monocytes and macrophages.In addition to THP-1 cells, there are three other immortalised human 
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monocyte-macrophage cell lines, including U937 and ML-2.U937 cells have properties of 
monoblasts with weaker positive for esterase, peroxidase, lysozyme, and surface receptors for 
immunoglobulins and complement, whereas THP-1 cells display a more mature monocytic 
phenotype (Altieri and Edgington, 1988b). However, it was shown that another human monocytic 
cell line, termed Mono Mac 6 (established from peripheral blood of a patient with monoblastic 
leukemia), showed an increased frequency of multinucleated cells, and appeared to be the only 
one of the cell lines studied (THP-1, U937) to constitutively express phenotypic and functional 
features of mature monocytes (Ziegler-Heitbrock et al., 1988). More importantly, the fact that this 
cell line can be cultured without any stimulus to form macrophages (Caito et al., 2008) renders 
them a much better cell model system to study the macrophage biology compared to the THP-1 
cells, as the possibility of a PMA-mediated effect on the HIF hydroxylase activity/availability can 
be excluded. 
Due to time limitations extensive studies with regard to the impact of 1% oxygen on the 
protein levels of HIF/HIF hydroxylases in monocytes (THP-1 monocytes, human monocytes) and 
macrophages (THP-1 macrophages, M1/M2 macrophages) have not been conducted and are 
discussed later (Future work).  
DMOG is a nonselective PHD inhibitor expected to interfere with all 2-OG-dependent 
oxygenases affecting a number of important cellular processes such as DNA repair, carnitine 
biosynthesis, and collagen modifications, and most likely many other functions within the cell, 
including the Krebs cycle (Schofield and Ratcliffe, 2004). A disadvantage of all the currently 
available HIF hydroxylase inhibitors is their lack of specificity and failure to selectively inhibit 
specific PHD isoforms, thereby restricting their clinical usefulness (Fraisl et al., 2009). Such 
novel compounds comprise aromatic heterocycles, related to pyridine derivatives, including 
pyrazolopyridines and 8-hydroxyquinolines (Hewitson et al., 2004). The generation of 8-
hydroxyquinolines is based on a previously described iso quinoline derivative that specifically 
inhibits PHDs. Co-crystallisation with PHD-2 revealed key interactions between this compound 
and the active site of the enzyme (McDonough et al., 2006), thereby serving as a basis for future 
design of selective inhibitors. Utilisation of all the above mentioned inhibitors could be 
considered in the context of this study and is discussed later (Future work). 
Whether HIF hydroxylation inhibition will result in undesired effects in healthy organs or 
not still remains an open question. For instance, pharmacological inhibition of PHD-1 might 
confer acute protection against an ischaemic insult; however, as hypoxia tolerance relies on 
energy conservation, energy expenditure is also reduced. So, strategies using therapeutic 
induction of hypoxia to induce hypoxia tolerance must ensure they do not excessively impair 
tissue performance and thereby inadvertently trigger organ failure (Aragones et al., 2008). In line 
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with these observations, PHD3-/- mice develop hypotension, and post-natal loss of PHD-2 results 
in polycythaemia (Bishop et al., 2008; Takeda et al., 2008). On a cautionary note, a Phase II 
clinical trial testing the therapeutic potential of a novel PHD inhibitor (FG-2216) for the treatment 
of anaemia had to be stopped because of the death of a patient, thus raising concerns regarding the 
prolonged administration of PHD inhibitors. Furthermore, chronic activation of the HIF pathway 
in humans, either through PHD-2 loss or gain of function of HIF-2α results in the development of 
erythrocytosis (Percy et al., 2008; Percy et al., 2006) whereas VHL mutation underpins congenital 
Chuvash polycythaemia, and has also been associated with thrombosis and vascular abnormalities 
(Ang et al., 2002; Gordeuk et al., 2004). Therefore, short-term or more local administration of 
PHD or FIH-1 inhibitors might represent safer alternative therapeutics options in inflammatory 
diseases associated with altered oxygen levels. Nevertheless, the challenge for the design of HIF 
hydroxylase isoform-specific inhibitors is becoming greater than ever.  
6.3 Future Work 
As previously mentioned, my data suggest that a modest reduction in PHD-2 protein 
levels might well account for the normoxic HIF stabilisation observed during monocyte to 
macrophage differentiation in the THP-1 model. The reason why, and the way how PHD-2 is 
downregulated throughout the differentiation process remains to be further elucidated. One 
possible explanation might be the effect of cytokines. It has been previously shown that TGF-β 
activates HIF in hepatoma and fibrosarcoma cells, by reducing PHD2 mRNA and protein 
expression via the Smad signalling pahway.To determine whether the observed reduction of 
PHD-2 protein levels is responsible for the accumulation of HIF-1α by TGF-β, I first need to 
observe if TGFβ expression is induced during monocyte to macrophage differentiation. This will 
be a first indication that TGF may affect PHD expression and will allow me to further investigate 
its downstream signalling effect on PHD-2 expression. One option will be to inhibit expression of 
TGF-b, or downstream components of TGF-b signalling, such as Smad using RNA interference 
(siRNA or lentiviral delivery of shRNAs), previous to PMA or M-CSF/G-MCSF stimulation and 
follow PHD-2 expression during the differentiation process. Since the TGFβ effect might be cell 
specific I would also investigate the effect of other cytokines such as TNFα and IL-1 on PHD-2 
expression during monocyte to macrophage differentiation.  
 Moreover, the use of commercially available antibodies targeting cytokines known to 
activate HIF (such as anti-IL-1β or anti-TNFα) would be informative in terms of other possible 
mechanisms regulating the HIF hydroxylases during the differentiation process. To address this 
hypothesis, I would add one or more of the above mentioned antibodies in parallel with the 
differentiation inducing agent, PMA, and study expression levels of the HIF hydroxylases as well 
as what is the impact of the addition of these antibodies on the HIF pathway. Given that cytokines 
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are known to primarily activate a plethora of signal transduction pathways including 
PI3K/Akt/mTOR, p44/42 MAPK and NFκB, pharmacological inhibition of these signalling axes 
could well unravel novel mechanisms of HIF hydroxylase regulation over the differentiation 
process. 
As previously mentioned reduced PHD-2 enzymatic activity might well also account for 
the observed normoxic HIF stabilisation during the differentiation process. To investigate this 
hypothesis, I would use cytoplasmic extracts from THP-1 cell suspensions and PMA-treated 
THP-1 cells (differentiated for days 1, 2 and 3), and I would measure the interaction between a 
bead immunopurified biotinylated synthetic HIF-α peptide and [35S]methionine-labeled VHL-HA 
as previously described in the literature (Tuckerman et al., 2004). Uncomplemented assays would 
be incubated in the presence of extract and peptide alone, whereas fully complemented assays 
would be additionally supplemented with FeCl2, 2-oxoglutarate, ascorbate and catalase. Finally, 
quantification of captured VHL by SDS-PAGE would verify (or disprove) my hypothesis. 
In my experiments the fact that addition of the Th2-like cytokine IL-4 did not induce the 
M2 macrophage phenotype any further (compared with PMA treatment alone) highlights the need 
to use other approaches to generate M1-like and/or M2-like THP-1 cells expressing a more robust 
phenotype marker expression profile. For instance, polarising PMA-treated THP-1 cells using a 
higher concentration of IFNγ (i.e. 20ng/ml) or using a combination of polarising cytokines (IFNγ 
together with LPS) might have led to a more robust M1 macrophage phenotype. The same would 
also apply to the M2 cells, in which case addition of a higher IL-4 concentration (30ng/ml) or 
addition of another M2-polarising cytokine such as IL-13 might have led to a more robust M2 
signature. 
In addition, silencing experiments against PHD-2 or PHD-3 would be informative in 
terms of the HIF-α isoform expression during the differentiation process. For this purpose I would 
first do some preliminary experiments on both THP-1 derived macrophages and also MDMs are 
both cell types seem to be difficult to transfect. The use of different transfection agents 
(Lipofectamine, Hiperfect, RNAi max) and also different concentartions of the siRNAs would 
help be to find the right conditions to silence gene expression in the cells. Since siRNA gene 
silencing only last 3 days, a more stable transfection using shRNA and lentivirus would be also a 
possibility, since such approaches are frequently and successfully use at our Institute (Beavis et 
al., 2011). 
Moreover, shifting between M1 to M2 macrophage phenotypes did not seem to affect HIF 
isoform or HIF hydroxylase expression levels, thus suggesting that possibly macrophages in both 
settings were fully differentiated, and that 1 day of stimulation with other differentiation inducing 
agent was not enough to convert one population into another. Therefore, differentiating M1 and 
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M2 cells for a shorter time period (1 day) followed by addition of the opposite polarisation 
cytokine for longer, might lead to the desired macrophage polarisation signature. 
Of relevance to my study, would be to measure the cytokines -using ELISA- secreted by 
M1 and M2 macrophages, 1 and/or 3 days post-differentiation before and after exposure to 
hypoxia. I hypothesize that M1 and M2 macrophages would secrete pro- and anti-inflammatory 
cytokines respectively, whereas upon hypoxic exposure M1 macrophages would no longer be able 
to respond by upregulating proinflammatory cytokines, and thus a shift toward a phenotype which 
resemble to that of M2 will happen. That would be in agreement with the DMOG-mediated 
shifting from M1 macrophage population to M2 phenotype in arthritic mouse paws. 
To screen the effect of 1% O2 on M1 and M2 polarised macrophages (differentiated for 1 
and/or 3 days) with regard to the expression of genes involved in the classical aspects of HIF 
functions (angiogenesis) the Angiogenesis RT2Profiler™ PCR Array (TebuBio, Peterborough, 
UK) could be used (Muz et al., 2012). For this purpose, elutriated human monocytes would be 
differentiated towards M1 and M2 macrophages for 1 and 3 days as previously described and they 
would then be exposed to 1% O2. The analysis would be completed with the software provided in 
combination with Excel and the 2-Ct method to calculate the fold change in gene expression, 
which would be achieved by normalising the data to the average of five housekeeping genes. A 2-
fold induction or reduction would be used as cut-off when evaluating the changes on the PCR 
array. 
In terms of the effects of modulating the HIF pathway in vivo, other approaches of turning 
the HIF hydroxylases inactive (apart from DMOG treatment) could also be informative, as 
different HIF inhibitors may have different levels of specificity and/or selectivity and therefore 
different phenotypic/functional outcomes. Given that the binding of the co substrate 2-OG to the 
catalytic domain of the HIF hydroxylases is critical for their function, any chemical compounds 
that structurally mimic 2-OG, such as N-oxalylglycine, can inhibit PHDs and FIH-1 by blocking 
the entry of the co-substrate. Other compounds also known to interfere with the catalytic activity 
of these enzymes are the iron chelating agents, such as DFO (desferrioxamine) (Fraisl et al., 
2009).  
The lack of specificity and failure to selectively inhibit specific PHD isoforms on behalf 
of all the currently available PHD inhibitors necessitates (Fraisl et al., 2009) the use of novel 
compounds (aromatic heterocycles, related to pyridine derivatives, including pyrazolopyridines 
and 8-hydroxyquinolines) (Hewitson et al., 2004) being able to exhibit a greater degree of 
selectivity/specificity. 
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In addition to the above listed compounds, two novel compounds structurally related to 
FG-0041 (an iron chelating, broad spectrum PHD inhibitor)-TM6008 and TM6089 have also been 
developed as PHD inhibitors that could be also used in the context of my PhD project. These 
inhibitors were shown to induce angiogenesis and protect organs against ischaemia in vivo 
(Nangaku et al., 2007). 
In addition to the pharmacological approaches for HIF hydroxylase inhibition mentioned 
above the utilisation of genetically modified mice would also be informative in terms of my PhD 
study. For that purpose wild type, PHD-1-/-, PHD-2+/- and PHD-3-/- mice generated as 
previously described (Aragones et al., 2008; Bishop et al., 2008; Mazzone et al., 2009) would be 
bred on a DBA/1 background (for imaging purposes the ODD-Luc background could be also 
used) and eight to twelve week old male mice would be used for CIA and/or AIA-induced 
arthritis studies. These experiments would shed more light on the roles of individual HIF 
hydroxylases in animal models of arthritis. 
Of relevance to my study would be to investigate expression of genes whose role is 
important in mediating some of the classical HIF-dependent functions such as angiogenesis and 
vascularisation. For this purpose nephrectomies from ODD-Luc mice that have received DMOG 
could be performed and RT-PCR analysis of genes such as Tie2, Arg1, CXCR4, HGF, Fizz, 
NRP1 would confirm whether DMOG treatment promotes new vessel formation, improves 
oxygenation leading to amelioration of arthritis. Histological analysis of arthritic paws or arthritic 
knees for angiogenic marker expression would also be informative regarding the angiogenic status 
of mouse paws/knees after receiving DMOG.  
Due to time limitations I was not able to investigate the angiogenic status of affected 
arthritic paws/knees after receiving DMOG. It would therefore be interested to know if DMOG 
treatment of arthritic paws and knees induces angiogenesis in in vivo or in vitro assays (e.g. EC 
chemotaxis assay, matrigel plug assay). In our laboratory, a human in vitro angiogenesis assay 
(AngioKit; TCS Cell Works, Buckingham, UK) is routinely applied to analyse the angiogenic 
activity of supernatants from RA synovial membrane cells or RA synovial fibroblasts. It has 
already been reported that RA synovial fibroblasts secrete ANG-1 after TNFα stimulation 
(Hashiramoto et al., 2007), therefore, it would be interesting to know, if the observed paw/knee 
swelling following DMOG treatment is because of enhanced blood vessel formation and 
improved oxygen perfusion.  
Utilisation of the AIA model on ODD-Luc mice failed to correlate arthritis incidence with 
hypoxia. I reason that due to the short time course of the AIA model (disease peaks on day 1 after 
induction and swelling reduces the day after) the bioluminescent signal generated by the knee was 
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not strong enough to be detected by the imager. Therefore, I hypothesize that repetition of this 
experiment using the CIA model (where the swelling remains robust for approximately 10 days) 
will lead to enhanced bioluminescence, and visualisation of the hypoxia will correlate arthritis to 
low oxygen tension in mice. Due to time limitations, O2 tensions have not been measured in joints 
from mice with arthritis. In 2002, oxygen and perfusion levels were measured polarographically 
using silver needle microelectrodes within mouse knee joints prior to and 10 days after the onset 
of experimentally induced arthritis. In addition, synovial cells were isolated from knee joints of 
naive, pre-arthritic and arthritic mice. The findings suggested that, the perfusion rates in naive and 
arthritic animals were not significantly different: in naive mice, the rate was 0.58 +/- 0.11 
ml/min/g and in arthritic joints, 0.64 +/- 0.17 ml/min/g. Furthermore, synovial cells isolated from 
the knee joints of naive animals did not express mRNA for VEGF, but significant levels were 
detected in cells from non-arthritic mice immunised with collagen. The onset of arthritis was also 
found to be associated with expression of VEGF mRNA and protein, and correlated negatively 
with pO2 levels (Etherington et al., 2002). 
Cytokine ELISAs and multiplex cytokine analysis would also be informative in terms of 
confirming the macrophage switch from M1 to M2 after DMOG treatment of mice. Therefore, 
peritoneal macrophages (from mice left either untreated or DMOG-treated) would be isolated as 
previously described (Saunders et al., 2010) and supernatants from in vitro cultures would be 
analysed by sandwisch ELISAs to quantify levels of specific pro- and anti-inflammatory 
cytokines. All cytokines (IL-1β, IL-6, IL-10 and TNF-α) would be measured with the DuoSet 
ELISA development system from R&D Systems following the manufacturers protocol. Another 
possibility would be to use  aultiplex analysis using the mouse pro-inflammatory  7-plex ultra-
sensitive kit from Meso Scale Discovery (K15048D;  Meso Scale Discovery, MD, USA), which 
measures 10 cytokines (IFN-γ, IL-1β, IL-10, IL-12 p70, IL-2, IL-4, IL-5, IL-6, KC/GRO, TNF-α) 
that are important in inflammation response and immune system regulations as well as numerous 
other biological processes. An MSD facility is available at the Kennedy Institute that uses the 
SECTOR Imager 2400 which provides multiplex assay capability (Alzabin et al., 2012). Analysis 
of joint fluid, tissues and blood for cytokine patterns that might effect changes in macrophage 
phenotype following DMOG treatment would also be very informative in the context of my study.  
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